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Atrial Septal Defects (ASDs) are relatively common both in children and adults. Recent 
reports of increase in the prevalence of ASD may be related use of color Doppler 
echocardiography. The etiology of the ASD is largely unknown. While the majority of 
the book addresses closure of ASDs, one chapter in particular focuses on creating atrial 
defects in the fetus with hypoplastic left heart syndrome. This book, I hope, will give 
the needed knowledge to the physician caring for infants, children, adults and elderly 
with ASD which may help them provide best possible care for their patients.
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defects (ASDs) cause  left to right shunt because the  left atrial pressure  is higher than 
that in the right atrium. This causes volume overloading of the right ventricle. While 
this is generally well tolerated during infancy and childhood, development of exercise 




In  the  first chapter,  I review  the clinical  features and management of ASDs. Patients 
with  small  defects  are  usually  asymptomatic while moderate  to  large  defects may 
present with symptoms. Physical findings include hyperdynamic precordium, widely 
split and fixed second heart sound, ejection systolic murmur at the  left upper sternal 
border  and  a mid‐diastolic  flow  rumble  at  the  left  lower  sternal border.  In patients 
with ostium primum ASDs, an apical holosystolic murmur may also be heard. Clinical 
diagnosis  is  not  difficult  and  the  diagnosis  can  be  confirmed  and  quantified  by 
echocardiographic  studies.  While  surgical  intervention  was  used  in  the  past, 
transcatheter  methods  are  currently  used  for  closure  of  ostium  secundum  ASDs. 
Surgical correction  is necessary  for  the ostium primum,  sinus venosus and coronary 
sinus defects. PFO is present in nearly one third of normal population and is likely to 
be a normal variant and such isolated PFOs do not need intervention. When associated 
with other CHDs,  the PFO  facilitates  intra‐cardiac shunt  to allow appropriate egress 
and/or mixing of blood  flow. Hypoxemia  in post‐surgical  residual defects  including 
Fontan fenestrations, right ventricular  infarction and platypnea‐orthodexia syndrome 
may be secondary to right to left shunt across PFO and these defects may need closure. 
PFO, presumed  to be  the  seat of paradoxical  embolism  resulting  in  stroke/transient 
ischemic  attacks  is  the  subject  active  investigation.  Similarly  the  role  of  PFO  in 
Caisson’s disease  and migraine  is  not well‐established. There  is  varying degrees  of 
evidence for benefit of transcatheter occlusion of these PFOs. 
In  the  second  chapter, Dr.  Balaguru  from  the University  of  Texas Medical  School, 
Houston,  Texas  discusses  issues  related  to  ASD  in  pregnant  women.  There  are 
remarkable  changes  in  cardiovascular  physiology  during  pregnancy;  the  cardiac 
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output  increases,  related  to  increased  stroke  volume  and  heart  rate.  The  systemic 
vascular  resistance decreases; however,  concurrent  increase  in  cardiac  output  keeps 
blood pressure  stable. The blood volume  increases  (by 1.5  times) by  raise  in plasma 
volume;  however,  this  is  out  of  proportion  to  the  increase  in  red  cell mass  with 
consequent  relative  anemia.  These  changes  are  tolerated well  because  the  changes 
occur gradually. During  the  third  trimester, enlarging uterus compresses  the  inferior 
vena  cava  (IVC)  in  supine  posture  leading  to  decrease  in  cardiac  output  and 
predisposes to deep vein thrombosis. In pregnant women with ASD, there is a greater 
increase  in right atrial and right ventricular size (compared to pregnant women with 
no  heart  defect)  and  a  higher  incidence  of  supraventricular  tachycardia.  The 
probability of paradoxical embolism via  the ASD  is high given  the predisposition  to 
deep vein  thrombosis and hypercoagulable state.    If  the diagnosis  is known prior  to 
pregnancy and  the ASD  is  large and associated with moderate or  severe  right heart 
enlargement  and  is  a  potential  candidate  for  supraventricular  tachycardia  and 
thromboembolic  events during pregnancy,  labor or postpartum,  the ASD  should be 
closed  prior  to  planned‐pregnancy.  Transcatheter  or  surgical  closure  could  be 
performed based on the size of the ASD and adequacy of septal rims.  When the ASD 
is diagnosed during pregnancy but,  the patient  is  asymptomatic without  functional 
compromise  (NYHA  Class  I  and  II)  and  has  no  heart  failure,  atrial  arrhythmia, 
pulmonary hypertension or history of  stroke,  the  these women are  likely  to do well 
throughout  pregnancy  and  do  not  require  transcatheter  or  surgical  closure. On  the 
contrary,  in the presence of any of these  issues, transcatheter or surgical closure may 
be  performed.  If  transcatheter  is  opted,  second  trimester  (13‐28 weeks)  is  preferred 
instead  of  first  trimester  to  avoid  irradiation  to  the  fetus.  Local  anesthesia  with 
conscious  sedation,  intracardiac  echocardiography  to  aid  balloon  sizing  and  device 
deployment  and  use  of  long  venous  sheath;  the  latter  two  to  avoid  or  reduces 
radiation,  may  be  appropriate.  If  the  ASD  is  unsuitable  for  transcatheter  closure, 
surgical closure of ASD may be performed in the second trimester with the following 
precautions:  infusion of high‐concentration of glucose  (to provide  energy  for  fetus), 
fetal monitoring, maintenance of high‐flow, high mean arterial pressure  (60 mmHg) 
and high hematocrit  (> 25%) and hyper oxygenation. The author  concludes  that  the 
need  for  closure  of ASD  during  pregnancy  is  rare  and  if  possible  avoided. When 
closure  is  indicated  transcatheter  or  surgical  closure  may  be  performed,  taking 
appropriate precautions. 
In the third chapter Reller from Oregon Health & Science University, Portland, Oregon 







Genetic  syndromes  associated with  secundum ASD  include Trisomy  21,  13  and  18; 
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Holt‐Oram  syndrome;  chromosome  22q11  deletion  in  association  with  DiGeorge 
syndrome; velo‐cardio‐facial syndrome; Noonan syndrome and NKX2‐5 gene defect. 
Patients with  secundum ASD  are more  likely  to  have  a  positive  family  history  of 
congenital  heart  disease.  There  is  higher  prevalence  of  secundum  ASD  in  girls. 
Secundum ASD is also associated with non‐cardiac malformations such as cleft palate 
and  VACTERL  association.  Fetal  alcohol  syndrome,  cytomegalovirus  (CMV)  and 
rubella infections during pregnancy and maternal diabetes are also associated with an 
increased  prevalence  of  secundum ASD.  Lower  gestational  age  (low  birth weight), 
small for gestational age, increased maternal age and multiple gestation pregnancy are 
also  associated with  higher  prevalence  of  secundum  ASD. With  regard  to  natural 
history,  the ASDs have a  tendency  to regress  in size,  including spontaneous closure. 
Small defects  (between 4‐5 mm) at  the  time of  initial diagnosis either spontaneously 
close or regress to a size considered to be insignificant (≤ 3 mm). Larger defects (> 10 
mm) do not  close  spontaneously  and  75% of  these patients may  require  surgical or 
device  closure.  It may be  concluded  that  secundum ASD  is  the  third most  common 
congenital  cardiac  defect  with  incidence  similar  to  peri‐membranous  VSD,  the 
prevalence of secundum ASD is increasing, the cause of which remain speculative and 





(2D‐US)  imaging  analysis  to  establish  fetal  interatrial  communications.  In  the  fetus 
with  hypoplastic  left  heart  syndrome  (HLHS)  and  restrictive  atrial  septum  leads  to 
irreversible pulmonary vascular damage. The current approach of ultrasound‐guided 
percutaneous puncture  through  both  the uterine wall  and  fetal  chest wall  to  create 
interatrial communications is associated with serious complications such as profound 
bradycardia, bleeding and hemopericardium and intracardiac thrombus formation. In 
addition,  closure of  the  in utero  created  atrial  septal defects  can  also occur prior  to 
delivery.  They  developed  a  new  approach with  HIFU  to  establish  fetal  interatrial 
communications with  potential  for minimal  adverse  effects. HIFU  ablation  requires 
highly accurate pinpoint delivery in real‐time based on computer‐aided auto‐tracking 
of  atrial  septum.  Their  system  features  automatic  detection  of  rate  of  heart  beat, 
automatic  estimation  of  atrial  septal  position  and  automatic  generation  of  HIFU 
delivery  timing.  They  describe  system  configuration  of  computer‐aided  automatic 
HIFU delivery,  automatic detection  of heartbeat  rates, position  of  the  atrial  septum 
and  other  procedural  details.  They  performed  a  feasibility  study  for  creation  of  an 
atrial  septal defect using  the beating heart of  four anesthetized adult  rabbits, which 
appear not  to  satisfactory. But,  the  authors  interpret  that  they were  able  to  confirm 
pinpoint  delivery  of HIFU  to  the  pulsating  atrial  septum within  beating  hearts  of 
anesthetized  adult  rabbits.  The  above  studies were  performed with  2D‐US.  Three‐
dimensional‐US  to  track movement  of  intrauterine  fetus may make  the  procedure 
more  accurate.  In  conclusion,  these  workers  developed  computer‐aided  automatic 
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closure  is  indicated  transcatheter  or  surgical  closure  may  be  performed,  taking 
appropriate precautions. 
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Holt‐Oram  syndrome;  chromosome  22q11  deletion  in  association  with  DiGeorge 
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Small defects  (between 4‐5 mm) at  the  time of  initial diagnosis either spontaneously 
close or regress to a size considered to be insignificant (≤ 3 mm). Larger defects (> 10 
mm) do not  close  spontaneously  and  75% of  these patients may  require  surgical or 
device  closure.  It may be  concluded  that  secundum ASD  is  the  third most  common 
congenital  cardiac  defect  with  incidence  similar  to  peri‐membranous  VSD,  the 
prevalence of secundum ASD is increasing, the cause of which remain speculative and 





(2D‐US)  imaging  analysis  to  establish  fetal  interatrial  communications.  In  the  fetus 
with  hypoplastic  left  heart  syndrome  (HLHS)  and  restrictive  atrial  septum  leads  to 
irreversible pulmonary vascular damage. The current approach of ultrasound‐guided 
percutaneous puncture  through  both  the uterine wall  and  fetal  chest wall  to  create 
interatrial communications is associated with serious complications such as profound 
bradycardia, bleeding and hemopericardium and intracardiac thrombus formation. In 
addition,  closure of  the  in utero  created  atrial  septal defects  can  also occur prior  to 
delivery.  They  developed  a  new  approach with  HIFU  to  establish  fetal  interatrial 
communications with  potential  for minimal  adverse  effects. HIFU  ablation  requires 
highly accurate pinpoint delivery in real‐time based on computer‐aided auto‐tracking 
of  atrial  septum.  Their  system  features  automatic  detection  of  rate  of  heart  beat, 
automatic  estimation  of  atrial  septal  position  and  automatic  generation  of  HIFU 
delivery  timing.  They  describe  system  configuration  of  computer‐aided  automatic 
HIFU delivery,  automatic detection  of heartbeat  rates, position  of  the  atrial  septum 
and  other  procedural  details.  They  performed  a  feasibility  study  for  creation  of  an 
atrial  septal defect using  the beating heart of  four anesthetized adult  rabbits, which 
appear not  to  satisfactory. But,  the  authors  interpret  that  they were  able  to  confirm 
pinpoint  delivery  of HIFU  to  the  pulsating  atrial  septum within  beating  hearts  of 
anesthetized  adult  rabbits.  The  above  studies were  performed with  2D‐US.  Three‐
dimensional‐US  to  track movement  of  intrauterine  fetus may make  the  procedure 
more  accurate.  In  conclusion,  these  workers  developed  computer‐aided  automatic 
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delivery  system  of HIFU  for  creation  of  an  atrial  septal defect  and  further work  to 
improve  precision  of  the  focus  positioning  of HIFU  delivery  and  improvement  of 
HIFU energy efficiency to intracardiac tissue is in progress. The concept appears good 













devices  at his/her disposal  so  that  an  appropriate device  that  suits  best  for  a  given 
patient  and  his/her  defect  is  available. A  brief  review  of  historical  aspects  of  PFO 
closure was also included. Majority of the ASD devices described in the ASD section, 
as and when they became available, have also been used to close PFOs; these include 
King’s,  clamshell,  buttoned,  Das‐Angel‐Wing  and  CardioSEAL  devices.  Existing 
devices were modified to address the anatomic features of the foramen ovale or new 
devices  were  designed  to  specifically  address  the  PFOs  and  the  latter  include, 
Amplatzer  PFO  occluder,  Cardia  devices  (PFO‐Star  and  several  of  its  subsequent 
generations), Premere occluder, Coherex Flat stent, PFx Closure System (not a device 
but employs monopolar radio frequency energy to effect closure of a PFO by welding 
the  tissues of  the septum primum with  the septum secundum), pfm PFO‐R, Solysafe 
PFO occluder and others. Amplatzer cribriform device was also used on off‐label basis 
to close PFOs. 
In  the next  chapter, Biliciler‐Denktas, also  from our  institution, describes  the  role of 
transesophageal  echocardiography  (TEE)  in  percutaneous  closure  of ASDs.  Initially 
the  embryologic  development  of  the  atrial  septum  was  reviewed.  Currently  used 
imaging  techniques  during  device  implantation,  namely,  transthoracic 
echocardiography,  TEE,  intracardiac  echocardiography  (ICE)  and  real  time  three‐
dimensional transesophageal echocardiography (3D TEE) were reviewed and relative 
advantages and disadvantages of each of  these  techniques were discussed; TEE and 
ICE  are  the  two most  commonly  employed  techniques.  The  importance  of  defined 
protocols to evaluate the heart, the atrial septal defect and the septal rims is stressed. 
Evaluation  prior  to  device  implantation  include,  examination  of  the  entire  atrial 
septum and  its  surrounding  structures and exclusion of additional defects  that may 
render  the defect unsuitable  for closure; measurement of  the number and size of  the 
defect(s);  color Doppler  imaging  to  define  the  shunt,  left  to  right    or  right  to  left; 
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dimensions of the septal rims and measurement of balloon stretched diameter of  the 
defect (when a sizing balloon is used) and identification of other defects while balloon 
occluding  the defect. The  echo and  the  interventional physicians work as a  team  to 
decide on the device size to be used for closure of ASD/PFO. Monitoring of the device 
deployment and verifying for correct position of the device prior to device release are 
germane.  Post‐implantation  study  will  follow  to  detect  impingement  on  valves, 
obstruction to venous return and residual shunting. TEE is also useful in the detection 
of  complications  of  device  closure  such  as  device  dislodgement  and  pericardial 
effusion/tamponade.  The  author  concludes  that  TEE  is  of  utmost  value  during 
percutaneous  closure  of ASDs  and  PFOs  and  is  the  preferred  imaging modality  in 
most catheterization laboratories. 




TEE,  the  authors  advocate  ICE  to  guide device  closure  of ASDs  and PFOs  because 
general  anesthesia  is  not  needed,  risks  of  anesthesia  are  avoided  and  patient 
discomfort  after  the  procedure  is  reduced.  Ultrasound  tipped  catheters  became 
available during the 1950s and 1960s and progressed thru’ the current state of the art 
ICE  catheters.  several  types  of  ICE  catheters  from  different  manufacturers  are 
currently  available  and  include, UltraICE mechanical  single‐element  system  (Boston 
Scientific Corp), AcuNav system (Siemens from Biosense‐Webster), ClearICE system (St 






ICE protocol  involves  obtaining different  views  (home  view,  septal  view,  long  axis 
view and short axis view) along with fluoroscopic  images. Then ICE  imaging during 
each  step, namely, balloon  sizing, deployment of  left and  then  right disks and after 





conclude  that  ICE  along with  fluoroscopy will  improve  the  safety  and  outcome  of 
percutaneous closure of ASDs. 
In the next chapter, Sullebarger from Tampa, Florida, describes approaches to patients 
with  technically  challenging  issues  for  transcatheter  occlusion  of  ASDs  and  these 
include patients with poor femoral venous access,  large defects and multiple defects. 
They  also  discuss  minimally  invasive,  hybrid,  transthoracic  approach  when 
percutaneous delivery of a device is not possible. 
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delivery  system  of HIFU  for  creation  of  an  atrial  septal defect  and  further work  to 
improve  precision  of  the  focus  positioning  of HIFU  delivery  and  improvement  of 
HIFU energy efficiency to intracardiac tissue is in progress. The concept appears good 
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in  adults.  ASDs  in  adult  subjects  should  be  closed  at  presentation,  electively, 
irrespective  of  their  age.  Evidence  was  presented  to  indicate  that  untreated  ASD 
patients  tend  to have decreased event‐free  survival  rates when  compared  to normal 
population  and  surgical  closure  is  safe  and  effective with  high  event‐free  survival 
rates. ASD  closure also prevents  functional deterioration,  improves  cardiac  function 
and  increases  functional  capacity. Consequently  hemodynamically  significant  (right 
ventricular  volume  overload)  ASDs  in  adults  should  be  occluded  irrespective  of 
symptomatology. When  the effect of age at closure of ASD was examined,  the Mayo 




closure  is  safe  and  effective,  device  closure  has  less  morbidity,  lower  number  of 
complications, requires less hospital stay and is less expensive than surgery. Multiple 
devices  have  been  investigated  over  the  last  few decades,  but  only Amplatzer  and 
HELEX devices  received  FDA  approval  as  of  this  time. The Amplatzer  is useful  in 
most ASDs while  the HELEX  device  is  useful  in  small  and medium‐sized  defects. 
Surgical repair is largely reserved for ASDs with poor septal rims. ASDs could also be 
closed  surgically when  intra‐cardiac  repair  of  other  defects  is  contemplated.  Some 
procedural  details  were mentioned  with  particular  emphasis  on  the  need  for  test 







(≥  70  years)  by  pointing  out  increasing  prevalence  of  congenital  heart  disease  in 
general  and ASDs  in  particular  in  this  age  group. He  also  states  that mortality  of 
congenital heart disease in the aged is increasing during past few decades. The clinical 
features of ASD  in  the elderly are different  from  those  in children and young adults 
because  they  present  with  hemodynamic  abnormalities  such  as  pulmonary 
hypertension,  valvar  regurgitation,  congestive  heart  failure  and  left  ventricular 
diastolic  dysfunction,  atrial  arrhythmias  and  co‐morbidities,  such  as  hypertension, 
chronic obstructive  lung disease, coronary artery disease, kidney disease and others. 
The  author  emphasizes  that  there  are  only  a  few  studies  in  the  aged population  re 
functional results of catheter and surgical closure of ASD and reviews his experience 
with catheter closure of ASD in geriatric patients as well as long‐term outcome. Of the 
420 patients who had attempted  transcatheter closure of ASD at  their  institution, 30 
patients were older than 70 years. Their mean age was 75.8 ± 3.8 years with a range of 
70  and  85  years. Mean  ASD  diameter  was  20.3  ±  6.4 mm  and mean  pulmonary‐
systemic flow (Qp/Qs) was 2.4 ± 0.7. Test balloon occlusion of ASD with measurement 
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of pulmonary  arterial wedge pressure was performed  in  only  7 of  30  cases. Device 
implantation was successful in 28 (93%) of the 30 patients. Significant improvement of 
NYHA  functional  class  in  20  (74%)  of  the  27  patients,  significant  improvement  in 
plasma  BNP  level,  decreased  resting  heart  rate,  improvement  of  tricuspid 
regurgitation in 11 of 17 patients (65%) and cardiac remodeling with improvement in 
RVEDD/LVEDD  ratio  at  follow‐up were  observed.  The  author  concludes  that  their 
experience  in  the elderly patients, while small,  indicates  that  transcatheter closure of 
ASD  can be performed  safely  and  contributes  to  improvement of NYHA  functional 
class and encourages positive cardiac remodeling. 
In  the  Chapter  11, Numan  from  the University  of  Texas Medical  School, Houston 
discusses the role of ASD/PFO in migraine. The incidence of migraine is 13% and has 
adverse  affect  on  social  life  and  potential  for  development  of  neurological 
complications. The age of migraine attacks  is said to 20 to 64 years with the majority 
occurring  prior  to  the  age  of  30  years. Migraine with  aura,  also  known  as  “classic 
migraine”  is  seen  in  only  25%  cases.  There  is  an  increased  prevalence  of  PFOs  in 




the right  to  left shunt across  the PFO. The author reviews several studies examining 
the effect of occlusion of PFOs with devices; most single institutional, non‐randomized 
studies show  improvement  in migraine; this  improvement  is greater  in patients with 
aura.  However,  Migraine  Intervention  With  STARFlex  Technology  (MIST),  a 
randomized  prospective  study  with  patients  blinded  for  PFO  closure  did  not 
demonstrate  statistical difference between  the  two groups. The author offers  several 
objections to the interpretation of the study, but concludes that the MIST study raises 
questions  to be addressed  in  future  studies. However,  it may be  concluded  that  the 
majority of the studies show benefit to patients suffering from migraine with aura. 
In  the  last  chapter, Daraban  and  her  associates,  also  from  the University  of  Texas 
Medical  School,  Houston  discusses  transcatheter  occlusion  of  atrial  defects  for 
prevention of  recurrence of paradoxical embolism. Stroke  is  the  third most common 
cause of death  in  the United States. Cryptogenic  stroke,  consisting of 40% of  stroke 
population  may  be  related  paradoxical  embolism  via  PFO  or  ASD.  Therapeutic 
measures  for  secondary  prevention  in  this  patient  population  include  medical 
treatment  or  surgical/percutaneous  closure  of  the  PFO/ASD.  The  authors  describe 
embryology,  fetal  and  postnatal  changes  of  PFO.  The  authors  then  describe  the 
anatomy  and  associated  anomalies  such  as  atrial  septal  aneurysms  (ASA),  Chiari 




The  authors  briefly describe  the devices used  for  occlusion  of PFO  and describe  in 
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The  authors  briefly describe  the devices used  for  occlusion  of PFO  and describe  in 
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detail  the  procedure  of  closure  using  Amplatzer  PFO  Occluder.  A  number  of 
randomized clinical studies comparing medical treatment with closure of atrial defect 
are underway. The authors describe  the CLOSURE  I, REDUCE and RESPECT  trials. 
CLOSURE I, a randomized trial compared the safety and efficacy of percutaneous PFO 
closure with STARFlex device versus best medical therapy. During a two year follow‐
up,  the  rates of  stroke or  transient  ischemic  attack  (TIA) were no different between 






trials,  favor device closure,  it  is  likely  that percutaneous PFO closure can be used  to 
prevent recurrence of paradoxical embolism and stroke. 
Of the major types of atrial defects, namely ostium secundum, ostium primum, sinus 
venosus  and  coronary  sinus  ASDs  and  PFO,  ostium  primum,  sinus  venosus  and 
coronary  sinus  defects  usually  require  surgical  closure.  Such  surgery  may  be 
performed  at  about  3  to  4  years  of  age  or  if  they  present  later,  at  the  time  of 
presentation. Earlier surgery  is not necessary unless heart  failure  is present.   Ostium 
secundum ASDs  can be  successfully  closed with  transcatheter methodology and  the 
majority of the book addresses the issues related such technology. PFOs are ordinarily 
considered as normal variants, although, sometimes they become the seat of right left 
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General Review of Atrial Septal Defects 
1
Atrial Septal Defect – A Review 
P. Syamasundar Rao 
University of Texas at Houston Medical School, Houston, Texas, 
 USA 
1. Introduction 
Defects in the atrial septum cause left to right shunt because the left atrial pressure is higher 
than that in the right atrium. This causes volume overloading of the right ventricle. While 
this is generally well tolerated in infancy and childhood, development of exercise 
intolerance and arrhythmias in later childhood and adolescence, and the risk for 
development of pulmonary vascular obstructive disease in adulthood make these defects 
important. There are four major types of atrial septal defects (ASDs) and these include 
ostium secundum, ostium primum, sinus venosus and coronary sinus defects. The clinical 
features are essentially similar and I will present detailed discussion of ostium secundum 
and primum ASDs followed by brief presentation of the other two defects.  
Persistent patency of the foramen ovale in nearly one third of normal population makes the 
patent foramen ovale (PFO) a normal variant, although these become important in the 
presence of other structural abnormalities of the heart and when they become the seat of right 
to left shunt causing paradoxical embolism resulting in stroke/transient ischemic attacks or 
other problems, such as migraine, Caisson’s disease and platypnea-orthodexia syndrome. The 
issues related these types of PFOs will be briefed at the conclusion of this chapter. 
2. Secundum atrial septal defect 
Atrial septal defects constitute 8% to 13% of all congenital heart defects (CHDs). 
Pathologically, there is deficiency of the septal tissue in the region of fossa ovalis. These may 
be small to large. Most of the time, these are single defects, although, occasionally multiple 
defects and fenestrated defects can also be seen. Because of left-to-right shunting across the 
defects, the right atrium and right ventricle are dilated and somewhat hypertrophied. 
Similarly, main and branch pulmonary arteries are also dilated. Pulmonary vascular 
obstructive changes are not usually seen until adulthood. 
Mitral valve abnormalities, including mitral valve prolapse and mitral insufficiency may be 
seen in some patients. It is not clear whether these abnormalities are to due to right 
ventricular volume overloading or intrinsic abnormality of the mitral valve. Pulmonary 
valvar pressure gradients are seen frequently and are thought to be related to increased flow 
and/or differences in expression of kinetic and potential energies in the right ventricle and 
pulmonary artery (Rao et al 1973); however, true pulmonary stenosis is present in only 5% 
of ASD patients. Persistent left superior vena cava may be present in 10% patients. 
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2.1 Clinical features  
The clinical features are essentially similar in all types of ASDs mentioned in the 
Introduction section. 
2.1.1 Symptoms 
Isolated ASD patients are usually asymptomatic and are most often detected at the time of 
preschool physical examination. Sometimes these defects are detected when 
echocardiographic studies are performed for some unrelated reason. A few patients do 
present with symptoms of heart failure in infancy, although this is uncommon. 
2.1.2 Physical examination 
The right ventricular and right ventricular outflow tract impulses are increased and 
hyperdynamic. No thrills are usually felt. The second heart sound is widely split and fixed 
(splitting does not vary with respiration) and is the most characteristic sign of ASD. Ejection 
systolic clicks are rare with ASDs. The ejection systolic murmur of ASD is soft and is of 
grade I-II/VI intensity and rarely, if ever, louder. The murmur is secondary to increased 
blood flow across the pulmonary valve and is heard best at the left upper sternal border. A 
grade I-II/VI mid-diastolic flow rumble is heard (with the bell of the stethoscope) best at the 
left lower sternal border. This is due to large volume flow across the tricuspid valve. There 
is no audible murmur because of flow across the ASD. 
2.2 Noninvasive evaluation 
2.2.1 Chest x-ray  
Chest film usually reveals mild to moderate cardiomegaly, prominent main pulmonary 
artery segment and increased pulmonary vascular markings. 
 
Fig. 1. Chest x-ray in posterior-anterior view demonstrating mild cardiomegaly, increased 
pulmonary vascular markings and a slightly prominent main pulmonary artery segment as 
seen in patients with atrial septal defect. 
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2.2.2 Electrocardiogram  
The ECG shows mild right ventricular hypertrophy; the so-called diastolic volume overload 
pattern with rsR' pattern in the right chest leads. 
 
Fig. 2. An electrocardiogram demonstrating rsR’ pattern in right chest leads, the so called 
diastolic overloading pattern, indicative mild right ventricular hypertrophy, seen in patients 
with atrial septal defects. 
2.2.3 Echocardiogram  
Echocardiographic studies reveal enlarged right ventricle with paradoxical septal motion, 
particularly well-demonstrable on M-mode echocardiograms in patients with moderate to 
large ASDs. Dilatation of the right ventricle may not be present in small defects. By two-
dimensional echocardiogram, the defect can be clearly visualized (Figure 3 left panel).  
 
Fig. 3. Two dimensional subcostal echocardiographic views of the atrial septum 
demonstrating secundum atrial septal defect (ASD) in the mid septum (left panel) and color 
Doppler with left to right shunt (right panel). LA, left atrium; RA, right atrium. 
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The type of ASD, ostium secundum (Figure 3) versus ostium primum (Figure 4) can also be 
delineated by the echocardiographic study.  
 
Fig. 4. Four chambered view of the heart demonstrates ostium primum atrial septal defect 
(ASD), arrow. Note absence of any atrial septal tissue superior to the crest of the ventricular 
septum. The right atrium (RA) and right ventricle (RV) are enlarged. LA, left atrium; LV. left 
ventricle. 
Apical and precordial views may show "septal drop-outs” without an ASD because of 
thinness of the septum in the region of fossa ovalis. Therefore, subcostal views should be 
scrutinized for evidence of ASD. In addition, demonstration of flow across the defect with 
pulsed Doppler and color Doppler (Figure 3, right panel) echocardiography is necessary to 
avoid false positive studies. In adolescents and adults transesophageal echo (TEE) is needed 
to make definitive diagnosis of ASD. (Figures 5 and 6) 
 
Fig. 5. Selected two-dimensional and color flow frame from a transesophageal 
echocardiographic (TEE) study (in adult patient) of the atrial septum shows an atrial septal 
defect (arrow) with left to right shunt (blue flow). Measurements of septal margins (1 Dist and 
3 Dist) and of the defect (2 Dist) are shown in the insert. LA, left atrium; RA, right atrium. 
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Fig. 6. Selected two-dimensional and color flow frame from a transesophageal 
echocardiographic (TEE) study (in another adult patient) of the atrial septum shows multi-
fenestrated atrial septal defect (arrows) with left to right shunt (blue flow). LA, left atrium; 
RA, right atrium. 
2.2.4 Other imaging studies 
Other imaging studies such as three-dimensional echo, MRI and CT can and do demonstrate 
the defect, but are not necessary for routine cases. 
2.3 Catheterization and angiography 
Clinical and echocardiographic features are sufficiently characteristic so that cardiac 
catheterization is not necessary for the diagnosis. However, cardiac catheterization is an 
integral part of transcatheter occlusion of the ASD. 
When catheterization is performed, one will observe step-up in oxygen saturation at the 
right atrial level. The right ventricular or pulmonary arterial saturations may be better to 
estimate the degree of shunting because of improved mixing in these distal sites. The 
pulmonary venous, left atrial, left ventricular and aortic saturations are within normal 
range. In large defects, the pressures in both atria are equal while in small defects, an inter-
atrial pressure difference is noted. The right ventricular and pulmonary arterial pressures 
are usually normal during childhood. Calculated pulmonary-to-systemic flow ratio (Qp:Qs) 
is used to quantify the degree of shunting and a Qp:Qs in excess of 1.5:1 is considered an 
indication for closure of ASD. 
Selective cineangiography in the right upper pulmonary vein at its junction with the left 
atrium in a left axial oblique view will reveal location and the size of the ASD. When 
anomalous pulmonary venous connection is suspected, selective left or right pulmonary 
arterial angiography should be performed and the levophase of angiogram should be 
scrutinized for anomalous pulmonary venous connections.  
To avoid missing a diagnosis of partial anomalous pulmonary venous return, we usually 
perform a number of routine maneuvers and these include (i) measurement of oxygen 
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saturations from both right and left innominate veins at the time of superior vena caval 
sampling, (ii) left innominate vein cineangiogram in posterior-anterior view with diluted 
contrast material, (iii) probe for all the four pulmonary veins from the left atrium and (iv) as 
mentioned before, obtain cineangiography from the right upper pulmonary vein at its 
junction with the left atrium in a left axial oblique (300 LAO and 300 cranial) view. 
2.4 Management 
The management of ASD patients is largely dependent of the age at presentation, presence 
of symptoms, particularly those of congestive heart failure and the size of the defect (and 
magnitude of the shunt).  
2.4.1 Medical management 
As mentioned earlier, congestive heart failure is rare with ASDs, although occasionally, 
failure symptoms may be present in infancy. In these infants anti-congestive measures 
(diuretics and digoxin) should be instituted. If they do not improve, surgical and more 
recently trans-catheter intervention to close the defects are considered.  
Small ASDs, not requiring closure may be followed at infrequent intervals. SBE prophylaxis 
and activity restriction are not generally recommended for ASD patients. 
2.4.2 Indications for closure 
Despite lack of symptoms at presentation, closure of moderate to large ASDs is 
recommended so as to 1) prevent development of pulmonary vascular obstructive disease 
later in life, 2) reduce chances for supra-ventricular arrhythmias and 3) prevent 
development of symptoms during adolescence and adulthood. Elective closure around age 4 
to 5 years is recommended. Closure during infancy is not undertaken unless the infant is 
symptomatic. Right ventricular volume overloading by echocardiogram and a Qp:Qs >1.5 (if 
the child had cardiac catheterization) are indications for closure. 
2.4.3 Surgical management 
Following the introduction of cardiopulmonary bypass techniques for open heart surgery 
and the description of surgical closure of ASD by Gibbon, Lillehei and Kirklin in 1950s, it 
rapidly became a standard treatment for atrial defects. The conventional treatment of choice 
of moderate and large defects until recently is surgical correction. Under general anesthesia, 
a median sternotomy or a right submammary incision is made, the aorta and vena cavae are 
cannulated and the patient placed on cardiopulmonary bypass. Right atriatomy is made and 
the defect exposed and closed either by approximating the defect margins with suture 
material or by using a pericardial patch, depending upon the size of the defect. 
While surgical closure of ostium secundum ASDs is safe and effective with low (<1%) 
mortality, the morbidity associated with sternotomy/thoracotomy, cardiopulmonary bypass 
and potential for postoperative complications cannot be avoided. Other disadvantages of 
surgical therapy are the expense associated with surgical correction, residual surgical scar 
and psychological trauma to the patients and/or the parents. Because of these reasons 
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several trans-catheter methods have been developed (Chopra and Rao, 2000; Rao, 2003) 
which will be reviewed in the next section. 
At the present time, surgical repair is largely reserved for defects with poor septal rims in 
which the interventional cardiologist deems that defect is difficult to close with trans-
catheter methodology or was unsuccessful in closing the defect. Also, if intra-cardiac repair 
of other defects is contemplated, surgical closure of ASD could be performed at the same 
time. 
2.4.4 Trans-catheter closure 
As alluded to above, a large number of devices have been developed over the last three and 
one-half decades. Some of the devices have been discontinued and others modified and 
redesigned (Rao, 1998; Rao, 2000; Rao, 2003b). Clinical trials have been undertaken with a 
large number of devices as reviewed elsewhere (Rao, 2000; Rao, 2003b) and feasibility, safety 
and effectiveness of these devices in occluding the ASD have been demonstrated.  
Clinical trials have been undertaken in a large number of patients with Bard clamshell septal 
occluder and buttoned device and feasibility and effectiveness of these devices in occluding 
the ASD have been demonstrated. Fractures of one or more arms of the clamshell device 
with occasional embolization, has prompted the investigators and the US Food and Drug 
Administration (FDA) to withdraw the device from clinical trials. The buttoned device has 
undergone clinical trials and, immediate and short-term follow-up results are encouraging 
(Rao et al 1992, Rao et al 1994, Rao et al 2000, Rao and Sideris 2001). However, pre-market-
approval (PMA) application was not made and consequently it is not approved by the FDA 
and is not available for general clinical use. Subsequently, a large number of other devices 
(Das Angel-Wing, ASDOS, Amplatzer, CardioSeal, HELEX and others) have been 
introduced and clinical trials began (Chopra and Rao 2000). At the present time however, 
Amplatzer Septal Occluder and HELEX are the only two devices that are approved for 
general clinical use by the FDA. The experience with Amplatzer for most defects has been 
encouraging. HELEX device is only useful in small to medium-sized defects. A number of 
other devices are in clinical trials either in the US or in other countries with local, national or 
regional IRB supervision. These devices, to the best of my knowledge, are 
CardioSeal/StarFlex devices, transcatheter patch, pfm ASD-R device, bio-absorbable NMT 
devices (Bio-STAR and Bio-TREK), Occlutech Flex device, Cardia devices (INTRASEPT, 
ATRIASEPT I/II-ASD and ULTRASEPT), Solysafe Septal Occluder, Heart R Septal Occluder 
(manufactured in China) and others. The Amplatzer Septal Occluder is rapidly becoming 
the device of choice because of ease with which the device can be implanted, retrieved and 
repositioned plus the comfort that the device is FDA approved. 
2.4.4.1 Amplatzer septal occluder 
Amplatzer septal occluder is a double disk device constructed with 0.004" to 0.007" Nitinol 
(nickle-titanium compound) wire with shape memory. A 4 mm wide waist connects the left 
and right atrial disks and stents the ASD. The left atrial disk is slightly larger than the right. 
Dacron polyester patches are sewn into each disk. Multiple sizes are available from the 
manufacturer (AGA); the device size is expressed as the size of waist of the device. The 
device can be withdrawn into a delivery sheath and can be implanted across the defect and 
if necessary pulled back into the sheath and repositioned. 
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2.4.4.1.1 Method of device implantation 
The procedure involves percutaneous right heart catheterization to confirm the clinical and 
echocardiographic diagnosis with particular attention to exclude partial anomalous 
pulmonary venous return. A left atrial cineangiogram in a left axial oblique view (300 LAO 
and 300 Cranial) with the catheter positioned in the right upper pulmonary vein at its 
junction with the left atrium is then performed. This is followed by transesophageal (TEE) or 
intracardiac (ICE) echocardiography to measure the size of the ASD, to visualize entry of all 
pulmonary veins into the left atrium and to examine the atrial septal rims. Static balloon 
sizing of the ASD using NuMed PTS or AGA Amplatzer sizing balloons is performed 
routinely by some cardiologists. During balloon occlusion, color Doppler evaluation of the 
atrial septum to rule out additional atrial defects should be carried out. However, I do not 
routinely perform balloon sizing, but rely on the TEE sizing; I utilize the thick margins of 
the defect to measure the size of the ASD, leaving out the flail margins, a method similar to 
that suggested by Carcagnì and Presbitero (2004). 
An Amplatzer Septal Occluder that is 1 to 2 mm larger than the diameter of the ASD is 
selected for implantation. The size of delivery sheath accommodating the selected device is 
then be positioned in the left upper pulmonary vein, taking appropriate precautions to 
avoid inadvertent air entry into the system. The selected device is screwed onto the delivery 
cable; the device is loosened by unscrewing by one turn and drawn into the loader sheath 
under saline. The device is deposited into the delivery sheath while flushing the loader 
sheath continuously with saline or a similar flushing solution. This is to prevent inadvertent 
air entry into the system. The device is advanced within the sheath under fluoroscopic 
guidance until it reaches the tip of the delivery sheath in the left upper pulmonary vein. It is 
important not to rotate the delivery cable to prevent inadvertent unscrewing of the device. 
The entire system is withdrawn until the tip of the sheath slips into the free left atrium and 
the device advanced, thus releasing the left atrial disk. Under echocardiographic guidance, 
the entire system is withdrawn such that the left atrial disk is flush against the left atrial side 
of the atrial septum occluding the ASD. Then, while the device cable is held steady, the 
delivery sheath is withdrawn releasing the waist of the device within the atrial septal defect, 
followed by further withdrawal of the sheath deploying the right atrial disk in the right 
atrium. The position of the device is verified by echocardiography and residual shunt 
looked for. If the device position is satisfactory, the device cable is moved back and forth (so 
called Minnesota Wiggle). The position of the device is again verified by TEE (or ICE). If the 
device position is unsatisfactory, the device can be withdrawn into the sheath and 
redeployed. Then the device cable is rotated counterclockwise, releasing the device. A 
repeat TEE to ensure good position of the device is undertaken. Right atrial 
cineangiography through the delivery sheath is performed by some cardiologists prior to 
withdrawal of the delivery sheath out of body.  
Arterial line to monitor the systemic pressures throughout the procedure, administration of 
heparin (100 units/kg) and monitoring the ACT to keep it above 200 seconds, and 
administration of Ancef or a similar antibiotic are routine parts of the procedure. Aspirin 5 
mg/kg as a single daily dose for six months is usually recommended. Clopidogrel (Plavix) is 
used in adult patients. 
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2.4.4.1.2 Complex defects 
Large defects, small septal rims, multiple defects and septal aneurysms pose additional 
problems and appropriate adjustments in the technique (Nagm and Rao 2004) should be 
undertaken to ensure success of the device implantation. 
2.4.4.1.3 Results 
Both immediate and mid-term follow-up results of Amplatzer Septal Occluder appear 
excellent with immediate complete closure rates varying from 62% to 96% which improved to 
83% to 99% at six to 12 month follow-up (Hamdan et al 2003). We undertook closure of 80 
ostium secundum defects with this device; there was a small residual shunt in two patients at 
the conclusion of the procedure. This shunt disappeared at one and six month follow-up visits 
respectively. No residual shunts were observed during a mean follow-up of 24 months. 
2.4.4.2 HELEX device 
HELEX device is constructed with a single stand super-elastic, Nitinol wire frame with 
ultrathin poly-tetra-fluro-ethelene (ePTFE) covering the entire length of the wire; the device 
can be loaded into a 9-F delivery sheath. The delivery system has three components, a 
delivery catheter, control catheter and a mandrel. When deployed, it forms two 
interconnected round disks, designed to be placed on either side of the atrial septum. The 
device is available in 15 thru' 35 mm diameter sizes in 5 mm increments.  
2.4.4.2.1 Method of device implantation 
The procedures of catheterization and defect sizing are similar those described in Amplatzer 
device section. The method of implantation is detailed elsewhere (Latson et al 2003). In brief, 
the delivery catheter (Green) is placed in the left atrium over a guide wire and the wire 
removed. Push-pinch-pull method is used to form the left atrial disk and the disk pulled 
back gently to engage the left side of the atrial septum, under fluoroscopic and/or TEE or 
ICE guidance. Then the delivery (Green) catheter is withdrawn over the control (Gray) 
catheter until the mandrel (Tan) engages the hub. Then the green catheter is held study 
while the gray catheter is advanced to deliver the right atrial disk on the right atrial side of 
the septum, again using the "push-pinch-pull" technique. Once the device position is 
verified by echocardiography (TEE or ICE), the device is locked and then released. Intra and 
post procedural management is similar to that described in the Amplatzer device section.  
2.4.4.2.2 Results 
Results of the multicenter trial (Jones et al 2007) suggest successful implantation in 87% 
patients with low incidence of residual leaks (2.6% at one year follow-up) and modest 
incidence (8%) of wire frame fractures. It is generally considered to be a good device for 
occlusion of small to medium-sized ASDs. 
2.5 Prognosis 
The prognosis following surgical or transcatheter closure of ASDs is excellent, provided that 
they do not have pulmonary hypertension or atrial tachycardia. Actuarial survival rate 
following surgery were 97%, 90%, 83% and 74% at 5, 10, 20 and 30 years respectively 
(Murphy et al 1990) and were slightly worse than that of control (normal) population (99%, 
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98%, 94% & 85%). However, if surgical correction is performed prior to 25 years of age, the 
actuarial survival rates are similar to normal population. Similar favorable results can be 
expected if the defect is closed by trans-catheter methodology prior to 25 years of age. 
3. Ostium primum ASDs 
Ostium primum ASDs belong to the group of defects called atrio-ventricular septal defects 
(AVSDs) and are thought to be caused by defective embryonic development of embryonic 
endocardial cushions. There is persistence of the embryonic ostium primum, located in the 
posterior portion of the lower part of the atrial septum, usually large in size. A cleft in the 
anterior leaflet of the mitral valve is present, causing mitral insufficiency of varying degree. 
Depending upon the direction of mitral insufficiency jet, there may be a left ventricular-to-
right atrial shunt as well. A cleft in the septal leaflet of the tricuspid valve may be present in 
some patients. These defects are formerly known as partial endocardial cushion defects. 
These defects are also called partial AVSDs; this is in contradistinction to complete AVSDs 
in which atrial and ventricular septal defects and clefts in the mitral and tricuspid valves 
with common atrio-ventricular valve are present. There may be associated ostium 
secundum ASD, patent foramen ovale or a persistent left superior vena cava draining into 
the coronary sinus. 
The left ventricular outflow tract is long and narrow and sometimes the abnormal 
attachments of the atrio-ventricular valve tissue may cause left ventricular outflow tract 
obstruction. 
Dilatation of the right heart structures is similar to that described for ostium secundum 
atrial septal defects. In the presence moderate to severe mitral insufficiency left ventricular 
dilatation may also be present. 
3.1 Clinical features  
The clinical features are essentially similar to that described for ostium secundum ASDs; 
however in the presence of significant mitral insufficiency symptoms of heart failure may be 
present.  
3.1.1 Symptoms 
Isolated ostium primum ASD patients are usually asymptomatic and are most often 
detected at the time of preschool physical examination. However, murmurs associated with 
mitral insufficiency of ostium primum defects may also result in early detection of these 
defects. A few patients do present with symptoms of heart failure in infancy or childhood 
especially in the presence of significant mitral insufficiency. 
3.1.2 Physical examination 
The right ventricular and right ventricular outflow tract impulses are increased and 
hyperdynamic. No thrills are usually felt. The second heart sound is widely split and fixed 
(splitting does not vary with respiration) and is the most characteristic sign of ASD. Ejection 
systolic clicks are rare with ASDs. The ejection systolic murmur of ASD is soft and is of 
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grade I-II/VI intensity and rarely, if ever, louder. The murmur is secondary to increased 
blood flow across the pulmonary valve and is heard best at the left upper sternal border. A 
grade I-II/VI mid-diastolic flow rumble is heard (with the bell of the stethoscope) best at the 
left lower sternal border. This is due to large volume flow across the tricuspid valve. There 
is no audible murmur because of flow across the ASD. A holosystolic murmur of mitral 
insufficiency is heard best at the apex with radiation into the anterior and/or mid axillary 
line. A grade I-II/VI mid-diastolic flow rumble, heard best at the apex may be appreciated 
in the presence significant mitral insufficiency. Signs of heart failure may be present in cases 
with severe mitral insufficiency. 
3.2 Noninvasive evaluation 
3.2.1 Chest x-ray  
Chest film usually reveals mild to moderate cardiomegaly, prominent main pulmonary 
artery segment and increased pulmonary vascular markings. In the presence of significant 
mitral insufficiency, the cardiomegaly may be more prominent. 
3.2.2 Electrocardiogram  
Prolongation of PR interval (first degree heart block) is commonly seen. Right atrial, left 
atrial or biatrial enlargement is seen nearly half of the patients. The ECG also shows mild 
right ventricular hypertrophy; the so-called diastolic volume overload pattern with rsR' 
pattern in the right chest leads. Left ventricular hypertrophy may be seen if there is 
significant mitral insufficiency. Characteristically, the mean frontal plane vector is oriented 
superiorly between -300 and -900, the so called left axis deviation and this is typical for 




Fig. 7. An electrocardiogram of a child with ostium primum atrial septal defect 
demonstrating left axis deviation (-450 - deep S waves in leads II, III and AVF), right atrial 
enlargement (tall P waves in leads I and V2) and right ventricular hypertrophy (tall R waves 
in lead V2 and deep S waves in leads V5 and V6). 
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3.2.3 Echocardiogram  
Echocardiographic studies reveal enlarged right ventricle with paradoxical septal motion, 
particularly well-demonstrable on M-mode echocardiograms in patients with moderate to 
large ASDs. By two-dimensional echocardiogram, the defect can be clearly visualized 
(Figure 4). The type of ASD, secundum versus primum can also be delineated by the 
echocardiographic study (Figure 3 & 4). Demonstration of flow across the defect with color 
Doppler (Figure 8) echocardiography is possible. Cleft in the mitral valve may be 
demonstrated in precordial short axis views and mitral insufficiency jet may be shown in 
four chamber views (Figure 8). 
 
 
Fig. 8. Four chambered view of the heart demonstrates left-to-right shunt (red flow) across 
the ostium primum atrial septal defect (short arrow). Also note mitral insufficiency  
(long arrow).  
3.2.4 Other imaging studies 
Other imaging studies such as three-dimensional echo, MRI and CT may also demonstrate 
the defects, but are not necessary for routine cases. 
3.3 Catheterization and angiography 
Clinical and echocardiographic features are characteristic for the defect and cardiac 
catheterization is not necessary for the diagnosis. If pulmonary hypertension is suspected or 
if there are issues that can't be resolved by echocardiography, catheterization may be 
undertaken. 
If catheterization is performed, step-up in oxygen saturation at the right atrial level is seen. 
The left heart saturations are within normal range. Because the defects are usually large, the 
mean pressures in both atria are equal. The right ventricular and pulmonary arterial 
pressures are usually normal during childhood. The left heart pressures are also normal 
unless there is left ventricular outflow tract obstruction. Calculated pulmonary-to-systemic 
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flow ratio (Qp:Qs) is used to quantify the degree of shunting and the Qp:Qs is usually in 
excess of 2:1. Pulmonary vascular resistance is usually normal. 
Selective left ventricular cineangiography reveals a long and narrow left ventricular outflow 
tract resulting in what is described as goose-neck deformity, characteristic of endocardial 
cushion defects.  
3.4 Management 
The management of ostium primum ASD patients is largely dependent of the age at 
presentation and presence of symptoms, particularly those of congestive heart failure.  
3.4.1 Medical management 
Congestive heart failure is rare with ostium primum ASDs, although failure symptoms may 
be present in the presence of significant mitral insufficiency. In these patients anti-
congestive measures (diuretics and digoxin) should be instituted. If they do not improve, 
surgical closure should be considered. 
Transcatheter occlusion, now a standard treatment for ostium secundum ASDs, is not 
feasible in patients with ostium primum ASDs because there are no inferior septal rims, but 
more importantly because the need for addressing mitral valve cleft and the accompanying 
mitral insufficiency. 
SBE prophylaxis is recommended and normal activity is permitted in the absence of severe 
mitral insufficiency.  
3.4.2 Indications for closure 
Although surgical correction can be performed at any age, surgery in asymptomatic patients 
is usually recommended at the age of 3 to 4 years. In the presence of symptoms or if there is 
associated severe mitral insufficiency, surgical repair may be performed at presentation, 
after medically controlling the heart failure.  
3.4.3 Surgical management 
The conventional treatment of choice of ostium primum ASDs is surgical correction. Under 
general anesthesia, a median sternotomy incision is made, the aorta and vena cavae are 
cannulated and the patient placed on cardiopulmonary bypass. Right atriotomy is made and 
the defect and mitral valve are exposed. Closure of the mitral valve cleft with interrupted 
suture material and additional reparative procedures to address observed mitral valve 
abnormalities (for example, annuloplasty) should be undertaken. Then the atrial defect is 
closed using an autologous pericardial patch and rarely other prosthetic material (Dacron or 
Gore-Tex). Associated ostium secundum ASD or a patent foramen ovale should also be 
surgically closed at the same sitting. 
3.4.4 Results 
Results are generally good with a mortality rate less than 3%. The risk factors for poor 
results are severe mitral insufficiency, failure to thrive and congestive heart failure.  
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3.5 Prognosis 
The prognosis is generally good. The actuarial survival at 20- and 40-year follow-up was 
87% and 76% respectively for a large group of patients that had repair of ostium primum 
ASDs at Mayo Clinic (El-Najdawi et al 2000). The survival was better if the mitral valve 
repair was performed prior to 20 years of age. Repeat surgery, mostly to address mitral 
valve disease was required in 11% patients. Development of sub-aortic stenosis and heart 
block, requiring intervention occurs in a minority of patents during long-term follow-up. 
4. Sinus venosus ASDs 
Sinus venosus defects constitute 5 to 10% of all ASDs and the majority of defects are located 
in the posterior superior portion of the inter-atrial septum, often overriding the superior 
vena caval orifice. These defects are frequently associated with anomalous connection of the 
right upper pulmonary veins to the superior vena cava or right atrium near the cavo-atrial 
junction. The right pulmonary veins from the entire right lung may be connected 
anomalously. Rarely, the defect may be located in the inferior-posterior part of the atrial 
septum, overriding the inferior vena caval orifice. The dilatation of right heart structures is 
similar to that described in ostium secundum ASDs as are the clinical features. The ECG, in 
addition to the findings of rsR' pattern of the QRS complex shows somewhat superiorly 
oriented P wave vector (<300). Echocardiogram shows right ventricular volume overloading, 
similar to ostium secundum ASDs, but without an obvious ASD in the secondum position. 
Subcostal views may show the defect. Turbulence in the right upper pulmonary veins may 
also help suspect this diagnosis. The indications for intervention are also similar to those 
discussed in the ostium secundum ASD section. However, these defects are not amenable to 
transcatheter closure and surgical correction is the treatment of choice. Diversion of the 
anomalously connected right pulmonary vein(s) into the left atrium along with the closure 
of the ASD should be undertaken. This may involve constructing a tunnel with an 
autologous pericardial patch along with enlargement of superior vena cava. 
5. Coronary sinus ASDs 
These are rarest types of ASDs; these are defects in the inferior and anterior portion of the 
atrial septum at the expected location of the orifice of the coronary sinus. These defects are 
often associated with a persistent left superior vena cava and unroofing of the coronary 
sinus, a complex described as Raghib syndrome. The defect may be seen in association with 
asplenia syndrome. Dilatation of right heart structures and clinical features are similar to 
that described in ostium secundum ASD section. Echocardiogram is useful in the evaluation 
and diagnosis of this anomaly. Surgical correction with patch closure of the defect, leaving 
the entry of coronary sinus in the left atrium is the conventional method of approach (Lee 
and Sade 1979). These defects are not usually amenable to transcatheter closure. However, 
some, particularly small, defects may be amenable to transcatheter occlusion (Di Bernardo et 
al 2003) 
6. Patent foramen ovale 
To complete the discussion of defects in the atrial septum, a brief review of PFO is in order. 
The foramen ovale in the fetus is kept patent because of the mechanical effect of streaming 
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of the inferior vena caval blood into the left atrium. At birth, a combination of increase in the 
left atrial pressure secondary to increased pulmonary venous return and decrease in the 
right atrial pressure due to eliminated placental return will result in apposition of the 
septum primum and septum secundum causing functional closure of the foramen ovale. 
Eventually anatomical closure occurs in most normal individuals.  
Continued patency of the foramen ovale is critical in neonates with right heart obstructive 
lesions (tricuspid or pulmonary atresia) as well as left-sided obstructive lesions (hypoplastic 
left heart syndrome and mitral or aortic atresia) so as to allow an obligatory right-to-left or 
left-to-right shunt across the atrial septum, respectively. Similarly the patency of the 
foramen ovale is important in total anomalous pulmonary venous connection where all 
pulmonary and systemic venous returns come into the right atrium and consequently the 
systemic blood flow is entirely derived from right-to-left shunting across the PFO. In 
neonates with transposition of the great arteries (TGA), the circulation is parallel (instead of 
normal in-series circulation) and some inter-circulatory mixing is essential for survival; this 
is usually provided by the ASD/PFO. With any of the above scenarios the foramen ovale 
can become restrictive and may need enlargement either by transcatheter or surgical 
methodology (Rao 2007). 
In patients with large patent ductus arteriosus (PDA) or ventricular septal defect (VSD), the 
pulmonary blood flow is markedly increased with consequent increase in the left atrial size; 
this left atrial enlargement may cause stretching of the patent foramen ovale resulting in an 
additional left-to-right atrial shunting. However, in clinical practice, the clinician needs to 
address the primary cardiac problem (PDA or VSD) and the PFO will either spontaneously 
resolve or become small so that it may not remain clinically significant.  
The prevalence of PFO, based on autopsy studies is 27%; this incidence was 34% in the first 
thirty years of life which decreased to 25% in 30 to 80 year-olds which further decreased to 
20% in 80 to 100-year-olds (Hagen 1984). Similar prevalence was observed by TEE 
examinations. Consequently the PFO should be considered a normal variant. However, 
some these PFOs are considered to be the seat of right to left shunt causing paradoxical 
embolism and cerebrovascular accidents (Lechat et al 1988, Webster et al 1988, Ende et al 
1996, Windecker and Meier 2003) and hypoxemia as seen in platypnea-orthodeoxia 
syndrome (Waight  et al 2000, Rao et al 2001). Right to left shunt thru’ PFO can also occur in 
patients who were previously treated for complex congenital cardiac anomalies (Rao et al 
1997), including Fontan fenestrations as well as in patients who had right ventricular 
infarction (Bassi et al 2005). Decompression (Caisson’s) illness (Wilmshurst et al 1996, Walsh 
et al 1999, Wilmshurst et al 2000) and migrane (Wilmshurst et al 2000) have also been 
attributed to right to left shunt across PFO. There is varying degrees of evidence regarding 
the benefits of transcatheter occlusion of PFOs in above described conditions; some of these 
issues are addressed in later chapters of this book. 
7. Summary and conclusions 
In this review, the clinical features and management of ASDs are discussed. Four types of 
defects namely, ostium secondum, ostium primum, sinus venosus and coronar sinus ASDs 
are included. Patients with small defects, especially in childhood, are usually asymptomatic 
while moderate to large defects in infancy, though rarely, may present with symptoms. 
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3.5 Prognosis 
The prognosis is generally good. The actuarial survival at 20- and 40-year follow-up was 
87% and 76% respectively for a large group of patients that had repair of ostium primum 
ASDs at Mayo Clinic (El-Najdawi et al 2000). The survival was better if the mitral valve 
repair was performed prior to 20 years of age. Repeat surgery, mostly to address mitral 
valve disease was required in 11% patients. Development of sub-aortic stenosis and heart 
block, requiring intervention occurs in a minority of patents during long-term follow-up. 
4. Sinus venosus ASDs 
Sinus venosus defects constitute 5 to 10% of all ASDs and the majority of defects are located 
in the posterior superior portion of the inter-atrial septum, often overriding the superior 
vena caval orifice. These defects are frequently associated with anomalous connection of the 
right upper pulmonary veins to the superior vena cava or right atrium near the cavo-atrial 
junction. The right pulmonary veins from the entire right lung may be connected 
anomalously. Rarely, the defect may be located in the inferior-posterior part of the atrial 
septum, overriding the inferior vena caval orifice. The dilatation of right heart structures is 
similar to that described in ostium secundum ASDs as are the clinical features. The ECG, in 
addition to the findings of rsR' pattern of the QRS complex shows somewhat superiorly 
oriented P wave vector (<300). Echocardiogram shows right ventricular volume overloading, 
similar to ostium secundum ASDs, but without an obvious ASD in the secondum position. 
Subcostal views may show the defect. Turbulence in the right upper pulmonary veins may 
also help suspect this diagnosis. The indications for intervention are also similar to those 
discussed in the ostium secundum ASD section. However, these defects are not amenable to 
transcatheter closure and surgical correction is the treatment of choice. Diversion of the 
anomalously connected right pulmonary vein(s) into the left atrium along with the closure 
of the ASD should be undertaken. This may involve constructing a tunnel with an 
autologous pericardial patch along with enlargement of superior vena cava. 
5. Coronary sinus ASDs 
These are rarest types of ASDs; these are defects in the inferior and anterior portion of the 
atrial septum at the expected location of the orifice of the coronary sinus. These defects are 
often associated with a persistent left superior vena cava and unroofing of the coronary 
sinus, a complex described as Raghib syndrome. The defect may be seen in association with 
asplenia syndrome. Dilatation of right heart structures and clinical features are similar to 
that described in ostium secundum ASD section. Echocardiogram is useful in the evaluation 
and diagnosis of this anomaly. Surgical correction with patch closure of the defect, leaving 
the entry of coronary sinus in the left atrium is the conventional method of approach (Lee 
and Sade 1979). These defects are not usually amenable to transcatheter closure. However, 
some, particularly small, defects may be amenable to transcatheter occlusion (Di Bernardo et 
al 2003) 
6. Patent foramen ovale 
To complete the discussion of defects in the atrial septum, a brief review of PFO is in order. 
The foramen ovale in the fetus is kept patent because of the mechanical effect of streaming 
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of the inferior vena caval blood into the left atrium. At birth, a combination of increase in the 
left atrial pressure secondary to increased pulmonary venous return and decrease in the 
right atrial pressure due to eliminated placental return will result in apposition of the 
septum primum and septum secundum causing functional closure of the foramen ovale. 
Eventually anatomical closure occurs in most normal individuals.  
Continued patency of the foramen ovale is critical in neonates with right heart obstructive 
lesions (tricuspid or pulmonary atresia) as well as left-sided obstructive lesions (hypoplastic 
left heart syndrome and mitral or aortic atresia) so as to allow an obligatory right-to-left or 
left-to-right shunt across the atrial septum, respectively. Similarly the patency of the 
foramen ovale is important in total anomalous pulmonary venous connection where all 
pulmonary and systemic venous returns come into the right atrium and consequently the 
systemic blood flow is entirely derived from right-to-left shunting across the PFO. In 
neonates with transposition of the great arteries (TGA), the circulation is parallel (instead of 
normal in-series circulation) and some inter-circulatory mixing is essential for survival; this 
is usually provided by the ASD/PFO. With any of the above scenarios the foramen ovale 
can become restrictive and may need enlargement either by transcatheter or surgical 
methodology (Rao 2007). 
In patients with large patent ductus arteriosus (PDA) or ventricular septal defect (VSD), the 
pulmonary blood flow is markedly increased with consequent increase in the left atrial size; 
this left atrial enlargement may cause stretching of the patent foramen ovale resulting in an 
additional left-to-right atrial shunting. However, in clinical practice, the clinician needs to 
address the primary cardiac problem (PDA or VSD) and the PFO will either spontaneously 
resolve or become small so that it may not remain clinically significant.  
The prevalence of PFO, based on autopsy studies is 27%; this incidence was 34% in the first 
thirty years of life which decreased to 25% in 30 to 80 year-olds which further decreased to 
20% in 80 to 100-year-olds (Hagen 1984). Similar prevalence was observed by TEE 
examinations. Consequently the PFO should be considered a normal variant. However, 
some these PFOs are considered to be the seat of right to left shunt causing paradoxical 
embolism and cerebrovascular accidents (Lechat et al 1988, Webster et al 1988, Ende et al 
1996, Windecker and Meier 2003) and hypoxemia as seen in platypnea-orthodeoxia 
syndrome (Waight  et al 2000, Rao et al 2001). Right to left shunt thru’ PFO can also occur in 
patients who were previously treated for complex congenital cardiac anomalies (Rao et al 
1997), including Fontan fenestrations as well as in patients who had right ventricular 
infarction (Bassi et al 2005). Decompression (Caisson’s) illness (Wilmshurst et al 1996, Walsh 
et al 1999, Wilmshurst et al 2000) and migrane (Wilmshurst et al 2000) have also been 
attributed to right to left shunt across PFO. There is varying degrees of evidence regarding 
the benefits of transcatheter occlusion of PFOs in above described conditions; some of these 
issues are addressed in later chapters of this book. 
7. Summary and conclusions 
In this review, the clinical features and management of ASDs are discussed. Four types of 
defects namely, ostium secondum, ostium primum, sinus venosus and coronar sinus ASDs 
are included. Patients with small defects, especially in childhood, are usually asymptomatic 
while moderate to large defects in infancy, though rarely, may present with symptoms. 
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Physical findings include hyperdynamic precordium, widely split and fixed second heart 
sound, ejection systolic murmur at the left upper sternal border and a mid-diastolic flow 
rumble at the left lower sternal border. Clinical diagnosis is not usually difficult and the 
diagnosis can be confirmed and quantified by non-invasive echocardiographic studies. 
Whereas surgical intervention was used in the past, transcatheter methods are currently 
used for closure of ostium secondum ASDs. Surgical correction is usually necessary for the 
other three types of defects.  
PFO is present in nearly one third of normal population and is likely to be a normal variant. 
In the presence of some structural abnormalities of the heart, their presence may facilitate 
intra-cardiac shunt to allow appropriate egress and/or mixing of blood flow. PFOs, 
presumed to be the seat of paradoxical embolism resulting in stroke/transient ischemic 
attacks deserve special consideration. Hypoxemia in post-surgical residual defects including 
Fontan fenestrations and right ventricular infarction may be secondary to right to left shunt 
across PFO. Other problems such as migraine, Caisson’s disease and platypnea-orthodexia 
syndrome are also attributed to shunts across PFO. Evidence for benefit of transcatheter 
occlusion of these PFOs is variable.  
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1. Introduction 
Success of surgical repair of congenital heart defects in the past five decades has enabled 
survival into adulthood. Women born with congenital heart diseases reach child-bearing age 
with or without surgical repair of those lesions. Specifically, atrial septal defect (ASD) is a 
non-lethal, acyanotic lesion in which survival into adulthood with or without surgery is 
common place. Types of ASD and hemodynamics have been discussed elsewhere in this 
book. Briefly, ASD causes left to right shunting leading to right atrial and right ventricular 
enlargement and increased pulmonary blood flow. Heart failure is uncommon before 4th 
decade. Mild pulmonary arterial hypertension may occur with advancing age. However, 
Eisenmenger’s syndrome is rare. 
Presence of ASD may be diagnosed for the first time during adulthood – probably during 
pregnancy when an asymptomatic murmur is evaluated using echocardiography. 
Pregnancy causes cardiovascular changes due to fetal demand for oxygen and nutrition and 
due to effect of maternal hormones on blood volume and hematocrit. In this chapter, effects 
of these cardiovascular changes on ASD hemodynamics and effect of ASD on the pregnancy 
will be discussed. Management strategies will be reviewed. 
2. Physiologic changes during pregnancy 
2.1 Cardiovascular changes 
Physiologic demands of pregnancy lead to significant changes in cardiovascular system 
during pregnancy, labor and postpartum (Strong et al. 1992). Cardiac output increases 
constantly in the first 30 weeks of pregnancy reaching ~140% of the pre-gestational level. After 
30 weeks, the increase is minimal. Initially, stroke volume increases more than the heart rate. 
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of these cardiovascular changes on ASD hemodynamics and effect of ASD on the pregnancy 
will be discussed. Management strategies will be reviewed. 
2. Physiologic changes during pregnancy 
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constantly in the first 30 weeks of pregnancy reaching ~140% of the pre-gestational level. After 
30 weeks, the increase is minimal. Initially, stroke volume increases more than the heart rate. 
In later part of pregnancy, heart rate increases. There is a 10-fold increase in blood flow to 
placenta and uterus during pregnancy. Since placenta offers very low vascular resistance, 
maternal systemic vascular resistance decreases. A reduction in left ventricular afterload 
occurs (Metcalfe & Ueland 1974). A corresponding increase in cardiac output occurs during 
the same period, keeping blood pressure stable in spite of the reduction in afterload. 
Overall, circulatory changes can be summarized as follows: Increase in stroke volume by 18-
25% with heart rate increase by 20%. Net effect of this is a 30-50% increase in cardiac output. 
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There is increased extraction of oxygen by the placenta leading to increase in arterio-venous 
difference of oxygen content. Both systemic and pulmonary vascular resistance decrease. 
However, the reduction in systemic vascular resistance is higher leading to decrease in left 
to right shunting across ASD. Systemic blood pressure shows a reduction in both systolic 
and diastolic pressure with a higher reduction in diastolic pressure, thus leading to a wide 
pulse pressure. (Perloff, JK et al.1992). 
2.2 Respiratory changes 
Concurrent to cardiovascular changes, changes occur in the respiratory system as well. 
There is a 45% increase in minute ventilation and 20% increase in oxygen consumption. 
There is a mild increase in respiratory rate. Functional residual capacity increases by 
approximately 40% (Perloff, JK et al. 1992). 
2.3 Hematologic changes 
Due to hormonal changes, blood volume increases to about 150% of the pre-gestational 
value (Figure 1). This is accomplished by increase in plasma volume out of proportion to the 
increase in red cell mass. Therefore, “physiologic” anemia occurs which in turn imposes a 





Fig. 1. Hematologic changes during pregnancy. Changes in blood volume, red cell mass 
(RBC mass) and hematocrit occur during pregnancy. RBC mass increases only 
approximately 110% while blood volume increases by approximately 150% resulting in 
“physiologic” anemia of pregnancy. (Figure adapted from Strong et al. 1992). 
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Greatest demand on the cardiovascular system occurs after 30 weeks of gestation. This is 
usually tolerated well in woman with normal heart or mild heart disease before conception 
(New York Heart Association Functional Class I and II) because the demand increases 
gradually. Increasing fetal demand of oxygen is met with increasing placental blood flow 
and slight increase in maternal hyperventilation in late pregnancy (Pitkin et al. 1990). 
2.4 Changes in last trimester and labor 
During the last trimester, enlarging uterus compresses the inferior vena cava (IVC) 
especially in supine posture resulting in two effects. One, decrease in venous return 
leading to decrease in cardiac output in supine posture. Second, predisposition to deep 
vein thrombosis in lower part of the body by creating sluggish circulation. (Metcalfe 
1978). 
During labor, significant changes occur in a short period of time. In first stage of labor, 
uterine contractions lead to compression of IVC and decrease in venous capacitances and 
increase in systemic vascular resistance. This leads to reduction in cardiac output during 
uterine contractions. However, when the uterus relaxes the cardiac output increases back to 
pre-contraction levels. In second stage of labor, cardiac output increases significantly due to 
vigorous expulsive effort. (Ueland & Metcalfe 1975).  
After delivery, removal of placenta leads to increase in systemic vascular resistance. Blood 
loss during labor is a stress on the heart. Equally important is the fact that several hormonal 
stimuli that occur during pregnancy are receding during postpartum, leading to return of 
blood volume, hematocrit and cardiac output to pre-conception levels. 
3. Effect of pregnancy on ASD 
Hemodynamic changes outlined above will affect the hemodynamics of ASD. In a study of 
54 pregnant women with ASD, an increase in right atrial and right ventricular size was 
found, more than the control group of pregnant women who did not have any heart defect. 
Indirect parameters of right ventricular strain were worse and estimated proportion of 
pulmonary blood flow to systemic blood flow was lower. There was a higher incidence of 
supraventricular tachycardia during pregnancy in women with ASD. ( Peisiewicz et al. 
2004).  
Higher incidence of thromboembolism during pregnancy due to venous stasis in the lower 
part of the body and hypercoagulable state due to high progesterone level was detected. 
Increased respiratory effort during pregnancy from hemodynamic changes and anemia, and 
straining during parturition increase the chances of paradoxical embolism.  These risks have 
been reported in several cases in the literature and raise the issue of whether closure of ASD 
during pregnancy is indicated. 
4. Effect of ASD on pregnancy 
Asymptomatic ASD without functional compromise (NYHA Class I and II) usually have no 
effect on pregnancy. However, if there is pre-existing heart failure, there is decrease in 
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uterine blood flow leading to compromised fetal growth (reflected in incidence of small for 
gestation age babies) and viability. In a review that consolidated outcome of 123 pregnancies 
in women with ASD, 1 arrhytmic event, no heart failure events, 2 cardiovascular events and 
1 endocarditis were reported. In this study, incidence of these reported events were less than 
what is expected for healthy women. Similarly, incidence of adverse neonatal events was 
also low including small for premature birth, small for gestational age and neonatal 
mortality (Drenthem et al. 2007). 
5. Risk of inheritance of ASD in the offspring 
If there is a recognizable genetic syndrome in the mother associated with ASD, the 
inheritance pattern of such syndrome will dictate the risk of congenital heart disease in 
the fetus. In the absence of such genetic syndrome in the mother, incidence of congenital 
heart disease is 2-4% if mother has congenital heart disease which is higher than 0.6 – 
0.8% incidence in general population. In a Danish study of 1.7 million persons, a 
recurrence risk of 7.1 in first-degree relatives of individuals with congenital heart disease. 
(Oyen et al. 2009). Another European study from Netherland, reported an occurrence of 
ASD in 2.4% of the offspring in a cohort of 291 pregnancies in women with ASD. 
(Drenthen et al. 2007) 
6. Management of pregnancy with ASD 
Management pregnancy in women with ASD depends on whether the ASD was diagnosed 
prior to pregnancy, size of ASD and pre-existing cardiac issues related to ASD such as 
chamber enlargement, heart failure, arrhythmia and pulmonary artery hypertension. In 
general, uncomplicated ASD need not be treated during pregnancy.  
6.1 Diagnosis known before pregnancy 
If the diagnosis of ASD were known prior to pregnancy and ASD is large associated with 
hemodynamically-significant shunt, associated with moderate or severe chamber 
enlargement, a potential for supraventricular tachycardia and thromboembolic events 
during pregnancy, labor or postpartum. Therefore, the patient should have ASD closed 
prior to planned-pregnancy. Current practice is to electively close asymptomatic, but 
significant size ASDs prior to child-bearing years. Transcatheter or surgical technique 
should be applied based on the location and size of ASD and presence of adequate rim of 
tissue around the ASD suitable for transcatheter device placement. If unsuitable for 
transcatheter closure, surgical repair is sought. 
6.2 ASD diagnosed during pregnancy 
6.2.1 Medical management 
ASD does not always require surgical or transcatheter closure. If the pregnant woman is 
asymptomatic (NYHA Functional Class I and II) without heart failure, atrial arrhythmia or 
pulmonary hypertension or history of stroke, an expectant management of ASD during 
pregnancy is acceptable. However, if any of the above stated risk factors exist, ASD may 
 
Pregnancy Issues in Women with Atrial Septal Defect 25 
need to be closed during pregnancy. Indications for intervention (surgical or transcatheter 
options) include severe hemodynamic compromise, NYHA class > II, recurrent stroke prior 
to or during pregnancy, etc. This usually constitutes a small number of patients. Medical 
treatment of arrhythmia may be necessary during pregnancy. 
6.2.2 Transcatheter closure of ASD during pregnancy 
Indication for treatment of ASD during pregnancy includes high risk of recurrent stroke, 
high risk for taking anticoagulation throughout pregnancy such as intracranial 
hemorrhage, prior intolerance to anticoagulation with complicating bleeding, 
thrombocytopenia, hypertension, preeclampsia or other system impairment such as renal 
or liver dysfunction. 
Several precautions are taken if such procedure is required. Radiation of the fetus and its 
teratogenic effect are an important consideration during transcatheter therapy for ASD. First 
trimester irradiation will be associated with higher incidence of fetal malformation. 
Therefore, catheterization is performed in second trimester (13-28 weeks). Use of long 
venous sheath avoids direct radiation exposure and reduces radiation dose to pelvic area. 
Use of intracardiac echocardiography for balloon sizing and guidance of device deployment 
greatly reduces overall radiation exposure to the mother as well as the fetus. (Orchard et al. 
2011) (Schrale et al. 2007). General anesthesia may be avoided by use of local anesthesia with 
conscious sedation for the catheterization procedure. 
6.2.3 Surgical closure of ASD during pregnancy 
Indication for surgical closure of ASD is rare. However, if the abovementioned indications 
for ASD closure exist and the ASD is unsuitable for transcatheter closure, surgical closure 
of ASD is indicated. Following precautions are suggested based on several observations. 
Ideal period for open heart surgery during pregnancy is second trimester (13 – 28 weeks) 
in order to avoid any fetal malformations (first trimester) and to avoid preterm labor, 
unfavorable maternal hemodynamics and increased maternal mortality (third trimester). 
During surgery, fetal bradycardia at the start of cardiopulmonary bypass may be avoided 
by infusion of high-concentration glucose to provide energy for fetus and intraoperative 
monitoring of fetal well being with cardiotachometer and fetal echocardiogram. During 
cardiopulmonary bypass, high-flow and high mean arterial pressure (60 mmHg), 
hyperoxygenation and maintenance of high hematocrit (> 25%) are advised. (Arnoni et al. 
2003). 
7. Outcome 
A study compared pregnancy outcome in women who have had surgical repair of ASD 
before conception with women who have not had repair. 60 women (115 pregnancies) had 
surgery for ASD while 20 women (48 pregnancies) had unrepaired ASD. Incidence of still 
births, recurrence of congenital heart defect in the offspring or long term cardiac 
complications were similar in both groups. However, incidence of miscarriage, preterm 
delivery and cardiac symptoms during pregnancy were higher in women who had 
unrepaired ASD. (Actis Dato et al. 1998). 
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Drenthen et al. (2007) reported 0.8% incidence of arrhythmias, no cases of heart failure 
during pregnancy, 5% occurrence of thromboembolic events in women with ASD. Figure 
2 provides the perspective of risk to the offspring in women with ASD compared with 
various congenital heart diseases. While outcome of pregnancy relatively better with ASD 
compared to other congenital heart diseases, a certain incidence of complications have 
been reported including preterm delivery (6%), small for gestational age at birth (2%), 
fetal mortality (2.4%), perinatal mortality (1.7%) and recurrence of heart disease (2%). 





Fig. 2. Risk to the offspring from pregnancy in women with ASD compared to women with 
other congenital heart diseases. (Reproduced with permission. Drenthen et al 2007). 
8. Contraception 
Pregnancy is not contraindicated in women with ASD. However, there may be social and 
other clinical circumstances that may require delaying ASD closure and therefore, the 
pregnancy. In such circumstances, conception may be used. Since ASD is an acyanotic 
heart disease, there are more options compared to women with cyanotic heart disease. 
Barrier methods and intrauterine devices may be used. When these devices are inserted or 
removed, endocarditis prophylaxis is not indicated in patients with ASD. Though not 
crucial, progesterone-only pills have lesser incidence of thromboembolism compared to 
combination pills of estrogen and progesterone. However, progesterone-only pills may 
cause irregular bleeding especially in the first month of use. Efficacy of progesterone-only 
pills is slightly lower than combined contraceptive pills.  Similarly, the morning-after pills 
are also safe and effective for women with heart disease. There are injectable forms of 
long-acting contraceptives available. From cardiac point of view, permanent methods of 
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sterilization such as tubal ligation or vasectomy for the partner are unwarranted in cases 
with ASD. 
9. Conclusion 
Pregnancy in women without heart disease has its own risks. Women with ASD who are 
asymptomatic, NYHA Class I or II are likely to have uneventful pregnancy. The ASD may 
be closed either surgically or by transcatheter technique if found suitable. For high risk 
patients, treatment of ASD during pregnancy may be undertaken. Second trimester is 
considered suitable for either transcatheter or surgical repair of ASD. Radiation dose is 
minimized by using intracardiac echocardiogram and modifications of the catheter 
procedure. Similarly, precautions are taken during open heart surgery should surgical 
repair were necessary. However, such need for closure of ASD during pregnancy should be 
rare and if possible avoided. 
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1. Introduction 
The goal of this chapter is to review data regarding the current prevalence estimates for 
secundum type atrial septal defect (ASD) and to give the reader a sense as to how these 
prevalence data compare relative to other common cardiac defects. This chapter will also 
review the current understanding of cardiac and non-cardiac findings known to be associated 
with secundum ASD. It is recognized that the prevalence estimates of cardiac defects have 
been impacted by the routine utilization of color flow Doppler-echocardiography in current 
clinical practice. This is particularly true for certain cardiac anomalies such as secundum ASD 
that frequently occur in asymptomatic infants and children. Several studies have indeed 
documented a significant increase in the apparent prevalence of congenital heart defects in 
general and specifically for certain common phenotypes including secundum ASD (Hoffman 
& Kaplan, 2002; Wren et al., 2000; Correa et al., 2007). Further, these studies have concluded 
that much of these increases are likely secondary to better ascertainment in recent years. This 
chapter will review the most recent estimates of the prevalence of secundum ASD using 
information obtained from a population-based surveillance system using strict definitions of 
what constitutes a secundum ASD. This chapter will also review a detailed list of what is 
presently known about the associated findings and potential risk factors for the development 
of secundum ASD. 
2. Definition of what constitutes a secundum ASD 
One of the difficulties recognized with the utilization of standard trans-thoracic color-Doppler 
echocardiography is the inability to differentiate a small secundum ASD from the physiologic 
communication (the patent foramen ovale) seen in most newborn infants. In other words, 
deciding what constitutes a “true” ASD has obvious implications for making accurate 
estimates of prevalence. In a recently revised heart classification system, the diagnosis of 
secundum ASD was made only when the atrial defect is greater than or equal to 4 mm in 
diameter (Riehle-Colarusso et al., 2007). If the specific size of the defect is not indicated in the 
imaging study, the diagnosis of ASD can also be made in the presence of documented right 
heart enlargement. In clinical practice, one can sometimes detect a flap associated with patent 
foramen ovale even in defects larger than 4 mm. However, as this finding is not reliably 
reported, the utilization of the 4 mm size requirement for secundum ASD was chosen. While 
admittedly arbitrary, this size is based on previous published studies showing that most (if not 
all) defects less than this size close spontaneously and are therefore not considered anatomic 
atrial defects (Ghisla et al., 1995; Radzik et al., 1993). The prevalence data that are reported for 
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secundum ASD in this chapter utilized this strict size cutoff. Investigations that do not make 
this distinction between small ASD and patent foramen ovale would be expected to give much 
higher estimates for the prevalence of secundum ASD.  
It is well recognized that secundum ASD commonly occurs with other congenital cardiac 
defects. When it occurs with other presumed “independent” heart defects (such as with 
ventricular septal defects), most investigators, when assessing prevalence, would count ASD 
as a distinct cardiac defect. However, when a secundum ASD occurs as an obligatory shunt 
(such as with the diagnoses of tricuspid and pulmonary atresia, transposition of the great 
arteries, complex single ventricle with mitral atresia, or hypoplastic left heart syndrome), it 
is typically not counted as a distinct cardiac defect. The prevalence data reported in this 
chapter were made using these same distinctions. 
3. Background and methods 
One challenge in assessing differences in prevalence of congenital cardiac defects across 
population groups and over time has been the variation in nomenclature and classification 
systems that have been utilized. The prevalence data reviewed in this chapter were obtained 
utilizing the Metropolitan Atlanta Congenital Defects Program (MACDP) using data that 
were analyzed for births that occurred between 1998 and 2005 (the most recent time-frame 
studied) (Reller et al., 2008). A major strength of the MACDP is that it is a population-based 
surveillance system that includes structural birth defects, chromosomal abnormalities, and 
clinical syndromes. It was established in 1967 by the Centers for Disease Control and 
Prevention (CDC), Emory University, and the Georgia Mental Health Institute (Correa et al., 
2007). This program has conducted surveillance for birth defects among live born and 
stillborn infants greater than 20 weeks gestation born to residents of the 5 central counties of 
metropolitan Atlanta through the use of active case-finding methods. While many of the 
cardiac defects in MACDP are diagnosed in infancy, cases can be ascertained up to 6 years of 
age. The MACDP recently completed a re-classification of all heart defects in its database 
(Riehle-Colarusso et al., 2007). All cases underwent a detailed review by pediatric 
cardiologists to classify congenital heart defects according to standard nomenclature used 
by the Society of Thoracic Surgeons congenital heart surgery database (Jacobs et al., 2004). 
4. Prevalence of secundum ASD 
Prevalence estimates are reported per 10,000 live births with the numerators representing 
the number of infants with secundum ASD (or any other cardiac defect) per 10,000 live 
births. The current overall prevalence of congenital heart defects is estimated to be 81.4 
infants per 10,000 births (~0.8% of live births). The prevalence of secundum ASD is 
estimated to be 10.3 per 10,000 births. As a frame of reference, the most common cardiac 
defect is muscular ventricular septal defect (VSD) with a prevalence of 27.5 per 10,000 live 
births. It is noteworthy that the prevalence of secundum ASD is comparable to peri-
membranous VSD (prevalence of 10.6 per 10,000 live births) and greater than any other 
specific cardiac defect (Reller et al., 2008). Based on current prevalence data, secundum ASD 
is the third most common cardiac defect, and together with muscular and peri-membranous 
VSD, account for slightly more than half of all recognized cardiac defects.  
Secundum ASD is by far the most common of the atrial septal defects, accounting for greater 
than 80% of all atrial defects where the specific sub-type is identified. Secundum ASD is ~ 6 
times more common than the ostium primum type ASD (1.7 per 10,000 live births) and ~ 25 
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times more common than the sinus venosus atrial septal defect (0.4 per 10,000 live births) 
(Reller et al., 2008).  
Last, it is recognized in clinical practice that many individuals with ASD are diagnosed later in 
life and indeed, are the most common un-diagnosed congenital cardiac defect presenting in 
adult congenital cardiology clinics (Rosas et al., 2004). Thus, while the prevalence data obtained 
from the MACDP database are the most current available, it is clear that these data (diagnosed 
in infants and children), are under-estimates of the “true” prevalence of secundum ASD. 
5. Associations and risk factors 
The cause(s) of secundum ASD, as is true for most congenital heart defects, remain largely 
unknown. Nonetheless, there are clearly recognized associations between secundum ASD 
and other cardiac and non-cardiac findings that are worth reviewing and may ultimately 
help to elucidate an etiology for at least some of the causes for secundum ASD. These 
associations are discussed in the paragraphs that follow. 
5.1 Associations with other cardiac defects  
Several investigations have documented the association of secundum ASD with peri-
membranous VSD as well as with valvular pulmonary stenosis (Botto et al., 2007). The 
relative frequency and non-randomness of these associations suggest that they may have 
specific risk factor profiles. Indeed, there is some suggestion that the combination of 
secundum ASD and peri-membranous VSD within families may occur in greater frequency in 
the setting of the NKX2-5 genotype (Schott et al., 1998). 
5.2 Genetic syndromes  
Infants with secundum ASD are more likely to have a positive family history of congenital 
heart disease than most other cardiac defects (Ferencz et al., 1997). The finding of a positive 
family history obviously suggests the possibility of genetic causation(s) yet to be 
determined. There are several recognized genetic syndromes that have been shown to be 
associated with secundum ASD. While Trisomy 21 is more commonly associated with the 
finding of partial or complete atrio-ventricular septal defects, infants with Down syndrome 
also have an increased risk for isolated secundum ASD as well (Ferencz et al., 1997; Boldt et 
al., 2002). It is generally recognized that secundum ASD is also seen in greater frequency 
with the chromosomal anomalies Trisomy 13 and 18.  
Other recognized genetic syndromes associated with an increased risk of secundum ASD 
include the Holt-Oram syndrome, where the association of radial limb anomalies and 
cardiac defects, primarily secundum ASD, is seen in at least half of affected individuals 
(Basson et al., 1994). Secundum ASD is also seen with chromosome 22q11 deletion in 
association with DiGeorge syndrome and velo-cardio-facial syndrome (Borgman et al., 
1999). Secundum ASD, occurring either in isolation, or in conjunction with pulmonary 
stenosis, is associated with Noonan syndrome (Mendez and Opitz, 1985). The NKX2-5 gene 
defect has been shown to be associated with familial causes of either isolated secundum ASD, 
or in combination with other cardiac defects, and with heart rhythm conduction anomalies 
(Schott et al., 1998; Benson et al., 1999).  
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5.3 Female gender 
The association with female gender has long been recognized. In the current prevalence 
estimates, secundum ASD was significantly more common in girls (58.6%) than boys. (Reller 
et al., 2008). In the Baltimore-Washington Infant Study, 65.3% of children with secundum 
ASD were girls (Ferencz et al., 1997).  
5.4 Non-cardiac malformations and pregnancy exposures/teratogens 
Certain common non-cardiac malformations such as cleft palate are associated with an 
increased incidence of secundum ASD (Ferencz et al., 1997). Some of these infants will have 
chromosome 22q11 deletion, as noted above. Secundum ASD is the most common congenital 
cardiac defect associated with a constellation of non-cardiac anomalies recognized as the 
VACTERL (Vertebral anomalies, Anal atresia, Cardiac defects, Tracheal anomalies, Esophageal 
atresia, Renal anomalies, and Limb anomalies) association (Ferencz et al., 1997). 
In addition, certain pregnancy exposures have been shown to be associated with secundum 
ASD and include maternal alcohol ingestion (fetal alcohol syndrome) (Mone et al., 2004). 
Exposure to certain viral infections such as cytomegalovirus (CMV) and rubella infections 
during pregnancy are also associated with an increased risk for secundum ASD (Ferencz et 
al., 1997). Last, the presence of maternal diabetes including gestational diabetes is associated 
with an increased risk of cardiac defects including secundum ASD (Ferencz et al., 1997; 
Loffredo al., 2001). 
5.5 Other pregnancy and pre-pregnancy-related “risk factors” 
As a group, infants with secundum ASD, compared to live-born infants in the general 
population, are significantly more likely to be born at a lower gestational age and have 
significantly lower birth weight (Reller et al., 2008; Ferencz et al., 1997). Further, infants with 
secundum ASD are more likely to be small for gestational age irrespective of their gestational 
age at delivery. Last, infants with secundum ASD (relative to infants in the general population), 
are more likely to be born of mothers of increased maternal age and are significantly more likely 
to be the product of a multiple gestation pregnancy (Reller et al., 2008; Mastroiacovo et al., 1999). 
The cause(s) of the association of secundum ASD with low gestational age and low birth weight 
is unclear at the current time. One possibility is that ASD might somehow impair normal fetal 
growth. Another possibility is that both altered fetal growth and secundum ASD represent co-
outcomes of an associated causal risk factor. Clearly, more investigation is necessary.  
Current data indicate that both older maternal age and multiple-gestation pregnancy are 
associated with secundum ASD. In addition, the association with older maternal age appears 
to be independent of the increased risk of genetic syndromes that occurs with older maternal 
age (Reller et al., 2008). It is recognized that older maternal age is more likely to be associated 
with the use of assisted reproductive technology, which is a strong risk factor for multiple 
gestation pregnancy. Thus, these findings of maternal age and multiple-gestation pregnancy 
may be inter-related. It is noteworthy that over the past 4 decades, one important demographic 
change has occurred in our society. In 1968, roughly 16% of mothers at the time of delivery 
were 30 years old or older compared with 42% in 2005 (Correa et al., 2007). During this same 
timeframe, the number of multiple-gestation pregnancies also nearly doubled from 1.8% to 3.4%. 
Last, recent epidemiologic data suggest that pre-pregnancy maternal obesity may be a risk 
factor for a variety of birth defects including congenital heart defects. Of the cardiac defects, 
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maternal obesity is specifically associated with an increased risk for both atrial and 
ventricular septal defects (Cedergren and Kallen, 2003). While the mechanism of this finding 
is uncertain, the current “epidemic” of obesity in western society makes this association a 
potentially significant risk factor. 
6. Natural history of secundum ASD 
There are data indicating that secundum ASD (defined as defects ≥ 4 mm in size) when 
diagnosed in the first 6 months of life have a tendency to regress in size including the 
potential for spontaneous closure. In addition, the strongest predictor for spontaneous 
closure was shown to be smaller size at the time of initial diagnosis. In one study, over half of 
ASD’s measuring between 4-5 mm at the time of diagnosis closed spontaneously and an 
additional 30% regressed to a size considered to be insignificant (≤ 3 mm) (Hanslik et al., 
2006). None of the larger defects (> 10 mm) closed spontaneously and over 75% required 
surgical or device closure (Hanslik et al., 2006). These data certainly suggest that size of the 
secundum ASD at initial diagnosis directly impacts the natural history and specifically the 
potential need for closure. Last, the recognition that spontaneous closure of secundum ASD 
can occur is important, and has obvious implications for prevalence estimates. 
7. Future trends regarding secundum ASD prevalence  
A key question that remains unanswered is whether the true prevalence of secundum ASD is 
in fact increasing. Since 1975, the reported prevalence of secundum ASD (as well as some of the 
other common cardiac defects) has increased significantly (Correa et al., 2007; Hoffman & 
Kaplan, 2002; Wren et al., 2000). Because most of the increase in heart defect prevalence has 
been seen in asymptomatic infants, (while prevalence in more severe heart defects have been 
stable), better ascertainment using current color-Doppler echocardiography is clearly felt to be 
a significant contributing factor. However, there are preliminary evidence that the prevalence 
of secundum ASD may still be increasing in the most recent time-frame when imaging 
modalities have not changed significantly (Riehle-Colarusso T, unpublished observation). If 
true, some of the changing demographic factors referred to in this chapter may be contributing 
factors. However, at the current time, it is not possible to state with certainty whether the 
actual prevalence of secundum ASD is increasing. 
8. Conclusion 
This chapter has reviewed data assessing the prevalence of secundum ASD using current 
imaging modalities and strict guidelines for diagnosis. Secundum ASD is the third most 
common congenital cardiac defect and, based on the prevalence data reported in this 
chapter, accounts for greater than 10% of all cardiac defects. In addition, these data show 
that it is nearly as common as peri-membranous VSD. This chapter has also reviewed the 
common associations and risk factors that have been identified with secundum ASD. While 
some of the societal trends mentioned in the review of risk factors for ASD are of interest, 
knowing whether the prevalence of secundum ASD is in fact, increasing, and if so, what 
might be causing this, remain speculative at the current time.  
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potential for spontaneous closure. In addition, the strongest predictor for spontaneous 
closure was shown to be smaller size at the time of initial diagnosis. In one study, over half of 
ASD’s measuring between 4-5 mm at the time of diagnosis closed spontaneously and an 
additional 30% regressed to a size considered to be insignificant (≤ 3 mm) (Hanslik et al., 
2006). None of the larger defects (> 10 mm) closed spontaneously and over 75% required 
surgical or device closure (Hanslik et al., 2006). These data certainly suggest that size of the 
secundum ASD at initial diagnosis directly impacts the natural history and specifically the 
potential need for closure. Last, the recognition that spontaneous closure of secundum ASD 
can occur is important, and has obvious implications for prevalence estimates. 
7. Future trends regarding secundum ASD prevalence  
A key question that remains unanswered is whether the true prevalence of secundum ASD is 
in fact increasing. Since 1975, the reported prevalence of secundum ASD (as well as some of the 
other common cardiac defects) has increased significantly (Correa et al., 2007; Hoffman & 
Kaplan, 2002; Wren et al., 2000). Because most of the increase in heart defect prevalence has 
been seen in asymptomatic infants, (while prevalence in more severe heart defects have been 
stable), better ascertainment using current color-Doppler echocardiography is clearly felt to be 
a significant contributing factor. However, there are preliminary evidence that the prevalence 
of secundum ASD may still be increasing in the most recent time-frame when imaging 
modalities have not changed significantly (Riehle-Colarusso T, unpublished observation). If 
true, some of the changing demographic factors referred to in this chapter may be contributing 
factors. However, at the current time, it is not possible to state with certainty whether the 
actual prevalence of secundum ASD is increasing. 
8. Conclusion 
This chapter has reviewed data assessing the prevalence of secundum ASD using current 
imaging modalities and strict guidelines for diagnosis. Secundum ASD is the third most 
common congenital cardiac defect and, based on the prevalence data reported in this 
chapter, accounts for greater than 10% of all cardiac defects. In addition, these data show 
that it is nearly as common as peri-membranous VSD. This chapter has also reviewed the 
common associations and risk factors that have been identified with secundum ASD. While 
some of the societal trends mentioned in the review of risk factors for ASD are of interest, 
knowing whether the prevalence of secundum ASD is in fact, increasing, and if so, what 
might be causing this, remain speculative at the current time.  
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1. Introduction 
Several fetal cardiac malformations have been increasingly treated before birth. Fetal cardiac 
intervention targets an in utero correction of simple intracardiac abnormalities that 
potentially progress to complex heart diseases in utero, such as fetal critical aortic stenosis 
that might cause to hypoplastic left heart syndrome (HLHS) and HLHS with restrictive 
atrial septum leading to irreversible pulmonary vascular damages (Kohl et al., 2000; 
Marshall et al., 2004; Makikallio et al., 2006). Current operative procedures for correction of 
fetal restrictive atrial septum with an atrial decompression are still invasive because they, 
percutaneously and through both the uterine wall and fetal chest walls, require ultrasound-
guided maternal puncture into the frequently-pulsating (120-180 counts per minute) cardiac 
cavity of tiny fetal hearts and to create interatrial communications. Accordingly, these 
procedures have been reportedly accompanied by serious complications including profound 
bradycardia, bleeding and hemopericardium, intracardiac thrombus formation, and 
recurrent in utero closure of the created atrial septal defects.  
To establish fetal interatrial communications with minimal adverse effects, we developed an 
entirely new approach with the use of high intensity focused ultrasound (HIFU) (Fig. 1). 
HIFU is acoustic modality using ultrasound energy with cavitation and/or coagulation 
effect focused to operate on an internally targeted tissue without damaging overlying 
and/or underlying tissues. HIFU has been employed predominantly for non-touch 
treatment of tumors including prostate cancer, breast cancer and uterine fibroids (Rebillard 
et al., 2005; Chan et al., 2002; Hengst et al., 2004). Unlike an extensive ablation of stationary 
tumors, the HIFU ablation to a frequently-pulsating narrow area in the beating and tiny fetal 
heart requires highly accurate pinpoint delivery in real-time based on computer-aided auto-
tracking of atrial septum.  
We developed a new automatic delivery system of HIFU with real-time two dimensional-
ultrasound (2D-US) imaging analysis. Features of this system are 1) automatic detection of 
heartbeat rates, 2) automatic estimation of atrial septum position, 3) automatic generation of 
HIFU delivery timing and we did feasibility study for creation of an atrial septal defect 
using the beating heart of anesthetized adult rabbits. 
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Fig. 1. New approach with HIFU to correct cardiac morphologic abnormalities less invasively. 
2. Methods 
2.1 System configuration 
The system configuration of the computer-aided automatic delivery system of HIFU consists 
of predominantly 5 parts (Fig. 2). The first one is a HIFU delivery device which comprises a 
monocoque spherical shaped piezo transducer and a diagnostic 2D-US imaging probe 
mounted on the transducer. The tomographic images are taken by the probe including the 
focal point of the transducer. The curvature radius of the transducer is 40 mm, and the focal 
point is located 40-mm apart from the edge face of the transducer. The focal point is an 
elliptical in shape (0.6-mm wide, 5.0-mm long). The second part is a diagnostic 2D-US 
imaging equipment (En-Visor C HD, Philips, Andover. MA) to scan a cardiac four-chamber 
view by 2D-US imaging probe (s12, Philips, Andover. MA). The equipment outputs gray  
 
Fig. 2. System configuration of the computer-aided automatic HIFU energy delivery. 
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scale NTSC-video data (640x480 pixels) into the workstation with 30 frames/sec through a 
video capture (ADVC-55, Canopus, Kobe) and IEEE1394 cable. The third part is a 
workstation (HP xw8400, Windows XP x64, Intel Xeon 2.33 GHz, Quad Core, 16GB 
RAM，DirectX9.0c) to analyze an input 2D-US tomographic image of cardiac four-chamber 
with our original real-time HIFU delivery control algorithm. The workstation detects 
heartbeat rates, estimates atrial septum positions, and generates HIFU delivery timing by 
RS-232 interface into a signal transform box automatically. The fourth part is a function 
generator (Agilent 33220A, Agilent technologies, Santa Clara, CA) to output intermittent 
sine-wave with certain frequency and voltage into the fifth part, and RF power amplifier 
(AG1012, T&C power Conversion Inc., Rochester, NY). The timing to drive the transducer 
by amplified sine-wave is determined by TTL trigger from the signal transform box. 
Automatic HIFU delivery is accomplished by some adjusting with various parameters. This 
setting is done through a graphical user interface on the monitor by surgeons (Fig. 3). 
 
Fig. 3. Graphical user interface for setting, adjusting and monitoring of automatic HIFU 
delivery. 
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2.2 Automatic detection of heartbeat rates 
The atrial septum, which is a target of this system to be perforated, repeats expansion, 
shrinkage and movement with heartbeat. It is assumed that the best timing to perforate an 
atrial septum safely by HIFU delivery system is when the atrial septum is expanded most. 
However, because the atrial septum has less features in 2D-US image, it is difficult to detect 
its movement directly. Therefore, using the fact that atrial septum expands when ventricle 
contracts, we tried to detect the timing when the left ventricle contracts most, which is easy 
to detect by 2D-US image. The left ventricular movement of expansion and shrinkage are 
caused by heartbeats, and its variation can be associated with the change of the left 
ventricular area in 2D-US image. In this paper, we utilized the automatic detection of the 
heartbeat period by the following procedures. 
1. Setting of Region of Interest (ROI) 
We set a rectangular ROI surrounding the left ventricle of 2D-US image on the display while 
confirming four chamber view of 2D-US image (Fig. 4(A)). ROI should be set so that the left 
ventricle, which repeats expansion, shrinkage and movement, doesn’t protrude it, and ROI 
should be the smallest to minimize calculation cost in the image processing. 
  
Fig. 4. (A) Setting of ROI and point of inside the left ventricle (LV). (B) Binary image of 2D-
US image, extraction of the left ventricle area and approximate LV ellipse.  
2. Pointing of inside the left ventricle 
Using 2D-US binarized image by white and black pixels, and the central of inside the left 
ventricle is pointed by manual in ROI to set target region of the left ventricle to be tracked 
(Fig. 4(A)). The amount of black pixels which is communicating with the point in ROI is 
extracted automatically as a left ventricular area. 
3. Adjustment of a threshold value in binarization of 2D-US image 
2D-US image for the image processing is expressed in gray scale of 256 brightness levels. 
The threshold value for binarization should be adjusted between 0 and 255 levels so as to 
extract the left ventricular area adequately. When it is adjusted most adequately, a shape of 
the left ventricle is approximated an ellipse (Fig. 4(B)). However depending on threshold, 
the outside of the left ventricle is detected by error and, to the contrary, inside of the left 
ventricle is not detected. These errors influence precision of the left ventricular area and 
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calculation of its geometry described below. Overestimation or underestimation of the left 
ventricular area causes “undetectable”. In our system the threshold value is adjusted 
empirically considering actual 2D-US image so that a ratio to be “undetectable” becomes as 
small as possible. 
4. Frequency analysis of the left ventricular area variation 
It becomes possible to take samples about variation of the left ventricular area at frequency 
of 30 times per seconds when the area is extracted adequately. This is because the variation 
of areas includes heartbeats, low-frequency component by breathing and high-frequency 
component by noise when 2D-US image is acquired and transferred to the workstation. It is 
necessary to remove these components by filtering with a small calculation cost. Our system 
uses the moving average calculation with 8 past samples to remove the low frequency 
component and the simplicity mean calculation with 2 past samples to remove the high-
frequency component. Using fast Fourier transformation the system calculates heartbeat 
period, frequency and period from 64 past samples without some noises automatically.  
2.3 Automatic estimation of atrial septum 
As mentioned previously, the atrial septum has less features in 2D-US image which is 
difficult to detect its position by image processing directly. Therefore the system is set to 
delivery HIFU only, when position of the atrial septum can be estimated from position and 
shape of the left ventricle, which is easy to be detected in 2D-US image, and its position 
corresponds to the focal point of HIFU delivery by a fixed transducer. In this study an 
automatic estimation of the atrial septum is realized according to following procedures. In 
addition, the positional information of estimated atrial septum is used as a safety 
conditional for HIFU delivery based on the allowable error. 
1. Position adjustment of HIFU transducer 
The transducer and 2D-US probe are fixed physically for one HIFU delivery device. At first, 
the focal point of HIFU delivery is confirmed precisely by 2D-US image when HIFU is 
delivering to a low decrement polymer-coated rubber with the acoustic impedance 
(Acoustic standoff, Eastek Corporation, Tokyo, Japan) that is approximately equivalent to a 
human body (Fig. 5). The resolution of this 2D-US image around the focus is about 0.5 mm 
in the direction that throws the beam and about 0.2 mm in the depth direction. We mark a 
circle to the focal position on this 2D-US image supported by orthogonally-crossed guide 
lines (Fig. 6(A)). The position and the posture of HIFU delivery device is fixed by manual so 
that position of the atrial septum corresponds to the focal point of HIFU transducer in the 
timing when left ventricle shrinks most. 
2. Making template information 
As well as preceding clause, we mark a cross on the atrial septum of the timing when the 
left ventricle shrinks most by manual operation and define the coordinate with (XAt, YAt). 
In addition, we define the fillet diameter of the left ventricle shape approximated by a 
ellipse with (RXt, RYt) and the coordinate of center of gravity position with (XGt, YGt), and 
use these parameters for the image analysis in the next clause as template information to 
estimate the atrial septum position (Fig. 6(B)). 
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Fig. 5. Confirmation of ablated focal point by HIFU delivery on 2D-US image. Ablated focal 
point is ellipsoid of 5-mm long and 2-mm wide. 
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of approximate LV ellipse (RXt, RYt) and its center of gravity (XGt, YGt) when the left 
ventricle is minimum. (C) Automatic estimation of atrial septum position (XA, YA) with 
geometric ratio between current information (fillet radius and center of gravity position) 
and template parameters. If estimated position is in the error margin circle of HIFU focus, 
HIFU delivery is allowed. 
3. Geometric estimation of the atrial septum position 
Using the left ventricular fillet diameter (RX, RY) and the geometric center of gravity 
position (XG, YG) detected in 30 frames per seconds, template fillet diameter (RXt, RYt) and 
template geometric center of gravity position (XGt, YGt). We estimate current atrial septum 
position (XA, YA) by formula (1) automatically (Fig. 6(C)). HIFU delivery is permitted only 




XA = XG + XAt + XGt  × RX / RXt





2.4 Definition of HIFU delivery timing 
It is determined the timing when HIFU should be delivered by analysis of the four chamber 
view in 2D-US image. However, there is the delay time (TD) constantly between acquisition 
of 2D-US image, image transformation by the video capture, image analysis with the 
workstation, trigger output to a function generator, sinusoidal amplification in the RF power 
amplifier and HIFU delivery by a transducer. It is about 33 ms in this system, which is just 
equal to the delay for 1 frame of 2D-US image. Therefore based on the image analysis results 
HIFU delivery is enabled the timing when the left ventricle shrinks most by the trigger of 
HIFU delivery at the time of “TS-TD“, which deducted the delay time from the predicted 
time that left ventricle shrinks most (TS) (Fig. 7). 
 
Fig. 7. Definition of HIFU delivery starting trigger timing with total delay time in the 
system. The timing is the delay time TD before the timing TS that the left ventricle area will 
be minimized locally.  
Atrial Septal Defect 44
 
 
Fig. 5. Confirmation of ablated focal point by HIFU delivery on 2D-US image. Ablated focal 
point is ellipsoid of 5-mm long and 2-mm wide. 
  
 
Fig. 6. (A) Pointing focus of HIFU with X-Y guide lines on the 2D-US image. (B) 
Determination of template parameters by pointing of atrial septum and getting fillet radius 
(C) 
Computer-Aided Automatic Delivery System 
of High-Intensity Focused Ultrasound for Creation of an Atrial Septal Defect 45 
of approximate LV ellipse (RXt, RYt) and its center of gravity (XGt, YGt) when the left 
ventricle is minimum. (C) Automatic estimation of atrial septum position (XA, YA) with 
geometric ratio between current information (fillet radius and center of gravity position) 
and template parameters. If estimated position is in the error margin circle of HIFU focus, 
HIFU delivery is allowed. 
3. Geometric estimation of the atrial septum position 
Using the left ventricular fillet diameter (RX, RY) and the geometric center of gravity 
position (XG, YG) detected in 30 frames per seconds, template fillet diameter (RXt, RYt) and 
template geometric center of gravity position (XGt, YGt). We estimate current atrial septum 
position (XA, YA) by formula (1) automatically (Fig. 6(C)). HIFU delivery is permitted only 




XA = XG + XAt + XGt  × RX / RXt





2.4 Definition of HIFU delivery timing 
It is determined the timing when HIFU should be delivered by analysis of the four chamber 
view in 2D-US image. However, there is the delay time (TD) constantly between acquisition 
of 2D-US image, image transformation by the video capture, image analysis with the 
workstation, trigger output to a function generator, sinusoidal amplification in the RF power 
amplifier and HIFU delivery by a transducer. It is about 33 ms in this system, which is just 
equal to the delay for 1 frame of 2D-US image. Therefore based on the image analysis results 
HIFU delivery is enabled the timing when the left ventricle shrinks most by the trigger of 
HIFU delivery at the time of “TS-TD“, which deducted the delay time from the predicted 
time that left ventricle shrinks most (TS) (Fig. 7). 
 
Fig. 7. Definition of HIFU delivery starting trigger timing with total delay time in the 
system. The timing is the delay time TD before the timing TS that the left ventricle area will 
be minimized locally.  
Atrial Septal Defect 46
2.5 Security condition for HIFU delivery 
HIFU delivery is conducted based on the timing when the left ventricle shrinks most in 
consideration of the delay time in the system. In order to avoid some issues, caused by 
various factors and disturbances, to deliver HIFU outside of the allowable circle The system 
is permitted to delivery HIFU as far as meeting following security conditions so as to avoid 
"shooting by mistake", which means that HIFU delivery is outside the allowable limit of 
error radius and ablated point is overshot the actual atrial septum, even if the point is inside 






Fig. 8. Monitoring of HIFU delivery condition defined by focal accordance, area of LV, 
heartbeat synchronous and circularity of LV. 
1. The upper limit of movement distance of the left ventricular geometric center of gravity 
2. The maximum value of the left ventricle area 
3. Success or failure of the heartbeat cycle detection by fast Fourier transformation 
4. The minimum value of the ellipsoid roundness, which is approximate shape of the left 
ventricle 
5. Whether an estimated position of the atrial septum is inside focal allowance limits of 
error or not 
These conditional thresholds are settable individually, and we can select any conditions. 
Delivery frequency decreases if the conditions are strict. On the other hand, it increases if 
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the conditions are easy. However, we have only a rough index for optimal parameters 
because individual difference is large by the delivered target of HIFU. Therefore, it is 
necessary to judge during securing safety as the trigger off for HIFU delivery while 
watching the temporal change in HIFU delivery condition on the display whether you can 
irradiate it more effectively, the parameters are appropriate, or more effective delivery is 
possible. 
3. In vivo experiment 
3.1 Purpose 
In this experiment, we confirmed feasibility of our computer-aided automatic delivery 
system of HIFU to perform atrial septal defect creation of animals in vivo. We used four 
healthy animals (Japanese white rabbit, male, 2.8 kg) with cardiac pulsation under 
anesthesia. Their bodies are slightly larger than our practical target fetus. 
3.2 Methods 
We tested HIFU delivery to adult rabbits of which limbs were fixed to the operating table. 
This is because it was covered by flat breast bone, and HIFU reflected the heart of the 
rabbit. We tried HIFU delivery in a state exposed with rabbit‘s heart by a median section 
and under the environment that which heart moves during the pulmonary respiration by 
the respirator unlike intrauterine fetuses. In the case of practical intrauterine fetuses, their 
undeveloped breast bone does not damp HIFU and they don’t breathe with lung. We 
performed this experiment in the following procedures strictly in accordance with the rule 
that the animal executive committee in National Center for Child Health and 
Development. 
1. Four adult rabbits (Japanese White, 2.8 kg, male) were anesthetized with xylazine (5 
mg/kg IM) and isoflurane by inhalation. 
2. After endotracheal intubation or tracheostomy placement, anesthesia was maintained 
on the mechanical ventilation with isoflurane and oxygen inhalation (20 cycles/min, 
240 ml/cycle). 
3. ECG, arterial blood pressure/oxygen saturation, and end-tidal carbon dioxide 
concentration were monitored intraoperatively in real time.  
4. The animals underwent median sternotomy to expose the heart, chest cavities were 
filled with buffering gel on both sides. The heart beats was set in the direct contact with 
a silicone sheet-bottomed tank filled with degassed water (37◦C ) (Fig. 9). 
5. A HIFU transducer combined with a diagnostic 2D-US imaging probe was fixed on a 
two-directional (X-Y) linear stage with a pivot hinge placed on the tank which was 
manually steered, so that the HIFU focal point could be roughly located on the atrial 
septum of the beating heart. 
6. Various parameters for HIFU delivery were specified. 
7. Automatic HIFU delivery was carried out with this system. 
8. After HIFU delivery, we confirm whether new blood flows is generated across the atrial 
septum using color Doppler echocardiography by the diagnostic 2D-US imaging 
equipment. 
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the conditions are easy. However, we have only a rough index for optimal parameters 
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irradiate it more effectively, the parameters are appropriate, or more effective delivery is 
possible. 
3. In vivo experiment 
3.1 Purpose 
In this experiment, we confirmed feasibility of our computer-aided automatic delivery 
system of HIFU to perform atrial septal defect creation of animals in vivo. We used four 
healthy animals (Japanese white rabbit, male, 2.8 kg) with cardiac pulsation under 
anesthesia. Their bodies are slightly larger than our practical target fetus. 
3.2 Methods 
We tested HIFU delivery to adult rabbits of which limbs were fixed to the operating table. 
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that the animal executive committee in National Center for Child Health and 
Development. 
1. Four adult rabbits (Japanese White, 2.8 kg, male) were anesthetized with xylazine (5 
mg/kg IM) and isoflurane by inhalation. 
2. After endotracheal intubation or tracheostomy placement, anesthesia was maintained 
on the mechanical ventilation with isoflurane and oxygen inhalation (20 cycles/min, 
240 ml/cycle). 
3. ECG, arterial blood pressure/oxygen saturation, and end-tidal carbon dioxide 
concentration were monitored intraoperatively in real time.  
4. The animals underwent median sternotomy to expose the heart, chest cavities were 
filled with buffering gel on both sides. The heart beats was set in the direct contact with 
a silicone sheet-bottomed tank filled with degassed water (37◦C ) (Fig. 9). 
5. A HIFU transducer combined with a diagnostic 2D-US imaging probe was fixed on a 
two-directional (X-Y) linear stage with a pivot hinge placed on the tank which was 
manually steered, so that the HIFU focal point could be roughly located on the atrial 
septum of the beating heart. 
6. Various parameters for HIFU delivery were specified. 
7. Automatic HIFU delivery was carried out with this system. 
8. After HIFU delivery, we confirm whether new blood flows is generated across the atrial 
septum using color Doppler echocardiography by the diagnostic 2D-US imaging 
equipment. 
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9. After this experiment, we inject pentobarbital into a peripheral venous path and 






Fig. 9. Experimental setup using an adult rabbit. HIFU delivery was done through a silicone 
sheet at the bottom of the degassed water tank. 
3.3 HIFU delivery condition 
The waveform output from a function generator is observable with an oscilloscope, which is 
amplified by RF power amplifier and is input to a transducer. In this experiment, the input 
waveform was sine wave of 3.3 MHz, 160 Vpp and 6.5 kW/cm2.  
For the total HIFU delivery time in one trial, we set three seconds from experiences of the 
prior pilot study. The allowable limit of error radius of HIFU delivery spot is set to the same 
value in all trial so that it was with the smallest circle which a focus shape of HIFU was fit 
into on a display. 
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Fig. 10. Heart specimens ablated with HIFU delivery. Left images are gross appearances of 
the inadvertent ablation with opening. Right images are magnifications of the area ablated 
by HIFU deliveries. (A) A small opening was made in the posterior wall of the left atrium. 
(B) Atrial septum apparently remained non-penetrated with mere coagulation changes. (C) 
Non-penetrated small hole was made on the atrial septum with hematoma formation. (D) 
Non-penetrated small hole was made on the atrial septum accurately. 
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The HIFU delivery began at the moment when a surgeon pushed the button for beginning 
of automatic delivery on a display and came back to the standby state when 3-seconds HIFU 
delivery was completed in total. 
3.4 Results 
Four rabbits were euthanized after HIFU delivery, and dissected their isolated hearts and 
observed around the atrial septum (Fig. 10(A) - (D)). In the first trial, it took 23 seconds from 
beginning of automatic HIFU delivery to the end (Fig. 10(A)). The penetration of the tissue 
in the chamber was completed, however the position was missed from the atrial septum 
toward posterior parietal side, which is the left atrium side. In the second trial, it took 57 
seconds by the end (Fig. 10(B)). A cauterization spot was found on the atrial septum in 
pinpoint, however the HIFU delivery did not achieve a penetration. In the third trial, it took 
44 seconds by the end (Fig. 10(C)). The perforation on the atrial septum was confirmed, 
however it did not achieved a penetration. In addition a hematoma-like change was found 
beside a perforation spot. In the last trial, it took 46 seconds by the end (Fig. 10(D)). The 
perforation on the atrial septum was confirmed, however it did not achieve a penetration. 
Unlike the third trial the hematoma was not found. 
4. Discussion 
In this study, we developed automatic delivery system of HIFU based on real-time 2D-US 
imaging analysis. In in vivo experiment we confirmed pinpoint delivery of HIFU to the 
pulsating atrial septum within beating hearts of anesthetized adult rabbits. 
In the field of cardiology, HIFU was investigated as a promising device to treat arrhythmia, 
relieve valvular stenosis and ameliorate obstructive hypertrophic cardiomyopathy. HIFU 
also enables us to create defects in cardiac tissues such as ventricles or cusp of the aortic 
valve in vitro or ex vivo (Otsuka et al., 2005; Fujikura et al., 2006; Lee et al., 2000; Xu et al., 
2004; Strickberger et al., 1999). Particularly in fetal cardiac intervention, less invasiveness  
of HIFU is effective for the mother as well. In addition, HIFU delivery can be a actual 
operative method with security, a short time and low cost. Our new system is useful for an 
approach into the heart chamber with more safety owing to detection of a heartbeat cycle 
only from 2D-US four chamber view without other measurement instruments and 
estimation of atrial septum position pulsating with heartbeats and breathing for more 
effective HIFU delivery. 
4.1 Detection of heartbeat 
In order to obtain heartbeat information, it is common to use an electrocardiogram (ECG). 
There is a reported study to try the treatment of arrhythmias using the HIFU delivery 
triggered by ECG (Strickberger et al., 1999). However, it is difficult to isolate only ECG of 
fetus from a maternal ECG definitely although fetal ECG monitoring is technically quite 
demanding because ECG of fetus is obtained only through the mother. Therefore, the 
method to detect the heartbeat cycle of fetus only from real-time 2D-US image in our system 
is thought to be appropriate for clinical application from convenient point of view. 
However, based on the image processing, the amount of calculation is larger and delay time 
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is longer than ECG signal analysis. This is because arrhythmic development is expected, and 
heartbeat cycle collapses with a diseased heart. It is better that the delay time is short to 
detect arrhythmic development quickly. We had a plan to introduce the system with fetal 
ECG together in near future. 
4.2 Estimation of atrial septum 
About the estimation of the atrial septum position, although the surgeon confirmed it by 
monitoring before HIFU delivery in vivo experimental qualitatively, ablated point was not 
so overshot the atrial septum, of which position was estimated from 2D-US image. 
However, when the 2D-US image was not clear, the left ventricular position and shape were 
not obtained precisely. There were some cases that estimation of the atrial septum was 
impossible. Consequently, HIFU delivery was not permitted by security conditions in this 
case. We were able to avoid shooting by mistake outside the allowable limit of error radius 
in 2D-US image. Also, we calculated geometric ratio between the left ventricular center of 
gravity position and the approximate fillet diameter for "correct answer" which a surgeon 
sets by manual operation as template information, however the procedure is limited on 2D 
plane. We don’t consider that the heartbeat includes movement and transformation 
(expansion, shrinkage and distortion) not only in 2D plane (X-Y plane), but also in the depth 
direction (Z-axis direction). It depends on how detection of the heartbeat and the estimation 
of the atrial septum position are accurate what appropriate four chamber view is acquired. 
The detection of the heartbeat from the extraction of the left ventricular area on 2D-US 
image is no more than approximation. Even if the focal point is inside allowable limit of 
error radius in 2D-US image, the HIFU delivery results in shooting by mistake three-
dimensionally because prior confirmation of the HIFU focal size and shape, fixation of the 
HIFU delivery device, and setting of the parameters about HIFU delivery condition were 
performed on the basis of 2D-US image only. This is the major reason of the HIFU delivery 
position error. For the solution of this issue, at least when HIFU delivery device is fixed on 
target we should use a three-dimensional ultrasound (3D-US) probe to recognize detail of 
3D positional relationship between the focal point and the actual atrial septum in beating 
heart for more accurate focal position alignment. It is expected that performance of the 3D-
US diagnostic equipment improves to acquire and analyze 3D-US voxel data in real time 
directly, which leads drastically higher precision of HIFU delivery with our system in near 
future. 
In addition, the real intrauterine fetus is floating in the amniotic fluid and is movable three-
dimensionally. During surgery, the fetus doesn’t exercise spontaneously because both 
mother and fetus are under anesthesia, however we have to track not only movement of the 
atrial septum but also the fetal movement of oneself. That is to say in addition to 2D-US for 
four chamber view of the heart. We need 3D-US to track movement of intrauterine fetus 
three-dimensionally. At the same time it is important to move HIFU delivery device itself 
mechanically to track fetal wide movement in utero (Koizumi et al., 2008). 
4.3 In vivo experiment 
We tried HIFU delivery to the animals which imitated intrauterine fetuses, however the 
results didn‘t achieved both delivery efficiency and delivery accuracy of HIFU. The only 
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one trial perforated tissue in the beating chamber, and the perforated point was on the 
adjacent tissue of the atrial septum. On the other hand, the three trials ablated just the 
atrial septum, and no perforations were generated. The HIFU delivery efficiency depends 
on the ratio of delivery time in one heartbeat and the total time to complete preset HIFU 
delivery in each trial. In all trials, we set the same delivery conditions on a respirator, size 
(weight) of the animal, the allowable limit of error radius around HIFU focal point, and 
the total HIFU delivery time. However, there were individual differences in animals‘ 
heartbeat cycle and 2D-US image of the left ventricle, and also, we found small differences 
in relative position relationship between animal body and HIFU delivery device because 
we made adjustments to delivery setting in each trial. Therefore, the variation occurred in 
the total time to complete preset HIFU delivery in each trial. To increase the safety, the 
shorter delivery ratio in one heartbeat and more strict security conditions are required. 
However, if the total time lead to longer to complete preset HIFU delivery, the one HIFU 
delivery interval gets longer, which results in no perforation of the tissue due to diffusion 
of converged HIFU energy into intracardiac blood flow. HIFU delivery frequency around 
3.3 MHz may cause heating effect and/or mechanical (cavitation) effect. If the perforation 
of tissue is caused by only mechanical effect of cavitation, we need not consider the 
diffusion of the HIFU energy in to the blood flow. In order to avoid cooling effect by the 
blood flow, it is more useful to take advantege of mechanical effect of cavitation 
positively. However, it is necessary to progress clarification about which is dominant 
heating effect or mechanical effect of cavitation by detailed simulation and local 
observation around the focal point. When heating effect is dominant, we should lengthen 
the delivery ratio in one heartbeat to raise HIFU delivery efficiency and make continuous 
HIFU delivery by loose of security conditions. However, the security of HIFU delivery 
tuens down by contraries and the possibility is reduced to be delivered in the point that 
we aim at. Assurance of security is in a relation of the trade-off with HIFU delivery 
efficiency, and balancing both is not easy. For safe and secure HIFU delivery we will 
progress further validation to investigate optimal HIFU delivery conditions from both 
hardware and software point of view. 
5. Conclusion 
We developed computer-aided automatic delivery system of HIFU for creation of an atrial 
septal defect which perforates tissue in the intracardiac chamber for less invasive cardiac 
intervention of intrauterine fetuses. In vivo experiment using animals, by only 2D-US image 
of four chamber view, it was possible to detect heartbeat period, estimate the atrial septum 
position, and determine HIFU delivery timing in real-time under heartbeats.  
In near future, we will aim at the clinical application as a minimal invasive surgical system 
in order to improve precision improvement of the focus positioning of HIFU delivery and 
improvement of HIFU energy efficiency to intracardiac tissue. 
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Historical Aspects of Transcatheter  
Occlusion of Atrial Septal Defects 
Srilatha Alapati and P. Syamasundar Rao  
University of Texas at Houston Medical School, Houston, TX,  
USA 
1. Introduction 
Following the description of surgical closure of atrial septal defect (ASD) in early 1950s 
(Bigelow et al., 1950; Lewis et al., 1953; Gibbon, 1953), it rapidly became a standard therapy 
of ASDs. Surgical closure of ostium secundum ASDs is safe and effective with negligible 
mortality (Murphy et al., 1990; Galal et al., 1994; Pastorek et al., 1994), but the morbidity 
associated with sternotomy/thoracotomy, cardiopulmonary bypass and potential for 
postoperative complications cannot be avoided. Other disadvantages of surgical therapy are 
the expense associated with surgical correction, residual surgical scar and psychological 
trauma to the patients and/or the parents. Presumably because of these reasons, several 
groups of cardiologists embarked upon developing transcatheter methods of closure of the 
ASD. The studies of King (King & Mills, 1974; Mills & King, 1976; King et al., 1976), 
Rashkind (Rashkind, 1975; Rashkind & Cuaso, 1977; Rashkind, 1983) and their associates 
paved the way for the future development of transcatheter ASD device occlusion 
methodology. In this chapter, history of development of ASD closure devices will be 
reviewed. Historical development for occlusion of patent foramen ovale (PFO) will be 
briefed at the end of the chapter. 
2. Closure of atrial septal defects 
Historical aspects of closure of atrial septal defect will be reviewed in this section. 
2.1 King and Mill’s device 
King and his associates were successful in occluding the ASD via a transcatheter delivered 
occluding device and were the first in doing so and reported their studies in mid 70s (King 
& Mills, 1974; Mills & King, 1976; King et al., 1976). This device is composed of paired, 
Dacron-covered stainless steel umbrellas (Figure 1A) collapsed into a capsule at the tip of a 
catheter. A number of sizes of the umbrella were manufactured. King & Mills (1974) initially 
attempted this technique in experimental animal models. ASDs were created by a punch 
biopsy technique in adult dogs. Successful device deployment was achieved in five of nine 
dogs in whom the procedure was attempted. Complete closure of the ASD and 
endothelialization of the implanted umbrellas was observed during the follow-up. 
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Following this experience in the dog model, the technique was extended to human subjects 
(Mills & King, 1976; King et al., 1976). Stretched ASD diameter was measured by balloon 
sizing (King et al., 1978) and a device 10 mm larger than the stretched ASD diameter is 
selected for deployment. The device delivery catheter is inserted through the saphenous 
vein at the sapheno-femoral venous junction by cut-down. The catheter tip is positioned into 
the left atrium through the ASD. The distal umbrella is extruded in the body of the left 
atrium and the catheter withdrawn into the right atrium. Then, the distal (left atrial) 
umbrella is fixed against the left side of the atrial septum and the proximal (right atrial) 
umbrella is opened in the right atrium. The umbrellas are locked to each other with a special 
locking mechanism. After the device is in place, the obturator wire is unscrewed and 
withdrawn, thus releasing the device. 
Eighteen patients were taken to the catheterization laboratory and ten (56%) of these were 
considered suitable candidates for device closure. Successful implantation of the device was 
accomplished in five (50%) patients. Their ages were 17 to 75 years with a median of 24. The 
stretched ASD diameter was 18 to 26 mm by balloon sizing. Ostium secundum ASD with 
left-to-right shunt was present in four patients. The fifth patient had an atrial defect with 
presumed paradoxical embolism and a stroke. Symptoms improved and the heart size 
decreased during observed follow-up. Repeat cardiac catheterization data did not show 
shunts by oximetry. However, trivial shunts were observed by hydrogen curves. In a 27 year 
follow up study, 4 patients remain alive with closed defects and there had been no adverse 
events related to the device. The deceased patient died from Hodgkin’s disease and a 
cerebral vascular accident 9 years after device closure (King & Mills, 2010). 
Although these results were encouraging, King and his associates did not continue their use 
nor did any other investigator, to our knowledge, pursued the technique. It may be 
presumed that this may be related to the need for a large delivery sheath and complicated 
maneuvering required for implantation of the device. 
 
Fig. 1. Photographs of King’s device (A), Rashkind’s hooked device (B), on-face and side 
views of the clamshell device (C) and buttoned device (D); see the text for detailed 
description of the devices. 
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2.2 Rashkind’s devices 
Rashkind developed a slightly different type of ASD closure device. Rashkind’s 
investigations appear to be parallel to those of King and Mills (Rashkind et al., 1985). The 
first Rashkind umbrella consisted of three stainless-steel arms covered with medical grade 
foam (Rashkind & Cuaso, 1977). The central ends of the stainless-steel arms are attached to 
miniature springs, which in turn are welded to a small central hub. The outer end of the 
stainless steel arm ended in a miniature “fish” hook. Rashkind subsequently modified this 
umbrella such that there are six stainless steel arms with the alternate arms carrying the 
hook (Figure 1B). He also designed an elaborate centering mechanism, which consisted of 
five arms bent to produce a gentle outward curve. The umbrella delivery mechanism is built 
on a 6 F catheter with locking tip, which interlocks with the central hub of the device. The 
entire system is threaded over a guide wire. Withdrawal of the guide wire after 
implantation of the device will unlock the mechanism, thereby disconnecting the umbrella 
from the delivery system. The umbrella collapsed into a pod, the centering mechanism 
folded and the delivery system can all be loaded into a 14 or 16 F long sheath. The umbrellas 
were manufactured in three sizes: 25, 30 and 35 mm. An umbrella that is approximately 
twice the stretched size of the ASD is chosen for implantation. First, the tip of the pod 
containing the umbrella is advanced into the left-atrium through the ASD (Figure 2 a). Then, 
the umbrella and centering mechanism delivered into the mid left atrium by retracting the 
tip of the sheath or pod (Figure 2 b). The entire system is then slowly withdrawn. The 
centering mechanism keeps the umbrella centered over the ASD. Further withdrawal results 
in embedding the hooks of the umbrella onto the left atrial side of the atrial septum (Figure 
2 c). After the umbrella is fixed to the atrial septum, the umbrella delivery system is 
disconnected and removed. Experimental studies in closing surgically created ASDs in dogs 
and calves have indicated the feasibility of the method with excellent endothelialization of 
the umbrella components (Rashkind, 1975). 
 
Fig. 2. Sequence of hooked prosthesis implantation (see text for details). 
The senior author had the privilege of spending a month-long mini-sabbatical with Dr. 
William Rashkind in mid-1979 and during that period, had the opportunity in performing 
ASD device closures with the hooked device, both in calf model and in patients under the 
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direction of Rashkind. Rashkind’s enthusiasm and dedication in developing transcatheter 
closure methodology is laudable and the diligence with which he pursued the project is 
admirable. Subsequently, Rashkind obtained investigational device exemption from the 
FDA and began organizing multi-institutional clinical trials in the US in early 1980s. This is 
probably the first clinical trial for device implantation in pediatric cardiac practice. 
Unfortunately, Rashkind did not live to witness the conclusion of these trials or to see the 
monumental effect that his work had on the evolution of transcatheter occlusion technology. 
Following experimental studies in animal models, Rashkind studied ASD closure in human 
subjects (Rashkind, 1983; Rashkind & Cuaso, 1977). A total of 33 patients were recruited for 
the clinical trial. Device implantation was not attempted in 10 patients because the defect 
was too large (N=6) to safely implant the device or too small (N=4) to warrant the potential 
risk of device placement. In the remaining 23 patients, 14 (61%) had adequate ASD closure 
and in nine (39%) the results were considered unsatisfactory. The initial six device 
implantations were three-rib umbrellas and the remaining were six-rib prostheses. Urgent 
surgical intervention was required in some patients to address the unsatisfactory 
implantations and others underwent elective surgery. However, uneventful surgical closure 
of the ASD and removal of the device were undertaken in all subjects. Clinical application in 
a limited number of patients by Beekman et al (1989) showed similar results. 
Although good results were achieved in >50% patients, a number of problems were 
identified: requirement of a large sheath for implantation, uncertainty of whether the tissue 
will bind to the entire rim of the single disc device and difficulty in disengaging and 
repositioning the device if the hooks of the umbrella accidentally engage onto the left atrial 
wall or mitral valve. Because of these reasons, Rashkind modified this device into a double 
disc prosthesis which he had successfully employed to close an ASD in a cow (Rashkind, 
1983). This modification was patterned after a concurrently developed Rashkind’s patent 
ductus arteriosus occluding device (Rashkind, 1983; Rashkind et al., 1987). 
2.3 Transformation from Rashkind to clamshell 
The double-umbrella Rashkind device was subsequently utilized in closing ASDs by other 
workers (Lock et al., 1987, 1989; Rome et al., 1990). Whilst the results appeared good, 
difficulty in delivering umbrellas on either side of the defect, centering the device because of 
the angle of the delivery catheter (Lock et al., 1987) and inability of the umbrellas to fold 
back against each other, the device was modified by introducing a second spring in center of 
the arms (Lock et al., 1989) and was named Lock Clamshell Occluder. The clamshell device 
was initially used to occlude experimentally created ASDs in lambs: successful implantation 
was accomplished in six of the eight lambs. Embolization occurred in the remaining two. 
Complete occlusion of the ASD was noted in four lambs. Endothelialization of the device 
components was demonstrated in two lambs followed for 1 and 2 months after device 
deployment. 
The clamshell device is composed of two opposing umbrellas made of 4 steel arms covered 
with woven Dacron material (Figure 1C). The steel arms are hinged together in the center of 
the device and the springs in the middle of the arm were introduced to facilitate folding 
back of the umbrellas against each other, thereby creating a clamshell configuration. The 
device is delivered through an 11 F sheath, a definitive improvement compared to the 
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sheath size required to implant King’s and hooked Rashkind’s devices. Several device sizes 
were manufactured: 17 mm, 23 mm, 28 mm and 33 mm. Balloon stretched diameter of the 
ASD was measured as in the previous device implantation reports and a device at least 1.6 
times larger than stretched ASD diameter was recommended for device placement. The 
delivery catheter is advanced into the left atrium across the ASD, and its tip positioned in 
mid-left atrium. The distal arms of the device are opened and the device is withdrawn 
against the atrial septum until the arms are seen to bend. The sheath is pulled back while 
keeping the device in position with resultant opening of the proximal arms in the right 
atrium. After ensuring the stability of the device across the atrial septum by fluoroscopic 
and echocardiographic imaging, the device is released by activating pin-to-pin mechanism. 
The preliminary clinical experience included 17 clamshell device implantations (Rome et al., 
1990). This report (Rome et al., 1990) combines the results of implantation of Rashkind 
double umbrella, prototype clamshell and clamshell devices and therefore the exact 
clamshell results are difficult to discern. Forty patients were taken to catheterization 
laboratory with intent to close, and of these, 34 (85%) had implantation of the device. With 
the exception of one major complication (death secondary to cerebral embolus, presumably 
related to dislodgment of iliac vein thrombus during placement of device delivery sheath), 
the procedures were successful. Embolization of the device into the descending aorta at iliac 
bifurcation occurred in two (6%) patients. The embolized devices were transcatheter 
retrieved and the patients sent to elective closure of their ASDs. At short-term follow-up, 12 
(63%) of 19 who had adequate echocardiographic study had no residual shunts. 
Hellenbrand et al reported use of this device; device implantation was attempted in eleven 
patients aged 13 months to 46 years (Hellenbrand et al., 1990). The device was implanted 
successfully in ten patients; the single failure was in their youngest patient weighing 11 kg. 
The procedures were performed under general anesthesia with endotracheal intubation and 
transesophageal echo-Doppler (TEE) monitoring; they advocated TEE monitoring during 
the procedure. Residual shunt was present in one (10%) patient. In the study by Boutin et al 
(1993), residual shunt was present in 91% immediately following device placement. The 
residual shunts decreased to 53% at a mean follow-up of 10 months. Actuarial analysis 
indicated progressive reduction of shunt with time (Boutin et al., 1993). Clinical trials by 
these and other investigators continued (Boutin et al., 1993; Latson, 1993; Perry et al., 1993). 
However, fractures of the arms of the device were reported in 40 to 84% of implanted 
devices with occasional embolization (Justo et al., 1996; Perry et al., 1993; Prieto et al., 1996), 
which were of concern. Consequently, further clinical trials with the device were suspended 
in 1991 by the investigators and the FDA. Subsequently the device was modified which will 
be reviewed later in this chapter. 
2.4 Buttoned device 
Sideris et al described "buttoned device" at about the time of transformation of Rashkind 
double disk device to clamshell device (Sideris et al., 1990 a & b). The device consisted of 
three components: occluder, counter-occluder and delivery system. The occluder consisted 
of an x-shaped, Teflon-coated wire skeleton covered with 1/8-in polyurethane foam (Figure 
1 D, left component). The wire skeleton of the occluder can be folded, making the wires 
parallel, which can then be introduced into an 8-French sheath. When delivered to site of 
implantation, the occluder springs opens into its original square-shaped structure. A 2-mm 
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direction of Rashkind. Rashkind’s enthusiasm and dedication in developing transcatheter 
closure methodology is laudable and the diligence with which he pursued the project is 
admirable. Subsequently, Rashkind obtained investigational device exemption from the 
FDA and began organizing multi-institutional clinical trials in the US in early 1980s. This is 
probably the first clinical trial for device implantation in pediatric cardiac practice. 
Unfortunately, Rashkind did not live to witness the conclusion of these trials or to see the 
monumental effect that his work had on the evolution of transcatheter occlusion technology. 
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the clinical trial. Device implantation was not attempted in 10 patients because the defect 
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and in nine (39%) the results were considered unsatisfactory. The initial six device 
implantations were three-rib umbrellas and the remaining were six-rib prostheses. Urgent 
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which were of concern. Consequently, further clinical trials with the device were suspended 
in 1991 by the investigators and the FDA. Subsequently the device was modified which will 
be reviewed later in this chapter. 
2.4 Buttoned device 
Sideris et al described "buttoned device" at about the time of transformation of Rashkind 
double disk device to clamshell device (Sideris et al., 1990 a & b). The device consisted of 
three components: occluder, counter-occluder and delivery system. The occluder consisted 
of an x-shaped, Teflon-coated wire skeleton covered with 1/8-in polyurethane foam (Figure 
1 D, left component). The wire skeleton of the occluder can be folded, making the wires 
parallel, which can then be introduced into an 8-French sheath. When delivered to site of 
implantation, the occluder springs opens into its original square-shaped structure. A 2-mm 
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string loop made of silk thread is attached to the center of the occluder; the loop is closed 
with a 1-mm knot (button). The counter-occluder is composed of a single strand, Teflon- 
coated wire skeleton covered with rhomboid shaped polyurethane foam (Figure 1 D, right 
component). A rubber piece is sutured in its center and becomes a buttonhole. The delivery 
system consisted of a) Teflon-coated 0.035-in guide wire (loading wire), b) a folded 0.008-in 
nylon thread passing through the guide wire, after having its core removed. The loop of this 
thread passes through the loop in the center of the occluder, c) an 8-French or 9-French long 
sheath for device delivery and implantation and d) an 8-French pusher catheter to advance 
the occluder and counter occluder within the sheath. This may be considered first 
generation buttoned device. The device was manufactured in 5-mm increments beginning 
with 25-mm size. The device size was measured by the diagonal length of the occluder and 
is same as the length of the counter-occluder. 
Atrial septal defects were produced in piglets. The buttoned device was successfully 
implanted in 17 (85%) of 20 attempts. The failures were in the first three animals; 
presumably related inexperience of the operator and design imperfections (Sideris et al., 
1990a). Full occlusion of the ASD and endothelialization of the device was demonstrated in 
all the 17 successful implantations. 
During the preliminary clinical experience with this device (Rao et al., 1992a), minutes after 
implantation of the device, it spontaneously dislodged from the ASD site in one child. 
Inspection of the surgically explanted device revealed that the tie binding the occluder with 
the counter-occluder was torn. It seemed that excessive force was used while buttoning the 
components of the device across the atrial septum, to ensure adequate buttoning. Based on 
this undesirable experience, the device was modified by a) strengthening the button-loop by 
replacing the silk tie with 4-lb proof nylon, b) introducing a radio-opaque marker on the 
button, so that passage of the buttonhole of the counter-occluder over the button can be 
visualized by fluoroscopy. Consequently, there will be no need to use excessive force and c) 
the 1/8-in polyurethane foam covering the wire skeleton was replaced with thinner 1/16-in 
foam. This is considered second-generation of the buttoned device (Figure 3, left). 
While incorporation of radio-opacity in the button made easy visualization of the button 
(Figure 4), it produced eccentricity of the button (Figure 3, left). This created additional 
difficulty in buttoning. Therefore, an additional loop of nylon thread was added 
immediately below the button (Figure 3, middle). This transformed the eccentric button of 
the second-generation device to be aligned straight, thus making it easier to button the 
occluder and counter-occluder across the atrial septum; this became third-generation device. 
Although the prevalence of unbuttoning decreased with the introduction of the additional 
loop (Rao et al,. 1994), buttoning across a thick atrial septum, especially when closing patent 
foramen ovale for prevention of presumed paradoxical embolism (Ende et al., 1996), became 
difficult with the radio-opaque wire of the counter-occluder swayed away from radio-
opaque button despite “adequate buttoning.” This, along with our experience with buttoned 
device for patent ductus arteriosus (Rao et al., 1993) in which we used two knots (buttons), 
the device was further modified such that an 8-mm string loop is attached to the occluder 
with two knots (buttons) on it, 4-mm and 8-mm from the occluder (Figure 3, right). Radio-
opaque spring buttons were incorporated into both the knots. A sketch with details of the 
button loop and photographs of the fourth generation device are shown in figures 5 and 6, 
respectively. 
 




Fig. 3. Second, third and fourth generation buttoned devices; see the text for details. Occ, 
occluder; ROB, Radio-opaque button, NT, nylon thread; LW, loading wire. 
 
Fig. 4. Selected cinefluorograms in AP view demonstration the buttoning: the occluder (O) 
and the counter-occluder (CO) are past the radio-opaque button (B). LW, loading wire. 
During the initial period of the clinical trials the device delivery required cutting the valve 
component of the delivery sheath which was then re-attached after loading the device into 
the sheath (Sideris et al., 1990b; Rao et al., 1991; Rao et al., 1992 a & b). This step was 
subsequently eliminated by directly loading the device into a short sheath which was then 
introduced thru' the valve of the delivery sheath (Rao, 2003). During this period the device 
was directly delivered across the defect. In cases with misplacement or slippage of the 
occluder into the right atrium, it was difficult to reposition the occluder and it had to be 
retrieved out of the patient, damaging the device. Therefore, over-the-wire delivery 
technique was developed. The implantation of the device is similar to direct delivery except 
the central foam part (close to middle of the X) is pierced with the end of 025" Amplatz wire 
and the wire is removed at the end of the procedure. The majority of devices were delivered 
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by the over-the-wire technique in the later part of fourth generation device trials (Rao & 
Sideris, 1998; Rao et al., 2000; Rao, 2003). 
 
Fig. 5. Cartoon of the fourth generation buttoned device (right) with details of the buttoned 
loop (BL) (left). The buttoned loop (BL) includes two “spring” buttons positioned 4-mm 
apart. During buttoning, the spring button becomes straightened in line with the button 
loop. After buttoning the radio-opaque spring button becomes perpendicular, preventing 
unbuttoning. COcc, counter-occluder; DW, delivery wire; NT, nylon thread; Occ, occluder; 
Sh, sheath. 
 
Fig. 6. Photographs of fourth generation buttoned device in multiple views. 
Concomitantly a number of other modifications of the device were introduced which 
include, centering device (Sideris et al., 1996) to center the device over the defect (Figure 7), 
inverted device (Rao et al. 1997;) to address closure of right to left shunts (Figure 8), 
centering on demand device (Sideris et al., 1997; Rao & Sideris 2001) to center the device 
when necessary (Figure 9) and hybrid device (Rao, 2003) to address closure of defects with 
associated with atrial septal aneurysm (Figure 10). 
 




Fig. 7. Photographs of centering buttoned device with the centering mechanism open  
(left panel) and closed (right panel). 
 
Fig. 8. Photograph of inverted buttoned device. COc, counter occluder; OCC, Occluder. 
 
Fig. 9. Photographs of centering on demand buttoned device with the centering mechanism 
open (left panel) and closed (right panel). 
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Fig. 10. Photograph of a hybrid device with square-shaped counter occluder on the aright 
atrial side, particular usefully with ASDs with atrial septal aneurysms. 
A comprehensive review and comparison from international and US trials of the first four 
generations of buttoned device and the COD device was presented in 2001 (Rao and Sideris, 
2001). The first three generation devices were used during a 3.5-year period ending in 
February 1993 in 180 patients at 16 institutions around the world (Rao et al., 1994). The ASD 
size varied between 5 and 25 mm. The device size varied between 25 and 50 mm. Successful 
implantation rate was 92% (166/180). Effective closure, defined as no (92 patients) or trivial 
(62 patients) shunt by echocardiography within 24 hours was achieved in 154 patients (92%). 
Unbuttoning occurred in 13 patients (7.2%) and of these, 10 (5.5%) had surgical retrieval and 
closure of their ASD. In a 7 -year follow-up study (Rao at al. 2000), residual shunts were 
closed surgically in 13 and by catheter methodology in 1 patient. In the remaining patients, 
the shunt either disappeared or decreased. The fourth generation device was implanted 
during a 4-year period ending in September 1997 in 423 patients at 40 institutions 
worldwide (Rao et al., 2000). The ASD size varied between 5 and 30 mm (median 17 mm). 
The device size varied between 25 and 60 mm and the successful implantation rate was 
99.8% (422/423). Unbuttoning diminished to 0.9% and device embolization occurred in only 
one patient. Four patients had device retrieval and subsequent surgical repair and one 
patient required urgent surgical retrieval and ASD repair. Effective closure, as previously 
defined, was 90% (377 /417). Follow-up data were available up to a 5-year period in 333 of 
417 patients (80%). During this period re-intervention occurred in 21 patients (5%) mainly 
due to residual shunts. This included 11 patients requiring surgical closure and 9 patients 
receiving a second device. In the remaining patients, there was a gradual reduction in 
residual shunt. The COD device was implanted in 65 of 68 patients (95.6%) during an 18 
month period ending in July 2000 (Rao and Sideris, 2001). In the remaining 3 patients, the 
device was not implanted either because of a large defect with deficient rims (n = 1) or 
because the device was unstable (n = 2). In the latter two patients, the device was 
transcatheter retrieved, and all three patients underwent successful surgical closure 
electively. Based on echo-Doppler studies performed within 24 hours of device 
implantation, effective occlusion defined as no (n = 45; 69%) or trivial (n = 17; 26%) shunt 
was seen in 62 (95.4%) of 65 patients. In the remaining three, residual shunts were small and 
were followed-up clinically. One pediatric patient had a suspected thrombus on the 
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occluder disc, which was treated with tissue plasminogen activator (tPA). The clot resolved 
without complications. At the time of that report (Rao and Sideris, 2001), short-term follow-
up indicated that no further interventions had been required. An updated experience in 80 
patients (Rao, 2003) indicated similar results. 
The device has also been successfully used to close atrial defects presumed to be responsible 
for paradoxical embolism and cerebrovascular accidents (Ende et al., 1996), patent foramen 
ovale causing hypoxemia in platypnea-orthodeoxia syndrome in the elderly (Rao et al., 
2001) and persistent right to left shunt associated with previously operated complex 
congenital cardiac anomalies, including Fontan fenestrations (Rao et al., 1997). 
A number of single institutional (Sideris et al., 1990; Rao et al., 1991; Rao et al., 1992a; Rao et 
al., 1992b; Rao et al., 1995; Arora et al., 1996; Haddad et al., 1996; Worms et al., 1996) and 
multi-institutional (Rao et al., 1994; Lloyd et al., 1994; Zamora et al., 1998; Rao et al., 1998; 
Rao & Sideris et al., 1998; Rao et al., 2000; Rao and Sideris, 2001) clinical trials were 
undertaken which demonstrated feasibility, safety and effectiveness of this device. 
However, pre-market-approval (PMA) application was not made and consequently the 
device is not approved by the FDA and is not available for general clinical use. 
2.5 Monodisk device 
Pavcnik et al (Pavcnik et al., 1993) designed a monodisk device. The device consists of a 
stainless steel ring constructed with wire coil covered with two layers of nylon mesh. Three 
hollow pieces of braided stainless steel wires were sutured onto the right atrial side of the 
device (Figure 11). Three strands of monofilament nylon pass through, one in each of the 
hollow wires. The nylon thread also passes through the delivery catheter. The entire system 
 
Fig. 11. Photographs of the monodisk device showing tilted side profile of the device after 
having opened it following passage through a model atrial septal defect (left top).  Right 
atrial views of the device after having the device pulled against the model atrial septal 
defect prior to (right upper) and after (right lower) releasing flexible wires against the atrial 
septum are shown. Final position of the device (left lower) after disconnecting device by 
cutting monofilament nylon. 
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occluder disc, which was treated with tissue plasminogen activator (tPA). The clot resolved 
without complications. At the time of that report (Rao and Sideris, 2001), short-term follow-
up indicated that no further interventions had been required. An updated experience in 80 
patients (Rao, 2003) indicated similar results. 
The device has also been successfully used to close atrial defects presumed to be responsible 
for paradoxical embolism and cerebrovascular accidents (Ende et al., 1996), patent foramen 
ovale causing hypoxemia in platypnea-orthodeoxia syndrome in the elderly (Rao et al., 
2001) and persistent right to left shunt associated with previously operated complex 
congenital cardiac anomalies, including Fontan fenestrations (Rao et al., 1997). 
A number of single institutional (Sideris et al., 1990; Rao et al., 1991; Rao et al., 1992a; Rao et 
al., 1992b; Rao et al., 1995; Arora et al., 1996; Haddad et al., 1996; Worms et al., 1996) and 
multi-institutional (Rao et al., 1994; Lloyd et al., 1994; Zamora et al., 1998; Rao et al., 1998; 
Rao & Sideris et al., 1998; Rao et al., 2000; Rao and Sideris, 2001) clinical trials were 
undertaken which demonstrated feasibility, safety and effectiveness of this device. 
However, pre-market-approval (PMA) application was not made and consequently the 
device is not approved by the FDA and is not available for general clinical use. 
2.5 Monodisk device 
Pavcnik et al (Pavcnik et al., 1993) designed a monodisk device. The device consists of a 
stainless steel ring constructed with wire coil covered with two layers of nylon mesh. Three 
hollow pieces of braided stainless steel wires were sutured onto the right atrial side of the 
device (Figure 11). Three strands of monofilament nylon pass through, one in each of the 
hollow wires. The nylon thread also passes through the delivery catheter. The entire system 
 
Fig. 11. Photographs of the monodisk device showing tilted side profile of the device after 
having opened it following passage through a model atrial septal defect (left top).  Right 
atrial views of the device after having the device pulled against the model atrial septal 
defect prior to (right upper) and after (right lower) releasing flexible wires against the atrial 
septum are shown. Final position of the device (left lower) after disconnecting device by 
cutting monofilament nylon. 
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can be loaded and the device delivered through a 9 F sheath. Once the device is opened in 
the left atrium, it is withdrawn against the atrial septum so that the hollow wires are 
positioned onto the right atrial side of the septum (Figure 11, right upper panel). The nylon 
filaments are cut, which allow the wires to spring back and detach the device from the 
delivery catheter (Figure 11, right lower and left lower). 
Device implantation to occlude five experimentally created ASDs in dogs was undertaken. 
The position of the device was good in all dogs and there was no residual shunt. In four 
dogs, postmortem studies were performed six months later, which showed the device to be 
in place with incorporation into the atrial septum and excellent endothelialization. The 
device was used successfully in two patients with secundum ASD (personal 
communication: D. Pavčnik, December 2000). More recently, a biodisk device was 
developed and animal experimentation suggested that device deployment is feasible, safe 
and effective (Pavčnik et al., 2010). The authors recommended long-term studies were to 
evaluate its long-term effectiveness. 
2.6 Modified Rashkind PDA umbrella device 
The Rashkind PDA umbrella (Rashkind et al., 1987) device was modified by bending the 
arms of the device such that there is a better apposition of the umbrellas against each other 
and the atrial septum (Redington & Rigby, 1994). The device was used to occlude four ASDs 
with left-to-right shunt. In two (50%) patients, the ASD was successfully closed. The 
remaining two (50%) patients required surgical removal of the device along with closure of 
the ASD. The device was also used to occlude 11 fenestrated Fontans. In nine patients, there 
was improvement in oxygen saturation. In the remaining two (18%), the procedure failed. 
To my knowledge, there are no other reports on the use of this modification by this or other 
workers. In addition, a similar bend placed in the clamshell device has resulted in breakage 
of the arms, forcing its removal from use. Therefore, advisability of introducing such a bend 
in the Rashkind PDA device was questioned (Rao & Sideris, 1995). 
2.7 Atrial Septal Defect Occluding System (ASDOS) 
Babic and his associates (Babic et al., 1991) described a double umbrella device implanted 
via arterio-venous guide wire loop in 1991. They named it ASDOS (atrial septal defect 
occluding system) (Sievert et al., 1995; 1998). In the initial prototype, once the device was 
locked in place, it required surgical removal for suboptimal positioning. The device 
underwent further modifications and the updated prototype was released in 1994. This 
version consists of two major components: (1) a prosthesis consisting of two self-opening 
umbrellas made of Nitinol wire frame and a thin membrane of polyurethane (Figure 12A) 
and (2) a delivery system. Each umbrella has five arms, which assume a round shape in the 
open position. When joined together, the umbrellas assume a discoid shape in profile and a 
“flower” shape in the frontal view. Umbrella sizes from 25 mm to 50 mm; with 5mm 
increments were manufactured. This system uses 11-F long sheath for device deployment. 
Inter-atrial communications were created with dilatation balloons in 20 pigs and their 
defects closed with ASDOS device. Examination 3, 4 and 6 months after device closure 
revealed that devices were completely covered with smooth, scar-like tissue after three 
months of the procedure (Schneider et al., 1995; Thomsen-Bloch, 1995). 
 




Fig. 12. Photographs of ASDOS (A), Das Angel Wing (B), CardioSEAL (C) and STARFlex (D) 
devices; see the text for detailed description of the devices. 
Initial clinical trials in adult subjects (Babic et al., 1991; Sievert et al., 1995) and children 
(Hausdorf et al., 1996) demonstrated feasibility of the method and a multi-institutional 
clinical trial in 20 European institutions began (Sievert et al., 1998). Babic (Babic, 2000; Babic 
et al., 2003) reviewed the experience with the ASDOS system, including the European multi- 
institutional study. Between 1995 and 1998, closure was attempted in 350 patients (ASDOS 
registry, December 1998); 261 had ASDs and 89 had PFOs. It should be noted that 800 
patients with ASD were screened and 261 (33%) of these were selected for device closure. 
Three hundred and eighteen patients (91%) had successful implantation. There were 32 (9%) 
failures; 26 devices were retrieved via catheter (7%) and 6 devices retrieved by surgery (2%). 
Early embolization was noted in 3 (0.9%), thromboemboli in 3 (0.9%), perforations in 6 
(1.6%) and suspected infections in 2 (0.6%). Embolizations were to the right ventricular 
outflow tract, the abdominal aorta and the pulmonary artery. There were no late 
dislodgments or embolizations. Residual shunts were noted in 25% to 30% of patients and in 
some patients the shunt closed over time. A medium-to-large shunt remained in 8% and the 
defects were surgically repaired because of no shunt reduction with time. During follow-up, 
surgical extraction was performed in 11 (3%) patients. The complications include frame 
fractures in 20% of patients, thrombus formation in 25% patients and atrial wall perforation 
in 1.5% patients. Presumably because of these complications, the device was renounced by 
the inventor (Babic et al., 2003) and is not currently used. A modified version with a stent 
between the umbrellas to provide optimal centering along with other changes was 
conceived, but not available for clinical use (Babic et al. 2003). 
2.8 Das Angel Wing Device 
In 1993, Das and his colleagues (Das et al., 1993) designed a self-centering device, delivered 
transvenously via an 11 F sheath and named it Das Angel Wing Device (Figure 12B). This 
device had two polyester fabric-covered square frames and a Nitinol frame with midpoint 
torsion spring eyelets. A circular hole with a diameter equal to one-half of the size of the 
disk was punched from the right disk with the margins sewn to the left-sided disk forming a 
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“flower” shape in the frontal view. Umbrella sizes from 25 mm to 50 mm; with 5mm 
increments were manufactured. This system uses 11-F long sheath for device deployment. 
Inter-atrial communications were created with dilatation balloons in 20 pigs and their 
defects closed with ASDOS device. Examination 3, 4 and 6 months after device closure 
revealed that devices were completely covered with smooth, scar-like tissue after three 
months of the procedure (Schneider et al., 1995; Thomsen-Bloch, 1995). 
 




Fig. 12. Photographs of ASDOS (A), Das Angel Wing (B), CardioSEAL (C) and STARFlex (D) 
devices; see the text for detailed description of the devices. 
Initial clinical trials in adult subjects (Babic et al., 1991; Sievert et al., 1995) and children 
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clinical trial in 20 European institutions began (Sievert et al., 1998). Babic (Babic, 2000; Babic 
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institutional study. Between 1995 and 1998, closure was attempted in 350 patients (ASDOS 
registry, December 1998); 261 had ASDs and 89 had PFOs. It should be noted that 800 
patients with ASD were screened and 261 (33%) of these were selected for device closure. 
Three hundred and eighteen patients (91%) had successful implantation. There were 32 (9%) 
failures; 26 devices were retrieved via catheter (7%) and 6 devices retrieved by surgery (2%). 
Early embolization was noted in 3 (0.9%), thromboemboli in 3 (0.9%), perforations in 6 
(1.6%) and suspected infections in 2 (0.6%). Embolizations were to the right ventricular 
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dislodgments or embolizations. Residual shunts were noted in 25% to 30% of patients and in 
some patients the shunt closed over time. A medium-to-large shunt remained in 8% and the 
defects were surgically repaired because of no shunt reduction with time. During follow-up, 
surgical extraction was performed in 11 (3%) patients. The complications include frame 
fractures in 20% of patients, thrombus formation in 25% patients and atrial wall perforation 
in 1.5% patients. Presumably because of these complications, the device was renounced by 
the inventor (Babic et al., 2003) and is not currently used. A modified version with a stent 
between the umbrellas to provide optimal centering along with other changes was 
conceived, but not available for clinical use (Babic et al. 2003). 
2.8 Das Angel Wing Device 
In 1993, Das and his colleagues (Das et al., 1993) designed a self-centering device, delivered 
transvenously via an 11 F sheath and named it Das Angel Wing Device (Figure 12B). This 
device had two polyester fabric-covered square frames and a Nitinol frame with midpoint 
torsion spring eyelets. A circular hole with a diameter equal to one-half of the size of the 
disk was punched from the right disk with the margins sewn to the left-sided disk forming a 
 
Atrial Septal Defect 
 
70
conjoined ring, the centering mechanism (Rickers et al., 1998). Device sizes ranging from 12 
to 40 mm were manufactured. The length of the square of the device determines device size. 
ASDs were produced surgically in 20 adult canines. Percutaneous closure was attempted in 
all and was successful in 19 (95%). Following closure, angiography revealed no shunts in 17 
and trivial shunts in 2. Six dogs were followed for 2 to 8 months; trivial shunt present in 1 
animal immediately after closure had closed by the time of the repeat study. Device 
embolization was not seen either at the time of device deployment or during follow-up. 
Microscopy at 8 weeks in 3 dogs showed the devices to be covered by smooth endocardium, 
enmeshed in mature collagen tissue. The authors conclude that this self-centering device, 
with effective and safe ASD closure in a canine model, supports its use in human clinical 
trials (Das et al., 1993). 
Clinical trials were undertaken in US and abroad (Rickers et al., 1998; Banerjee et al., 1999). 
Phase I clinical trial included 90 patients; 50 of these were ostium secundum ASDs (Banerjee 
et al., 1999; Das et al., 2003). The ASD size varied between 2 and 20 mm. The device size 
varied between 18 and 35 mm. The device was successfully implanted in 46 (92%) patients; 
in the remaining four patients surgical retrieval of the mal-positioned device along with 
surgical closure of ASD was accomplished without additional complications. Significant 
procedure related complications were seen in three patients. Follow-up echo studies were 
available in 34 and in 31 of these, there was no residual shunt. A phase II trial involving 47 
patients followed with essentially similar results as those of phase I trials (Das et al., 2003). 
Prior to the conclusion of phase II trial, the investigation was halted in attempts to 
reconfigure the device. The new device modification, Guardian Angel wing (Angel wing II) 
included rounded right and left atrial disks, to be easily retrievable, to be easily repositioned 
and to maintain the self-centering mechanism. Although it was stated that the re-made 
device will enter clinical trials in the near future (Das et al., 2003), to our knowledge, there 
has been no further activity reported of either the Angel Wing or Guardian Angel devices; it 
would appear that the device was shelved. 
2.9 CardioSEAL and STARFlex devices 
As mentioned in the previous section of this paper, following withdrawal of clamshell 
device because of breakage of arms (stress fractures), the device was redesigned by 
replacing stainless steel of the umbrella arms with MP35N, a nonferrous alloy and by 
introducing an additional bend in the arms of the device; the device was named 
CardioSEAL (Figure 12 C) in 1996 (Ryan et al., 1998). Subsequently the device was modified 
to introduce self-centering mechanism by attaching micro springs between the umbrellas, 
and is named STARFlex (Figure 12 D) in 1998 (Hausdorf et al., 1999). 
Both CardioSEAL and STARFlex devices were used in the European multicenter trial 
(Carminati et al., 2000; Bennhagen et al., 2003) conducted from October 1996 to April 1999; 
device implantation was attempted in 334 patients with success in 325 (97.3%) patients. Device 
to balloon stretched ASD diameter ratio was 2.16 (mean). Embolization of the device occurred 
shortly after the procedure in 13 patients (4%); 12 embolized to the pulmonary artery and one 
to the left ventricle. In ten patients, surgical retrieval and ASD closure was performed while 
the remaining three had catheter retrieval with successful re-implantation of another device. 
One patient had hemiplegia four hours after the procedure. A residual shunt was present in 
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41% immediately following the procedure, which decreased to 31% at time of discharge and to 
21% six and 12 months later. During follow-up surgery was required in two more patients and 
wire frame fractures were observed in 6.1% patients. The authors concludes that these devices 
are useful to close small to moderate ASDs and when used to close large defects, complications 
or less than optimal results are likely. Similar results were reported in the Canadian experience 
with CardioSEAL device in 50 patients (Pedra et al., 2000). 
STARFlex was further modified by replacing Dacron with bio-absorbable materials: 
BioSTAR and BioTREK; these devices will be discussed in a latter section of this paper. 
2.10 Amplatzer septal occluder 
In 1997, a new self-expanding Nitinol prosthesis was developed by Dr. Kurt Amplatz, which 
consists of two self-expandable round disks connected to each other with a short connecting 
waist (Sharafuddin et al., 1997) and is commonly referred to as Amplatzer septal occluder 
(Figure 13 A). Nitinol is a nickel-titanium compound consisting of 55% nickel and 45% 
titanium and has a property of resuming the original shape (shape memory) when 
deployed. The device size is determined by the waist diameter and ranges from 4 to 40 mm. 
The disk diameters increase with increasing waist diameters. 
 
Fig. 13. Photographs of Amplatzer septal occluder (A), PFO Occluder (B), fenestrated 
Amplatzer device (C) and cribriform Amplatzer device (D). 
ASDs were created surgically in 15 mini-pigs; the ASD diameter ranged between 10 and 16 
mm. Amplatzer septal occluder was used to percutaneously close the ASDs (Sharafuddin et 
al., 1997). Successful implantation of the device was accomplished in 12 (80%) animals. 
Angiography revealed complete closure of ASD in 7 of 12 animals immediately after device 
placement and in 11 of 12 one week later. Fibrous incorporation of the device with 
neoendothelialization was seen within 3 months. The authors concluded that occlusion of 
secundum ASDs is feasible with this new device. 
The device has been used widely in PFOs, ASDs, and Fontan fenestrations. The results of 
first clinical trial were reported by Masura in 1997 (Masura et al., 1997). The device was 
approved by FDA in December 2001 and has since been used extensively worldwide. 
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Detailed description of the device, implantation procedure and results were described in 
Chapter 1 and several other chapters in this book and will not be further discussed. Several 
modifications of the Amplatzer device were introduced: 1. PFO Occluder (Figure 13 B) to 
close patent foramen ovale (Han et al., 1999), 2. fenestrated Amplatzer device (Figure 13 C) 
to keep atrial septal defects or Fontan fenestration open to maintain cardiac output (Amin et 
al., 2002), restrict the size of defect to reduce the atrial shunt (Holtzer et al., 2005) or to serve 
as pop-off mechanism in severe pulmonary hypertension (Lammers et al., 2007), 3. 
cribriform device (Figure 13 D) to occlude multiple or fenestrated ASDs (Hijazi et al 2003) 
and 4. nanoplatinum coating to prevents nickel release from Amplatzer devices 
(Lertsapcharoen, 2008), thus preventing Kounis syndrome. 
2.11 HELEX septal occluder 
The HELEX septal occluder is made up of a single length of 0.012-in diameter Nitinol wire 
covered by an ultra thin membrane of ePTFE. The configuration, once delivered to the site of 
implantation, was two round and flexible disks (Figure 14 A), one on either side of the ASD. 
During delivery, the flexible frame is elongated around a central mandrel and fits through a 
9F sheath. The wire mandrel except for the central locking mechanism is covered with 
ePTFE membrane so that only a small portion of Nitinol wire is exposed in the vascular 
system. Several sizes from 15 to 35 mm, in 5 mm increments were manufactured. 
Device closure was performed in 24 dogs with surgically created ASDs with 100% successful 
implantation. Initial occlusion rate of 88% was found by transesophageal echocardiography 
which improved to l00% at 2-week follow-up (Zahn et al., 1999; 2001). These animal studies 
also demonstrated coverage of the defect components with fibrous connective tissue 
followed by neo-endothelialization, usually within three months. 
The first clinical implant was performed by in 1999 (Latson et al., 2000), and the Food and 
Drug Administration phase I feasibility trial began in 2000. Feasibility study involving 63 
patients, multicenter pivotal study including 143 subjects and continued access study that 
enrolled 156 patients (Feldman, 2010) demonstrated feasibility, safety and effectiveness of 
the device. The HELEX occluder was approved by FDA in 2006 and from then on it has been 
used extensively worldwide for closing small to medium sized ASDs and PFOs. 
2.12 Sideris’ Wire-less devices including transcatheter patch 
Majority of ASD-occluding devices are double disc devices with wire components and have 
limitations. The major disadvantages are requirement of sufficient septal rims to hold the 
device in place and complications related to wire components (wire fractures and 
perforations) of the device. To address these problems, Sideris and colleagues developed 
wireless, transcatheter-implantable devices to occlude large ASDs (Sideris et al., 1999 a & b; 
Zamora et al., 2000; Sideris, 2003). Two devices were developed (Sideris, 2003): detachable 
balloon device and the transcatheter patch (Figure 14 B). 
The detachable balloon device (DBD) consisted of balloon occluder, made from Latex in 
different sizes and a floppy disk, similar to the counter occluder described in the buttoned 
device section above. The DBDs were used to occlude of experimentally created ASDs in 20 
piglets (Sideris et al., 2000a); in three experiments detachable double balloon devices were 
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used. One device embolized into the descending aorta and complete occlusion was noticed 
in remaining pigs. Follow-up studies revealed that the detachable balloons lost their content 
and became flat in approximately two months and the device was covered by endothelial 
tissue in 3 to 4 weeks. Human feasibility study (Sideris et al., 1999a) involved six ostium 
secundum ASDs (among others); one device embolized, one patient had residual shunt 
which increased over time and four had good occlusion. 
 
Fig. 14. Photographs of HELEX device (A), transcatheter patch (B), BioSTAR device  
(C) and BioTREK device (D). 
The transcatheter patch device consisted of a flat or sleeve patch, a balloon support catheter 
and a safety thread; the patch, made up of polyurethane foam, covers the distal balloon. The 
occluding distal balloon (balloon/patch) is inflated at volumes 2 mm larger than the test- 
occluding diameter of the defect and held in place. The balloons were deflated and removed 
48 hours later. This device was also tried in 20 experimentally created ASDs (Sideris et al., 
2000b); ten were flat patches and ten sleeve patches. The patches were supported by balloon 
catheters from one to six days. Good occlusion of ASDs was seen if the supporting catheter 
was withdrawn 48 hours or later. Histological studies revealed formation fibrin and 
inflammatory cells. The sleeve patch appeared to be better centered over the defect than a 
flat patch. Initial clinical trials were performed in a limited number of patients (Sideris, 
2003). Subsequently (Sideris et al., 2010), a larger number (N=74) of patients participated in 
the clinical trial. The age of the subjects varied from 1.5 to 67 years and their defect sizes 
were from 13 to 35 mm (mean=25) in diameter; 88% had effective occlusion immediately 
after deployment of the patch which increased to 96% at follow-up (Sideris et al., 2010). 
Initially, this device required keeping the balloon in place up to 48 hours to allow the patch 
to adhere to the septal wall, an obvious disadvantage of this technique (King & Mills, 2010). 
To address this problem, Sideris et al (2010) developed accelerated release technique by 
applying polyethylene glycol-based surgical adhesive to the surface of the patch 
immediately prior to its implantation. This method was used in 9 patients with ASD 
diameters ranging from six and 25 mm. Effective occlusion immediately after implantation 
occurred in 78% which improved to 100% a follow-up. An immediate release patch (IRP) 
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Detailed description of the device, implantation procedure and results were described in 
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was developed which uses a single latex balloon, a safety bioabsorbable thread (Vicryl, 
Ethicon, a Johnson & Johnson company, Somerville, NJ) and polyurethane patch with 
surgical adhesive that was used in accelerated release technique. The addition of the 
adhesive makes the device release immediate and attachment to the septum (mediated by 
fibrin formation) takes place in approximately 48 hours (Sideris et al., 2010). The IRP was 
used in 10 subjects with defects ranging from 12 to 26 mm; 100% full occlusion both at 
implantation and at follow-up was reported (Sideris et al., 2010). Further clinical trials are 
planned. 
2.13 New devices 
Subsequent to the development of the devices reviewed in the preceding sections additional 
devices were designed and tested. None of these are approved by the FDA for routine 
clinical use and will be reviewed briefly. 
These devices, to the best of our knowledge, are bio-absorbable NMT devices (Bio-STAR 
and Bio-TREK), Occlutech device, Cardia devices (INTRASEPT, ATRIASEPT I/II-ASD and 
ULTRASEPT), Solysafe Septal Occluder, pfm ASD-R device, Heart R Septal Occluder 
(manufactured in China) and others. 
2.13.1 BioSTAR and BioTREK 
When occluding devices are implanted to close ASDs, the left atrium is essentially 
inaccessible, should trans-septal intervention becomes necessary later in life such as 
mapping and ablation of left-sided accessory pathways, mitral valve interventions, left atrial 
appendage occlusion and others. To address this concern, NMT Medical Inc. (Boston, MA) 
modified the STARFlex device by replacing Dacron with heparin-coated, acellular, tissue 
engineered, porcine intestinal collagen matrix that allows absorption and replacement of the 
membrane with human tissue, and was named BioSTAR (Figure 14C). Studies in sheep 
model (Jux et al., 2003; 2006) demonstrated rapid endothelialization of the device and 
resorption of intestinal collagen matrix over a period of 2 years. Feasibility, safety, and 
effectiveness of closure of ASDs with BioSTAR both in adults (Mullen et al., 2006) and 
children (Hoehn et al., 2010) were demonstrated. 
The supporting arms (ribs) of the BioSTAR device however, continue to be metallic and are 
not bio-absorbable. BioTREK device (Figure 14 D) was developed and designed to be 100% 
reabsorbable. The covering discs as well as support ribs are made up of poly-4- 
hydroxybutyrate. Over time, the patches and the connecting ribs disappear, leaving the 
fibrous septum. The device was reported in preclinical testing (Kramer, 2010). Other 
workers are developing additional biodegradable devices (Duong-Hong et al., 2010). 
2.13.2 Occlutech 
Occlutech septal occluder, initially designed to close PFOs (Krizanic et al. 2008) has been 
modified to close ASDs. The device is similar to Amplatzer in design (double-disc device 
composed of self-expanding Nitinol mesh wire), but with use of unique braiding 
technology; the amount of metal is reduced by 50%. In addition, the left atrial hub is 
removed. The devices were implanted in 29 patients with PFO and in 12 patients with ASD. 
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TEE studies showed a residual shunt in 11.2% after 60 days in patients with PFO and a left- 
to-right shunt in 9.1% of the remaining patients with ASD. After 180 days only 1 patient 
(3.7%) with PFO had a right-to-left shunt. No residual shunts were observed in the patients 
with ASD (Krizanic et al., 2010). 
2.13.3 Cardia devices (INTRASEPT, ATRIASEPT I/II-ASD and ULTRASEPT) 
PFO-Star device, consisting of Ivalon foam double umbrella was developed in late 1990s by 
Cardia Inc. (Eagan, MN) for percutaneous closure of PFOs (Braun et al., 2002; Schraeder et al, 
2003). This device may be considered Generation I and was modified several times, addressing 
its deficiencies with resultant development of Generation II, Generation III, Generation IV 
(INTRASEPT), Generation V (ATRIASEPT I-ASD and ATRIASEPT II-ASD) and Generation VI 
(ULTRASEPT) devices (Turner & Forbes, 2010). Generation V and VI devices were designed to 
deal with ostium secundum ASDs. Clinical trials with ATRIASEPT I-ASD device (Stolt et al., 
2010; Turner & Forbes, 2010) showed favorable early results. Clinical trials with ATRIASEPT 
II-ASD and ULTRASEPT devices are planned (Turner & Forbes, 2010). 
2.13.4 Solysafe septal occluder 
The Solysafe Septal Occluder device (Swissimplant AG, Solothurn, Switzerland), designed 
by Dr. Lazlo Solymar of Gothenburg, consists of two foldable polyester patches attached to 
eight cobalt-based alloy (Phynox) wires. The course of the wires through the patches enables 
the device to center itself within the defect. The maximum diameter is given by the distance 
of the wires that are fixed in the patches. Several sizes, 25 mm thru’ 44 mm are 
manufactured (Ewert, 2010). Two clinical trials with 44 and 32 patients (Ewert et al., 2008, 
Kretschmar et al., 2010) respectively were reported with implantation rates of 87% and 
closure rate of 100% at six month follow-up. The worldwide experience with this device was 
said to approximate 1,400 patients (Ewert, 2010). 
2.13.5 The pfm ASD-R device 
The pfm ASD-R devices were made up of tightly woven single piece of Nitinol wire mesh 
without welding or hubs and in their final form have a double-disc configuration. Animal 
experimentation in pigs revealed complete endothelialization in three weeks without 
significant inflammatory reaction (Granja & Freudenthal, 2010). The initial clinical 
application in 23 patients demonstrated good results and a multi-institutional phase II 
clinical trial in Argentina is planned (Granja & Freudenthal, 2010). 
2.13.6 Other devices 
Other devices such as Cardi-O-Fix Septal Occluder, Heart R Septal Occluder, cocoon, 
Lifetech device (also called sears device), some manufactured in China and others that may 
have escaped detection by our literature search may be in development. 
3. Closure of patent foramen ovale 
Some cerebrovascular accidents and other systemic arterial emboli, especially in young 
subjects are presumed to be due to paradoxical embolism through an atrial defect, most 
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frequently a patent foramen ovale (PFO). Closure of such atrial defects is an alternative 
option to life-long anticoagulation. Non-surgical transcatheter occlusion of such a defect was 
first reported with King’s device in 1976 (Mills & King, 1976). Mills and King effectively 
occluded an atrial defect with a 25 mm device in a 17-year-old male who had a hemiperetic 
stroke secondary to paradoxical embolism. Subsequently, clamshell (Bridges et al., 1992) and 
buttoned (Rao et al., 1992 a & b; Chandar et al., 1996; Ende et al., 1996) devices have been 
used to successfully occlude PFOs presumed to be the site of paradoxical embolism. 
In addition, some PFOs are considered to be the seat of right to left shunt causing 
hypoxemia as seen in platypnea-orthodeoxia syndrome. Right to left shunt thru’ PFO can 
also occur in patients who were previously treated for complex congenital cardiac anomalies 
including Fontan fenestrations as well as in patients who had right ventricular infarction. 
Decompression (Caisson’s) illness and migraine have also been attributed to right to left 
shunt across PFO. 
Majority of the ASD devices described in the preceding sections, as and when they became 
available, have also been used to close PFOs to address the above listed conditions. 
Moreover, either the existing devices were modified to address the anatomic features of the 
foramen ovale or new devices were designed to specifically address the PFOs and these 
include, Amplatzer PFO occluder, Cardia devices (PFO-Star and several of its subsequent 
generations), Premere occluder, Coherex Flat stent, PFx Closure System (not a device but 
employs monopolar radio frequency energy to effect closure of a PFO by welding the tissues 
of the septum primum with the septum secundum), pfm PFO-R, Solysafe PFO occluder and 
others. Because of limitation in space and the intent to mainly address history of ASD device 
closure, no further discussion of PFOs will be included. 
4. Summary and conclusion 
In this chapter, historical aspects of transcatheter atrial septal occluding devices are 
reviewed. Since the initial description of an ASD closing devices by King, Rashkind and 
their associates, a large number of single disc and double disc devices have been designed 
and tested in animal models followed by clinical trials in human subjects. Feasibility, safety 
and effectiveness have been demonstrated with most devices. However, design, redesign, 
testing and re-testing have been the typical path with most devices. Currently, only two 
devices are approved by the FDA in the US and these are: Amplatzer septal occluder and 
HELEX septal occluder. Several other devices are in development, some at the stage of 
animal experimentation and some in clinical trials in Europe or US. We will await for 
additional devices to be approved for general clinical use so that the practicing 
interventional cardiologist will have several devices at his/her disposal so that an 
appropriate device that suits best for a given patient and his/her defect. A brief review of 
historical aspects of PFO closure was also included. 
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available, have also been used to close PFOs to address the above listed conditions. 
Moreover, either the existing devices were modified to address the anatomic features of the 
foramen ovale or new devices were designed to specifically address the PFOs and these 
include, Amplatzer PFO occluder, Cardia devices (PFO-Star and several of its subsequent 
generations), Premere occluder, Coherex Flat stent, PFx Closure System (not a device but 
employs monopolar radio frequency energy to effect closure of a PFO by welding the tissues 
of the septum primum with the septum secundum), pfm PFO-R, Solysafe PFO occluder and 
others. Because of limitation in space and the intent to mainly address history of ASD device 
closure, no further discussion of PFOs will be included. 
4. Summary and conclusion 
In this chapter, historical aspects of transcatheter atrial septal occluding devices are 
reviewed. Since the initial description of an ASD closing devices by King, Rashkind and 
their associates, a large number of single disc and double disc devices have been designed 
and tested in animal models followed by clinical trials in human subjects. Feasibility, safety 
and effectiveness have been demonstrated with most devices. However, design, redesign, 
testing and re-testing have been the typical path with most devices. Currently, only two 
devices are approved by the FDA in the US and these are: Amplatzer septal occluder and 
HELEX septal occluder. Several other devices are in development, some at the stage of 
animal experimentation and some in clinical trials in Europe or US. We will await for 
additional devices to be approved for general clinical use so that the practicing 
interventional cardiologist will have several devices at his/her disposal so that an 
appropriate device that suits best for a given patient and his/her defect. A brief review of 
historical aspects of PFO closure was also included. 
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1. Introduction 
The incidence of atrial septal defect (ASD) is 1 in 1000 live births and account up to one third of 
the acyanotic shunts in the adult population. (Brickner et al. 2000; Yared et al. 2009) Patent 
foramen ovale (PFO) is found more than 25% of the adults. (Yared, Baggish et al. 2009) 
Historically, surgical closure of ASDs has been the most common therapy until new catheter-
based techniques began to develop pioneered by King and Mills in 1975. (King et al. 1976; 
Yared et al. 2009) Currently, transcatheter closure of ASDs and PFOs is preferred to surgery in 
otherwise uncomplicated and favorable anatomy cases because it is technically simple and is 
associated with negligible morbidity and mortality. These procedures are performed for 
hemodynamically significant left to right shunting, to prevent stroke from recurrent 
paradoxical embolism and for the platypnea orthodeoxia syndrome. In addition to the above, 
closure of the surgically created fenestrations after Fontan operations and also baffle leaks after 
Mustard and Senning surgeries are all performed in the catheterization laboratory. (Hanrath 
2001; Sengupta & Khandheria 2005) Several echocardiographic techniques including 
transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), intracardiac 
echocardiography (ICE) and real time three-dimensional transesophageal echocardiography 
(3D TEE) are being used by many centers. (Silvestry et al. 2009) In this chapter, we will review 
the role of TEE in transcatheter occlusion of atrial septal defects.  
2. Development of interatrial septum 
A good knowledge of the cardiac anatomy is needed for the echocardiographers to identify 
the structures and share them in a common language with the rest of the team involved in 
the care of the patient before, during and after the procedure.  
The major septa of the heart are formed between the 27th and 37th days of development. One 
method by which a septum may be formed involves actively growing masses of tissue that 
approach each other until they fuse dividing the lumen into two separate canals 
(symmetrical growth). Septum may also be formed by active growth of a single tissue mass 
that continues to expand until it reaches the opposite side of the lumen (asymmetrical 
growth). (Fig. 1) 
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Fig. 1. Formation of septa. Symmetrical (middle) and asymmetrical (right) growth (Courtesy 
of Dr. Stephen W. Carmichael) 
Atrium starts as a common chamber. At the end of the 4th week, a sickle cell shaped crest 
grows from the roof of the common atrium into the lumen. This is the first portion of the 
septum primum. 
The opening between the lower rim of the septum primum and the endocardial cushions is 
the ostium primum. (Fig. 2) 
 
Fig. 2. Septum primum (in pink) and ostium primum (in red) (Courtesy of Dr. Stephen W. 
Carmichael) 
With further development, extensions of the endocardial cushions grow along the edge of 
the septum primum closing the ostium primum. Before closure is complete, cell death 
produces perforations in the upper portions of the septum. (Fig. 3) 
 
Fig. 3. Closure of ostium primum (in blue) and perforations in the septum (in red) (Courtesy 
of Dr. Stephen W. Carmichael) 
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Holes in septum primum coalesce to form ostium secundum. When the lumen of the right 
atrium expands as a result of the incorporation of the sinus horn, a new crescent shaped fold 
appears. Septum secundum begins to grow over ostium secundum. Septum secundum is to 
the right of septum primum and is more rigid. (Fig. 4) 
 
Fig. 4. Septum secundum (in green), septum primum (in blue) and ostium secundum (in 
red) (Courtesy of Dr. Stephen W. Carmichael) 
Free concave edge of the septum secundum begins to overlap the ostium secundum. The 
tunnel like opening left by the septum secundum is the foramen ovale. Eventually within 
the first few years of life, the septum secundum fuses with the septum primum in most of 
the population thus separating the two atria. (Fig. 5) 
 
Fig. 5. Septum secundum (in green) and foramen ovale (in red arrow) (Courtesy of Dr. 
Stephen W. Carmichael) 
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Ostium secundum ASDs are caused either by excessive cell death and resorption of the 
septum primum or by inadequate development of the septum secundum.  
PFO which is the result of lack of fusion between the septum primum and the septum 
secundum is not considered a true ASD and stays functionally closed as long as the left 
atrial pressure is higher than the right atrial pressure. There is a potential for right to left 
shunting resulting in paradoxical embolism and stroke if the right atrial pressure rises 
(mostly observed with valsalva) enough to open the PFO. (Johri et al. 2011) 
3. Echocardiographic techniques  
Echocardiography has been the widely used imaging technique that complements the 
fluoroscopy during closure of ASDs and PFOs. Compared to computed tomography and 
magnetic resonance imaging, echocardiography has the major advantage of being portable 
and real time. In this way, echocardiography can be performed before, during and after 
transcatheter interventions. (Silvestry et al. 2009) Even though fluoroscopy is the main 
imaging modality during interventional procedures, it does not provide direct assessment of 
cardiac anatomy as good as echocardiography. In addition to defining the intracardiac 
structures important in the ASD closure process, echocardiography is helpful in showing the 
relationship between catheters or devices and the adjacent structures. (Brochet & Vahanian 
2010) The use of echocardiography as an adjunct to fluoroscopy has decreased the amount 
of total fluoro time to close an ASD.  
Once the diagnosis of ASD or PFO and a decision to close it has been made, atrial septum 
should be assessed immediately before the procedure in the cardiac catheterization 
laboratory to confirm the diagnosis, during the procedure to help with device occlusion and 
after the procedure to reconfirm the success of the procedure without complications.  
There are multiple techniques for the imaging of the atrial septum.  
3.1 TTE 
TTE is the simplest technique to use. It can show the device in multiple planes but does not 
have adequate imaging of the lower rim of the atrial septal tissue, which is above the inferior 
vena cava (IVC) especially after device placement. In addition to this, since the distance from 
the septum to the transducer is farther in TTE than TEE or ICE, the color imaging at the atrial 
septal level may be suboptimal. Access to the patient’s body through the sterile field also poses 
a problem. Even though TTE may be the initial diagnostic tool, it is infrequently used in the 
catheterization laboratory to aid in ASD closures. (Silvestry et al. 2009) 
3.2 TEE  
In contrast to TTE, TEE offers better image resolution and definition of anatomy during the 
transcatheter closure of ASDs. It has become the standard imaging modality in many centers 
to monitor and guide interventional procedures because of its easy application, lower cost, 
portability and real time imaging. It is mostly agreed that TEE is superior to fluoroscopy in 
defining the defect margins and to position the device and/or its arms. (Hanrath 2001) The 
main limitation of TEE is the need for general anesthesia. (Brochet & Vahanian 2010) It also 
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requires a dedicated echocardiographer to perform the study. TEE in ASD closure will be 
discussed further in the rest of the chapter.  
3.3 ICE  
ICE has been introduced to cardiac imaging techniques more than 10 years ago. It has 
evolved from cross sectional imaging using a rotating transducer to sector based imaging 
using a phased-array transducer. There are three ICE catheters available with respective 
ultrasound systems. Most frequently used ones are 8F or 10 F ultrasound catheters. Some 
centers prefer ICE to other imaging modalities because of its superiority in imaging 
especially the inferior rim of the atrial septum, which is important in decision making to 
close the defect. (Kim et al. 2009) It is advantageous to TEE mostly because it avoids the 
need for general anesthesia. The cost of the catheter is one of the main drawbacks of using 
ICE. Even though closure of PFO under the guidance of ICE is safe and effective, ICE may 
not be sensitive enough to detect all patients with right to left shunting. (Van et al. 2010; 
Pedra, Fleishman et al. 2011) In addition to this, limited field view for far field device 
complications, the need for a second venous sheath, the requirement for additional 
training, potential trigger of atrial arrhythmias are among the disadvantages of ICE. In the 
setting of a single operator, it may be a more challenge to manipulate the ICE catheter at 
the same time the closure device. It is up to the center and the interventionalist to prefer 
ICE to other imaging techniques and there are many catheterization laboratories and 
interventionalists who prefer this technique during transcatheter closure of ASDs. (Kim et 
al. 2009; Yared et al. 2009) 
3.4 3D TEE 
After the introduction of 3D TTE during interventions, a more practical technique, 3D TEE 
was developed. Real time 3D TEE images have high spatial and temporal resolution that 
allows detailed views of the cardiac structures. (Lee et al. 2010; Tsang et al. 2011) The use of 
3D TEE acquired en face views of the defect and surrounding structures allows accurate 
measurement of the ASD and any other additional defects like fenestrations. Since the same 
probe can be used for 2D TEE and 3D TEE imaging and the operator can switch in between 
the two modalities, this method has become one of the newer and promising techniques in 
evaluation of the atrial septum during ASD device occlusion.  
4. ASD/PFO closure devices 
Currently there are a number of devices approved in the USA for closure of ASDs and some of 
these are also used off label for closure of PFOs. It is very important for the echocardiographer 
to be familiar with these devices, their design and release mechanisms since the method of 
implantation is different and unique for each device. (Silvestry et al. 2009) 
Atrial septal defect occlusion devices are categorized into two as non-self centered or single 
pin device and the waist or self-centered device. The cribriform device- AGA Amplatzer 
multi fenestrated septal occluder (AGA, Plymouth. Minnesota USA) (Fig. 6) and the Gore 
Helex septal occluder (GL Gore & Associates, Flagstaff, Arizona, USA) (Fig. 7) are among 
the family of single pin devices. Both the Cribriform and the Gore Helex devices are 
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approved for closure of small ASDs but are widely used for PFO closure as off label 
indication. The self-centered devices have two atrial disks that connect with a waist. AGA 
Amplatzer septal occluder (AGA) (Fig. 6) and the NMT CardioSeal StarFlex septal occluder 
(NMT Medical, Boston, Massachusetts, USA) (Fig. 7) are the two self centered devices 








Fig. 7. CardioSeal StarFlex Septal Occluder (left) and Gore Helex Septal Occluder (right) 
5. TEE in ASD device closure 
5.1 TEE protocol 
Even though ASD/PFO closure evaluation asks for certain measurements, for all cases, it is 
very important to follow a protocol using multiplane views and available windows from 
gastric to mid and upper esophagus to complete a segmental approach used in evaluation of 
congenital heart disease. (Fig. 8) In this way, the previous findings seen by other 
echocardiography modalities will be confirmed and any additional defects will not be 
missed. (Masani 2001) Many centers already are using TEE protocols that they have 
developed and these can be incorporated into TEE in interventional studies.  
Role of Transesophageal Echocardiography  




Fig. 8. Multiplane views of the atrial septum. (Courtesy of Dr. Duraisamy Balaguru) 
5.2 Imaging of atrial septum pre-, during and post-, device closure 
The goals of TEE are: detailed imaging of the defect and its relation to the surrounding 
structures, identification of patients with suitable anatomy for device closure of their 
ASD/PFO and guidance for the device positioning and deployment. (Brochet & Vahanian 
2010) It should also be kept in mind that the rotation of the transducer to specific angles is a 
good initial guide but not a strict rule. The defects and other normal structures of the heart 
may be imaged at closer but different angles.  
5.2.1 Pre-procedure  
1. Evaluation of the entire atrial septum and its surrounding structures; exclusion of 
additional defects that may render the defect unsuitable for closure 
2. Defining the defect: ASD vs. PFO  
3. Color Doppler imaging of the defect and definition of the shunt (left to right, right to 
left) at rest, with Valsalva 
4. In cases of PFO requiring further information of the shunt, injection of agitated saline 
micro bubbles at rest and with Valsalva to visualize any right to left shunting 
5. Measurement of the defect number and size 
6. Maximal dimensions of the length of the atrial septum and distance of the ASD from 
the surrounding structures (rims) (Fig. 12) 
7. Measurement of the diameter of the stretched balloon across the defect when a sizing 
balloon is used and identification of any residual left to right shunting (Fig. 15) 
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Fig. 9. Secundum atrial septal defect with surrounding rims. (1. Atrioventricular valve rim; 
2. Aortic rim; 3. SVC rim; 4. Posterior rim; 5. IVC rim; 6. Coronary sinus rim) (Courtesy of 
Dr. Duraisamy Balaguru)  
  
Fig. 10. Atrial septal aneurysm with small left to right shunting 
  
Fig. 11. PFO with bidirectional shunting.  
Role of Transesophageal Echocardiography  




Fig. 12. Four chamber view. Septal defect size, rims (left) and total atrial septal length (right) 
measurements  
A PFO is defined as any anatomical communication through the foramen ovale and a 
stretched PFO is defined as any left to right flow on color Doppler imaging seen at rest or 
intermittently. Furthermore, an atrial septal aneurysm is defined as 11-15 mm of total 
movement of a 15 mm base of atrial tissue. (Silvestry et al. 2009) Sinus venosus, ostium 
primum or coronary sinus defects cannot be closed by transcatheter intervention and 
require surgical closure. In addition to this, associated abnormalities of the superior and 
inferior vena cava, coronary sinus, pulmonary veins and atrioventricular valves that may 
hinder the device closure should be carefully evaluated. Once the defect is diagnosed as a 
secundum ASD or a PFO, then the number (more than one defect at the atrial septum or 
fenestrations) and size of the defect needs to be identified. Currently, defects up to 40 mm in 
diameter and also multiple defects can be successfully closed with percutaneous transcatheter 
occlusion. (Silvestry et al. 2009) In addition to the size of the defect, the distance of the defect 
from the surrounding structures called “rims” play an important role in deciding whether a 
defect can be closed or not. A surrounding rim of 4-5 mm is considered to be adequate for 
closure except for the aortic rim which could be less. Posterior, superior (SVC) and especially 
the inferior (IVC) rim are to be investigated and measured from multiple TEE views for 
accuracy. (Fig. 14) In the cardiac catheterization laboratory, the operators should be very much 
familiar with the terminology when rims are mentioned. Alternatively, an easier and 
according to their relation to less complicated definition of the rims may be  specific structures. 
In smaller patients, especially the pediatric population, the total septal length is also crucial 
since this may limit the size of the device that can be placed successfully without early or late 
morbidity. (Momenah et al. 2000) 
While interrogating the atrial septum, certain views are recommended for measurements. 
The diameter of the defect and the color Doppler across it should be obtained from 
midesophageal four chamber, from short axis at the base of the heart, from gastro 
esophageal junction and from bicaval view and the largest diameter should be considered 
while deciding on the size of the device. (Fig 12 and 13) Inferior rim of the defect to mitral 
valve and tricuspid valve and the total septal length can easily be visualized from mid 
esophageal four chamber view. (Fig. 12) The short axis view at the base of the heart gives  
the antero-superior rim (to aortic root), posterior rim (to pulmonary vein) and the total  
septal length. (Fig 13) With the gastro esophageal junction (0) or oblique (130) imaging  
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Fig. 13. ASD and aortic rim visualized from short axis view (35º) (left); left to right color flow 
at ASD (right) 
  
Fig. 14. Bicaval view showing IVC and SVC rims, ASD (left) and fenestrated ASD (right) 
with left to right shunting 
 
Fig. 15. Balloon sizing of ASD. Note the measurement (in red) at the waist of the stretched 
balloon 
visualization and measurement of the superior rim to superior vena cava and inferior rim to 
inferior vena cava in addition to the total septal length. (Fig. 14) The color flow entering the 
RA from vena cava and coronary sinus should not be misdiagnosed. (Masani 2001) Another 
very important structure is the crista terminalis that extends as a linear structure from the 
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RA wall close to the IVC to the septum adjacent to the SVC. This structure and the valve of 
the IVC, Eustachian valve or Chiari network, can both be mistaken as the atrial septum thus 
ending in a wrong diagnosis. (Masani 2001) 
5.2.2 During device closure/deployment 
The echocardiographer and the interventionalist work as a team to decide on the device size 
to be used for ASD/PFO closure. The measurements from both the TEE and cardiac 
catheterization should be used in choosing the right size device. Once the device is being 
introduced into the heart and through the defect, the echocardiographer guides the 
catheterization team with the correct positioning taking into fact the adjacent structures 
especially AV valves and the entrapment of rims in between the discs (for AGA and Gore 
Helex septal occluders) and the double umbrella (for NMT CardioSeal). (Fig. 16) Once 
appropriate placement is confirmed with 2D and no significant left to right shunting seen by 
color Doppler, the device can then be deployed. (Fig. 17) Small central shunting is 
frequently seen through the device especially the AGA septal occluders, and this should not 
hinder the deployment. (Fig. 16) The slight pull of the device by the delivery system is  
relieved once it is deployed and the device is seen saddling in a much better fashion over 
the defect.  
  
Fig. 16. AGA septal occluder. Note the device malpositioning- vertical to the atrial septum 
and the ASD rather than parallel (left) and normal central shunting (right) 
  
Fig. 17. AGA septal occluder. Correct positioning at bicaval (SVC-IVC) view (left). 
Straddling the aortic rim (right) 
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5.2.3 Post device closure 
Following deployment, a detailed post procedure TEE should be performed to visualize any 
impingement on valves, veins and the outflow tract in addition to any residual peripheral 
shunting. (Fig. 18) In case of acute complications, most of the ASD/PFO occlusion devices 
can be retrieved in the catheterization laboratory so early post procedure identification of 
these findings is very important. (Johri et al. 2011) 
  
Fig. 18. Gore Helex septal occluder after successful ASD closure (left) and AGA septal 
occluder with residual peripheral shunting (right) 
6. Complications after ASD/PFO device closure 
Potential complications after percutaneous device closure of ASDs and PFOs can be 
categorized into acute/early and chronic/late. In both the acute and late complications TEE 
plays a very important role. Initially, TEE is helpful in identifying the early complications 
some of which will be evident in the catheterization laboratory right after deployment.  
One of the major but rare complications is device embolization which can embolize to any 
cardiac chamber or vessel and/or cause valvular dysfunction. Device embolization is 
commonly secondary to underestimation of the septal defect or the deficiency of the inferior 
or the superior rims. TEE may be limited in visualization if the device embolizes outside the 
heart especially beyond the abdominal aorta at the hepatic level or into the peripheral 
vasculature. (Yared et al. 2009) Once the diagnosis is made by TEE and fluoroscopy, 
retrieval is attempted in the catheterization laboratory. If unsuccessful, surgical retrieval is 
done.  
Pericardial tamponade though rare is an important complication that may be seen during or 
acutely after device deployment. Tamponade most frequently is a result of left atrial 
appendage perforation during the anchoring of the trans septal guide wire though other less 
commonly encountered reasons may also be from right atrium, right ventricle, or right or 
left pulmonary vein perforation and though usually a late complication, device erosion 
through adjacent cardiac tissue. (Yared et al. 2009) 
Transient heart block should raise the suspicion of the ASD closure device’s impingement 
on the atrioventricular node. This finding needs to be closely followed afterwards. 
Residual shunting seen immediately after device closure may decrease or disappear as the 
devices endothelizes within several months after deployment. As long as, the residual 
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shunting is not hemodynamically significant, by many, this finding is not considered to be a 
complication. (Yared et al. 2009) 
7. Pitfalls 
Even though TEE is one of the most widely used echocardiographic modalities, it also has 
pitfalls. It requires expert imaging personal to avoid any wrong diagnosis from 
misinterpretation of normal and abnormal anatomy of the heart, atrial septum and the 
defect. Even though it is superior to TTE in imaging because the probe in the esophagus is 
close to the heart, there may still be disturbance in image quality secondary to air within the 
esophagus and stomach or the air filled trachea or bronchi. In addition, during prolonged 
monitoring the transducer may reach its heat limit and may need to be turned off until it 
reaches a cooler temperature. (Sengupta & Khandheria 2005) 
8. Conclusion and future directions 
During percutaneous closure of ASDs and PFOs, in addition to fluoroscopy, 
echocardiographic input is of utmost value to the interventionalist. Among the other 
imaging modalities which include TTE, ICE and 3D TEE, TEE has long been the standard 
imaging modality in many centers to monitor and guide interventional procedures because 
of its easy application, lower cost, portability and real time imaging. With the introduction 
of smaller transducers, it is also used in the smaller patients, especially the pediatric 
population. It is the preference, comfort and the expertise of the interventionalist and the 
echocardiographer to choose the best imaging technique for percutaneous ASD/PFO 
closure. Since TEE has been used for a long time with good results, it still is the choice of 
imaging in many of the catheterization laboratories; ICE and 3D TEE are the upcoming 
competitors.  
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1. Introduction 
Nowadays transcatheter closure of atrial septal defects (ASDs) is a reality in the vast majority 
of countries; this procedure can be done safely and effectively in skilled hands and with the 
appropriate devices. Accurate and precise knowledge of the anatomy of the secundum atrial 
septal defect and the nearby structures is essential for the effectiveness and safe performance 
of ASD closure. Improvements in ultrasound technology over the last several decades have 
been particularly useful for guidance during this particular invasive procedure.  
Transesophageal echocardiography (TEE) has been the conventional imaging method for 
guidance in transcatheter closure of ASDs in children and adults; TEE has been shown to be 
safe and effective for closure of ASDs but in the majority of cases it has to be done under 
general anesthesia with subsequent increase in the procedure time, increased risks of 
anesthesia and patient discomfort after the procedure.  
Intracardiac echocardiogram (ICE) was developed to provide accurate and precise 
knowledge of the anatomy of the intracardiac structures. ICE was first used in 1980s for the 
visualization of the coronary arteries and then it was also used as a guiding tool during 
radiofrequency ablation and to assist transeptal puncture techniques in difficult cases. It was 
our group who reported for the first time in 2001 on the use of ICE to guide device closure 
of ASDs and patent foramen ovale.  
Since then, multiple improvements in the ICE catheter have been developed and now it is 
well recognized imaging tool for guidance of several interventional cardiac and 
electrophysiological procedures.  
Unlike TEE, ICE doesn’t require general anesthesia, it provides accurate real time images 
and the procedure can be done faster with successful results.  
2. History 
During the 1950s and 1960s, the first ultrasound tipped catheters were introduced because of 
the advancement in percutaneous procedures in the medical field, the need for close 
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assessment of the organs to be studied as well as the need for guidance of procedures under 
real time image. The first ultrasound tipped catheters were created to obtain organ dimensions 
and organ distances. No Doppler velocities or cross sectional images were obtained 
In 1956, Cieszynsky et al. used the first ultrasound tip catheter in dogs; he found it to be 
useful without injury to the system being observed. In the mid-1960s, Kossofs et al used the 
first ICE in measuring the thickness of the ventricular septum and ventricular wall by M-
mode with surprising precision, but the catheter lacked mobility when it was inside the 
heart. In 1969, a mechanically rotating 4-element probe was developed by Eggleton et al and 
during the same time the first two dimensional real time ultrasound tip catheter was 
developed by Bom et al.  
In 1974 Reid introduced the Doppler system by measuring Doppler velocities of femoral and 
coronary artery in dogs and in 1975 Gichard et al developed a new concept of catheter in 
which the shaft was more flexible with the ability to rotate inside the heart.  
In the mid-1980s, percutaneous transluminal coronary angioplasty was adopted in many 
centers as the procedure of choice for coronary artery disease. This advancement in the field 
of cardiac catheterization created the need for development of an ideal device for 
intracardiac echo. The goal was to create a catheter with a flexible shaft, predictable 
orientation inside the heart with lower frequency transducers, superior imaging depth as 
well as enhanced tissue penetration. 
Pandian et al in 1990 used the ICE catheter for the first time in humans in detecting iliofemoral 
artery obstructing disease with the ability to distinguish diseased arteries from normal vessels. 
Subsequently he used ICE in guidance of PTCA with encouraging results.  
ICE was introduced to the field of congenital structural heart disease when Valdez-Cruz et 
al in 1991 described successful results of percutaneous closure of atrial septal defect (ASD) 
under ICE guidance in piglets. Since then, the utility of ICE has expanded. 
Electrophysiology studies demanded more accurate assessments during and after ablation 
studies. The first ablation procedure described under ICE guidance was by Seward et al in 
1996 in dogs; it was found to have more accurate assessment of the size of the ablation 
injury, enhanced visual detection of intramyocardial hematoma and thrombus formation 
which were not well seen by fluoroscopy or even by TEE.  
In the subsequent years as we mentioned above, ICE has had a tremendous advancement in 
technology and it has been described to be useful in the guidance of most cardiac 
interventional procedures such as ASD/PFO/VSD device closure, balloon valvuloplasty, 
aortic coarctation angioplasty/stent placement or other central vascular stenosis, transeptal 
puncture, percutaneous pulmonary and aortic valve placement, left atrial appendage 
closure and many others.  
3. ICE catheters  
Over the past several years, improvements in technology have allowed the development of 
intracardiac transducers of lower frequency as well as Doppler imaging capability with 
improved depth penetration and better image resolution.  
At present, there are five different transducer technologies for real-time intracardiac 
ultrasonic imaging  
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1. The ultraICE mechanical single-element system (Boston Scientific Corp, San Jose, CA, 
USA) 
2. The AcuNav system from Siemens from Biosense-Webster 
3. The Clear ICE system from St Jude Medical 
4. The SoundStar Catheter system from Biosense-Webster 
5. The ViewMate Z Intracardiac Ultrasound System and ViewFlex Plus ICE Catheter from St 
Jude Medical.  
The UltraICE system (Boston Scientific Corp, San Jose, CA, USA) is a 9 MHz single element 
transducer incorporated in a 9F catheter. The catheter is not steerable and it lacks Doppler 
capabilities. This system provides cross-sectional images in a 360° radial plane with only 5 
cms radial field depth which provides near-field clarity but poor tissue penetration; hence 
the left sided structures are not possible to obtained when the ultrasound catheter is in the 
Right heart. It has been used in guidance of coronary artery interventional procedures 
because of the catheter’s capability of producing near - field images. Three-dimensional 
reconstruction of the anatomy can be obtained as well.  
The ClearICE device (St. Jude Medical, Inc) has a 64-element phased-array transducer with a 
highly steerable catheter and bidirectional steering up to 140º. It works with the Vivid 
system (GE Healthcare Technologies, Wauwatosa, WI). It has two sets of electrodes for 
integration of 3D localization with NavX. Apart from grayscale and tissue Doppler; it also 
allows for synchronization mapping and 2D speckle tracking. 
The SoundStar Catheter system (Biosense-Webster) has the same characteristics like AcuNav 
catheter but with CARTO magnetic sensor in the tip. 
The ViewFlex Plus catheter (St. Jude Medical, Inc.) uses the ViewMate Z ultrasound system 
(EPMedSystems, Inc., Berlin, NJ). It has a 64-element phased-array transducer with a 
frequency of 4.5 to 8.5 MHz, and an imaging depth of 12 cm. it has a steerable catheter via 
two-way articulation; it can be rotated axially and steered in anterior and posterior 
directions up to 120° with enhanced tip stability. It also allows a two-way flex color Doppler 
and grayscale. This catheter has the ability to quickly produce exceptional images in a 
compact, cart-based system. 
Currently AcuNav catheter (Biosense Webster, Inc, Diamond Bar, CA, USA) (FIGURE 1) is 
the most popular ICE catheter used for guidance of percutaneous closure of an ASD. The 
catheter size decreased from 11F to 8 F in diameter in the last years and now requires only 
an 8 Fr introducer with subsequent fewer traumas to the vessel entered. The catheter 
consists of a miniaturized 64-element phased-array transducer with color, tissue and 
spectral Doppler capabilities; the frequency of the transducer varies from 5.5 to 10 MHz and 
it provides a 90° sector image with excellent tissue penetration up to 16 cm for the 8F 
catheter, allowing visualization of left-sided structures from the right heart. The catheter is 
somewhat stiff but with a brilliant four-way articulation that provides excellent 
maneuverability inside the heart; the handle has a locking knob that allows the catheter tip 
to be fixed in a desired position. This is an important feature of this catheter. It works with 
Sequoia, Cypress, or Aspen imaging systems, all of which are manufactured by Siemens 
Medical Solutions USA, Inc. (Malvern, PA). It can be introduced by a femoral or internal 
jugular approach; The 8 F catheter is 90-110 cms long and careful advancement from the 
groin to the heart under continuous fluoroscopic guidance is recommended, unless a long 
sheath (>30 cms) is used in the femoral vein. 
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assessment of the organs to be studied as well as the need for guidance of procedures under 
real time image. The first ultrasound tipped catheters were created to obtain organ dimensions 
and organ distances. No Doppler velocities or cross sectional images were obtained 
In 1956, Cieszynsky et al. used the first ultrasound tip catheter in dogs; he found it to be 
useful without injury to the system being observed. In the mid-1960s, Kossofs et al used the 
first ICE in measuring the thickness of the ventricular septum and ventricular wall by M-
mode with surprising precision, but the catheter lacked mobility when it was inside the 
heart. In 1969, a mechanically rotating 4-element probe was developed by Eggleton et al and 
during the same time the first two dimensional real time ultrasound tip catheter was 
developed by Bom et al.  
In 1974 Reid introduced the Doppler system by measuring Doppler velocities of femoral and 
coronary artery in dogs and in 1975 Gichard et al developed a new concept of catheter in 
which the shaft was more flexible with the ability to rotate inside the heart.  
In the mid-1980s, percutaneous transluminal coronary angioplasty was adopted in many 
centers as the procedure of choice for coronary artery disease. This advancement in the field 
of cardiac catheterization created the need for development of an ideal device for 
intracardiac echo. The goal was to create a catheter with a flexible shaft, predictable 
orientation inside the heart with lower frequency transducers, superior imaging depth as 
well as enhanced tissue penetration. 
Pandian et al in 1990 used the ICE catheter for the first time in humans in detecting iliofemoral 
artery obstructing disease with the ability to distinguish diseased arteries from normal vessels. 
Subsequently he used ICE in guidance of PTCA with encouraging results.  
ICE was introduced to the field of congenital structural heart disease when Valdez-Cruz et 
al in 1991 described successful results of percutaneous closure of atrial septal defect (ASD) 
under ICE guidance in piglets. Since then, the utility of ICE has expanded. 
Electrophysiology studies demanded more accurate assessments during and after ablation 
studies. The first ablation procedure described under ICE guidance was by Seward et al in 
1996 in dogs; it was found to have more accurate assessment of the size of the ablation 
injury, enhanced visual detection of intramyocardial hematoma and thrombus formation 
which were not well seen by fluoroscopy or even by TEE.  
In the subsequent years as we mentioned above, ICE has had a tremendous advancement in 
technology and it has been described to be useful in the guidance of most cardiac 
interventional procedures such as ASD/PFO/VSD device closure, balloon valvuloplasty, 
aortic coarctation angioplasty/stent placement or other central vascular stenosis, transeptal 
puncture, percutaneous pulmonary and aortic valve placement, left atrial appendage 
closure and many others.  
3. ICE catheters  
Over the past several years, improvements in technology have allowed the development of 
intracardiac transducers of lower frequency as well as Doppler imaging capability with 
improved depth penetration and better image resolution.  
At present, there are five different transducer technologies for real-time intracardiac 
ultrasonic imaging  
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1. The ultraICE mechanical single-element system (Boston Scientific Corp, San Jose, CA, 
USA) 
2. The AcuNav system from Siemens from Biosense-Webster 
3. The Clear ICE system from St Jude Medical 
4. The SoundStar Catheter system from Biosense-Webster 
5. The ViewMate Z Intracardiac Ultrasound System and ViewFlex Plus ICE Catheter from St 
Jude Medical.  
The UltraICE system (Boston Scientific Corp, San Jose, CA, USA) is a 9 MHz single element 
transducer incorporated in a 9F catheter. The catheter is not steerable and it lacks Doppler 
capabilities. This system provides cross-sectional images in a 360° radial plane with only 5 
cms radial field depth which provides near-field clarity but poor tissue penetration; hence 
the left sided structures are not possible to obtained when the ultrasound catheter is in the 
Right heart. It has been used in guidance of coronary artery interventional procedures 
because of the catheter’s capability of producing near - field images. Three-dimensional 
reconstruction of the anatomy can be obtained as well.  
The ClearICE device (St. Jude Medical, Inc) has a 64-element phased-array transducer with a 
highly steerable catheter and bidirectional steering up to 140º. It works with the Vivid 
system (GE Healthcare Technologies, Wauwatosa, WI). It has two sets of electrodes for 
integration of 3D localization with NavX. Apart from grayscale and tissue Doppler; it also 
allows for synchronization mapping and 2D speckle tracking. 
The SoundStar Catheter system (Biosense-Webster) has the same characteristics like AcuNav 
catheter but with CARTO magnetic sensor in the tip. 
The ViewFlex Plus catheter (St. Jude Medical, Inc.) uses the ViewMate Z ultrasound system 
(EPMedSystems, Inc., Berlin, NJ). It has a 64-element phased-array transducer with a 
frequency of 4.5 to 8.5 MHz, and an imaging depth of 12 cm. it has a steerable catheter via 
two-way articulation; it can be rotated axially and steered in anterior and posterior 
directions up to 120° with enhanced tip stability. It also allows a two-way flex color Doppler 
and grayscale. This catheter has the ability to quickly produce exceptional images in a 
compact, cart-based system. 
Currently AcuNav catheter (Biosense Webster, Inc, Diamond Bar, CA, USA) (FIGURE 1) is 
the most popular ICE catheter used for guidance of percutaneous closure of an ASD. The 
catheter size decreased from 11F to 8 F in diameter in the last years and now requires only 
an 8 Fr introducer with subsequent fewer traumas to the vessel entered. The catheter 
consists of a miniaturized 64-element phased-array transducer with color, tissue and 
spectral Doppler capabilities; the frequency of the transducer varies from 5.5 to 10 MHz and 
it provides a 90° sector image with excellent tissue penetration up to 16 cm for the 8F 
catheter, allowing visualization of left-sided structures from the right heart. The catheter is 
somewhat stiff but with a brilliant four-way articulation that provides excellent 
maneuverability inside the heart; the handle has a locking knob that allows the catheter tip 
to be fixed in a desired position. This is an important feature of this catheter. It works with 
Sequoia, Cypress, or Aspen imaging systems, all of which are manufactured by Siemens 
Medical Solutions USA, Inc. (Malvern, PA). It can be introduced by a femoral or internal 
jugular approach; The 8 F catheter is 90-110 cms long and careful advancement from the 
groin to the heart under continuous fluoroscopic guidance is recommended, unless a long 
sheath (>30 cms) is used in the femoral vein. 
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Fig. 1. AcuNav Catheter; the control handle has three knobs: one to move the tip in 
posterior/anterior directions, one to move the tip in right/left directions, and the last knob 
is a locking one that will fix the tip in the desired orientation. 
4. ICE catheter insertion techniques 
The catheter can be introduced by femoral or internal jugular approach; however the 
femoral vein approach is the most popular among most of the interventionalists because it is 
closer to the table, allowing easier manipulation of the control handle. The 8 F AcuNav 
catheter is 90-110 cms long and careful advancement from the groin to the heart under 
continuous fluoroscopic guidance is recommended because of its rigidity (stiffness) and 
possible advancement of the catheter into side branches with potential vessel injury before 
reaching the right atrium (RA); it is recommended to use a long 8 french sheath (30 cms) in 
either femoral vein in order to avoid vascular complications or possibly entanglement below 
the level of the IVC. This approach offers easy accessibility and allows fairly free movement 
of the catheter inside the heart. In adult patients, the catheter can be introduced in the same 
vein used for the device delivery (FIGURE 2). For patients with weight below 35 kg, access 
in the opposite femoral vein is recommended (FIGURE 2). 
 
Fig. 2. ICE catheter insertion; Left: Adult patient with ICE catheter (red arrow) and delivery 
sheath (white arrow) in same femoral vein. Right: Pediatric patient with ICE catheter (red 
arrow) and delivery sheath (white arrow) in opposite veins. 
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The superior vena cava (SVC) is another option to achieve access to the RA. This approach 
can be accomplished either from the right internal jugular vein or the left subclavian vein 
into the RA.  
5. ICE guidance protocol for ASD closure  
The ICE catheter is introduced in the usual fashion and advanced from the inferior vena cava 
(IVC) into the RA. We start the ICE protocol obtaining first the home view, septal view, long 
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posterior/anterior directions, one to move the tip in right/left directions, and the last knob 
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of the catheter inside the heart. In adult patients, the catheter can be introduced in the same 
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Fig. 2. ICE catheter insertion; Left: Adult patient with ICE catheter (red arrow) and delivery 
sheath (white arrow) in same femoral vein. Right: Pediatric patient with ICE catheter (red 
arrow) and delivery sheath (white arrow) in opposite veins. 
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The superior vena cava (SVC) is another option to achieve access to the RA. This approach 
can be accomplished either from the right internal jugular vein or the left subclavian vein 
into the RA.  
5. ICE guidance protocol for ASD closure  
The ICE catheter is introduced in the usual fashion and advanced from the inferior vena cava 
(IVC) into the RA. We start the ICE protocol obtaining first the home view, septal view, long 
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Fig. 3. Fluoroscopy and ICE assesment of an ASD; (A) Home view. Left, heart diagram with 
the position of the ICE catheter in the neutral ‘home view’ position. The shaded area 
represents structures seen in this view. Middle, A-P Fluoroscopic image of the ICE catheter 
positioned in the mid RA (arrow) and parallel to the spine. Right, ICE 2-D image in the 
neutral home view position. The tricuspid valve, right atrium (RA), right ventricle (RV), RV 
outflow tract, pulmonary artery (PA) and aorta in short axis are well seen in this position. 
(B) Septal view. Left, heart diagram with the position of the ICE catheter in the posterior 
flexed position looking at the atrial septum ‘septal view’. The shaded area represents 
structures seen in this view. Middle, Fluoroscopic A-P image of the ICE catheter (arrow) in 
the RA pointing to the right side of the heart and the transducer flexed posterior looking at 
the septum. Right, ICE 2-D image septal view position. The right atrium (RA), left atrium 
(LA) and the atrial septal defect are well seen (arrow) in this position.  
(C) Long-axis ‘caval view’. Left, heart diagram with the position of the ICE catheter in the 
posterior flexed position with a more superior advancement looking at the atrial septum 
and the superior vena cava. The shaded area represents structures seen in this view. Middle, 
A-P Fluoroscopic image of the ICE catheter (black arrow) demonstrating catheter pointing 
posteriorly to the septum and positioned higher than the septal view closer to the SVC 
(white arrow). Right, ICE 2-D image in the long axis view position. The atrial septal defect 
(arrow), right atrium (RA), left atrium (LA), left upper, left lower pulmonary veins (LUPV, 
LLPV), and the superior vena cava (SVC) are all well seen.  
(D) Short-axis view. Left, heart diagram with the position of the ICE catheter in the flexed 
position but now positioned near the tricuspid valve and below the aortic valve. The shaded 
area represents structures seen in this view. Middle, Fluoroscopic A-P image of the ICE 
catheter pointing to the right side of the spine, next to the tricuspid valve and just below the 
aortic valve. Right, ICE 2-D image in the short-axis view. The atrial septal defect (arrow), the 
left atria (LA), right atria (RA) and the aortic valve are all well seen in this view.  
5.1 Standard views 
5.1.1 Home view 
This view can be obtained by advancing the ICE catheter to the mid right atrium. Catheter is 
parallel to the spine with the transducer portion facing the tricuspid valve. Subtle counter 
clockwise movements in the knob of the catheter can be done to obtain the home view 
image. When you are in home view you should see the right atrium, the tricuspid valve, the 
right ventricle, right ventricular inflow and outflow and a portion of the aortic valve in short 
axis view. The anterior portion of the septum can be occasionally visualized as well. 
(FIGURE 4).  
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Fig. 4. Septal View: Left A) ICE 2-D image demonstrating a large ASD (arrow), right atrium 
(RA), left atrium (LA), the superior anterior rim (s-a) and the inferior posterior rim (i-p) a) 
ICE color image demonstrating a large ASD (arrow) with left to right shunt. Long axis view: 
Center B) ICE 2-D image demonstrating large ASD (arrow), superior vena cava (SVC) right 
atrium (RA), left atrium (LA), superior rim (s) and inferior rim (i). b) ICE color image 
showing a large ASD (arrow) with left to right shunt and SVC drainage to RA. Short Axis 
View: Right C) ICE 2-D image demonstrating a large ASD (arrow), right atrium (RA), left 
atrium (LA), aortic valve (AV), anterior rim (a) and posterior rim (p). c) ICE color image 
showing a large atrial septal defect with left to right shunt. 
5.1.2 Septal view 
After the home view image is obtained, slight movements of the anterior-posterior knob 
posteriorly and the right-left knob rightward will make the transducer face the atrial 
septum. In this view you can see the entire length of the atrial septum. The image closer to 
the ICE catheter (superior) is the RA and distal to the image (inferior) is the left atrium. 
Atrial Septal Defect 104 
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flexed position looking at the atrial septum ‘septal view’. The shaded area represents 
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posterior flexed position with a more superior advancement looking at the atrial septum 
and the superior vena cava. The shaded area represents structures seen in this view. Middle, 
A-P Fluoroscopic image of the ICE catheter (black arrow) demonstrating catheter pointing 
posteriorly to the septum and positioned higher than the septal view closer to the SVC 
(white arrow). Right, ICE 2-D image in the long axis view position. The atrial septal defect 
(arrow), right atrium (RA), left atrium (LA), left upper, left lower pulmonary veins (LUPV, 
LLPV), and the superior vena cava (SVC) are all well seen.  
(D) Short-axis view. Left, heart diagram with the position of the ICE catheter in the flexed 
position but now positioned near the tricuspid valve and below the aortic valve. The shaded 
area represents structures seen in this view. Middle, Fluoroscopic A-P image of the ICE 
catheter pointing to the right side of the spine, next to the tricuspid valve and just below the 
aortic valve. Right, ICE 2-D image in the short-axis view. The atrial septal defect (arrow), the 
left atria (LA), right atria (RA) and the aortic valve are all well seen in this view.  
5.1 Standard views 
5.1.1 Home view 
This view can be obtained by advancing the ICE catheter to the mid right atrium. Catheter is 
parallel to the spine with the transducer portion facing the tricuspid valve. Subtle counter 
clockwise movements in the knob of the catheter can be done to obtain the home view 
image. When you are in home view you should see the right atrium, the tricuspid valve, the 
right ventricle, right ventricular inflow and outflow and a portion of the aortic valve in short 
axis view. The anterior portion of the septum can be occasionally visualized as well. 
(FIGURE 4).  
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Fig. 4. Septal View: Left A) ICE 2-D image demonstrating a large ASD (arrow), right atrium 
(RA), left atrium (LA), the superior anterior rim (s-a) and the inferior posterior rim (i-p) a) 
ICE color image demonstrating a large ASD (arrow) with left to right shunt. Long axis view: 
Center B) ICE 2-D image demonstrating large ASD (arrow), superior vena cava (SVC) right 
atrium (RA), left atrium (LA), superior rim (s) and inferior rim (i). b) ICE color image 
showing a large ASD (arrow) with left to right shunt and SVC drainage to RA. Short Axis 
View: Right C) ICE 2-D image demonstrating a large ASD (arrow), right atrium (RA), left 
atrium (LA), aortic valve (AV), anterior rim (a) and posterior rim (p). c) ICE color image 
showing a large atrial septal defect with left to right shunt. 
5.1.2 Septal view 
After the home view image is obtained, slight movements of the anterior-posterior knob 
posteriorly and the right-left knob rightward will make the transducer face the atrial 
septum. In this view you can see the entire length of the atrial septum. The image closer to 
the ICE catheter (superior) is the RA and distal to the image (inferior) is the left atrium. 
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Occasionally you can see the pulmonary venous return to the left atrium and the coronary 
sinus as well. Once you lock the catheter you can make fine movements in the knob or rotate 
the entire catheter to get the image that suits better guidance of the procedure. (FIGURE 4)  
5.1.3 Long axis view 
This view can be obtained after having the catheter in the septal view, followed by slight 
superior advancement of the ICE catheter in the RA towards the SVC. The catheter can 
either face the atrial septum, the SVC or both; it depends on the position of the catheter. 
Advancing the flexed catheter in the direction of the SVC can profile much better the SVC 
and the respective posterior superior rim. Withdrawal of the flexed catheter towards the 
IVC will profile the inferior part of the atrial septum and the posterior inferior rim as well. 
This view is good for measurements of an atrial septal defect as well. The right and left 
pulmonary venous drainage can be seen just rotating the catheter clockwise or 
counterclockwise as well as with flexion/anteflexion. (FIGURE 4). 
5.1.4 Short axis view 
The catheter is still flexed in its locked position; to obtain the image, the entire catheter 
should be moved from the sheath hub in a clockwise manner in order to place it inferior to 
the aortic valve and near the tricuspid valve; this is followed by slight adjustments in the 
posterior anterior knob with less posterior flexion and more leftward rotation on the 
right/left knob. Fluoroscopy image shows the position of the catheter. This view is the 
opposite of the short axis view that can be obtained using TEE with the near field image 
being the right atrium and the far field image being the left atrium. The superior anterior 
rim and inferoposterior rim can be obtained as well (FIGURE 4). 
5.2 ICE guidance during and after device deployment 
5.2.1 The defect is crossed with a wire; this image is crucial in complex atrial septal defects 
or fenestrated ASD’s to confirm that the largest defect is being crossed by the wire. 
Subsequently the delivery sheath is advanced and placed in one of the left pulmonary veins 
(Figure 5) 
5.2.2 Balloon sizing is also of significant importance in large or complex defects for further 
delineation of the atrial septal defect (FIGURE 6) and to measure the “stop-flow diameter” 
of the defect. 
5.2.3 The device is advanced and the left disk deployed in the left atrium and positioned 
in a way that is oriented with the atrial septum. The left disk is slowly pulled back to the 
atrial septum. The device position is constantly evaluated by ICE, making sure its 
position in relation to the left side of the atrium is maintained. When the device makes 
contact with the defect; it is important well seated; it makes good well seated; makes 
good contact with all available rims and the left disk doesn’t protrude to the RA . this is 
followed by deployment of the right atrial disk in the right atrium. Deployment of the 
device is always done under fluoroscopic and ICE guidance for successful results 
(FIGURE 7A-7B) 
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Fig. 5. Wire and delivery sheath assessment. Left A) A-P fluoroscopic image of the wire 
(arrow) crossing the ASD and positioned in the left upper pulmonary septal view 
demonstrating the wire (arrow) crossing the large ASD and the tip located in the left upper 
pulmonary vein. Right B) fluoroscopic image showing sheath (arrow) crossing the ASD and 
positioned in the left upper pulmonary vein. b) ICE septal view demonstrating the sheath 
(arrow) crossing the ASD and positioned in the left upper pulmonary vein. 
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contact with the defect; it is important well seated; it makes good well seated; makes 
good contact with all available rims and the left disk doesn’t protrude to the RA . this is 
followed by deployment of the right atrial disk in the right atrium. Deployment of the 
device is always done under fluoroscopic and ICE guidance for successful results 
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Fig. 5. Wire and delivery sheath assessment. Left A) A-P fluoroscopic image of the wire 
(arrow) crossing the ASD and positioned in the left upper pulmonary septal view 
demonstrating the wire (arrow) crossing the large ASD and the tip located in the left upper 
pulmonary vein. Right B) fluoroscopic image showing sheath (arrow) crossing the ASD and 
positioned in the left upper pulmonary vein. b) ICE septal view demonstrating the sheath 
(arrow) crossing the ASD and positioned in the left upper pulmonary vein. 
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Fig. 6. Balloon “Stop-flow” diameter assessment; . I) Balloon sizing deflated (arrow) crossing 
the ASD. II) Balloon inflated with evidence of residual shunt (arrow). III) Balloon inflated 
again with evidence of very mild residual shunt (arrow). IV) Balloon stop flow diameter 
(white arrows) achieved without evidence of residual shunt. Image in top demonstrating an 
A-P fluoroscopic image of the stop flow balloon sizing diameter (white arrows), ICE catheter 
(black arrow) positioned in the septal view during balloon inflation.  
 
Fig. 7A. Left and right atrial Disks Deployment. Left) Fluoroscopic image of the left atrial 
disk (arrow) deployed in the LA. Right) A-P Fluoroscopic image in the hepatoclavicular 
view demonstrating the right atrial disk (arrow) deployed in the RA. 
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Fig. 7B. A) ICE image in short axis view demonstrating the left atrial disk (arrow) deployed 
in left atrium in alignment with the ASD. B) Continuous ICE assessment in septal view of 
the left disk while is pulled back to the left side of superior and inferior posterior rims. C) 
ICE image in septal view demonstrating the waist of the device (arrow) before complete 
deployment of right disk D) ICE image in septal view demonstrating the deployment of 
right atrial disk (arrow).  
5.2.4 After right disk is deployed, subsequent assessment of the position and stability of the 
device is done. Long axis view view and short axis view are the best views for assessment of 
the device position prior to its release. Assessment of device stability, residual shunt , SVC 
and IVC is important before releasing the device. Again fluoroscopic image correlation with 
ICE images is essential for assessment of device position and stability before releasing the 
device (FIGURE 8A-8B). 
5.2.5 After releasing the device, further assessment for device stability is performed with 
fluoroscopy and ICE; Evaluation of nearby structures and assessment of any residual shunt 
is done again in short axis, septal and long axis views (FIGURE 9A-9B). 
It is very important to remember that before pulling out the ICE catheter from the sheath, it 
must be unlocked before withdrawal to the IVC. 
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Fig. 6. Balloon “Stop-flow” diameter assessment; . I) Balloon sizing deflated (arrow) crossing 
the ASD. II) Balloon inflated with evidence of residual shunt (arrow). III) Balloon inflated 
again with evidence of very mild residual shunt (arrow). IV) Balloon stop flow diameter 
(white arrows) achieved without evidence of residual shunt. Image in top demonstrating an 
A-P fluoroscopic image of the stop flow balloon sizing diameter (white arrows), ICE catheter 
(black arrow) positioned in the septal view during balloon inflation.  
 
Fig. 7A. Left and right atrial Disks Deployment. Left) Fluoroscopic image of the left atrial 
disk (arrow) deployed in the LA. Right) A-P Fluoroscopic image in the hepatoclavicular 
view demonstrating the right atrial disk (arrow) deployed in the RA. 
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Fig. 7B. A) ICE image in short axis view demonstrating the left atrial disk (arrow) deployed 
in left atrium in alignment with the ASD. B) Continuous ICE assessment in septal view of 
the left disk while is pulled back to the left side of superior and inferior posterior rims. C) 
ICE image in septal view demonstrating the waist of the device (arrow) before complete 
deployment of right disk D) ICE image in septal view demonstrating the deployment of 
right atrial disk (arrow).  
5.2.4 After right disk is deployed, subsequent assessment of the position and stability of the 
device is done. Long axis view view and short axis view are the best views for assessment of 
the device position prior to its release. Assessment of device stability, residual shunt , SVC 
and IVC is important before releasing the device. Again fluoroscopic image correlation with 
ICE images is essential for assessment of device position and stability before releasing the 
device (FIGURE 8A-8B). 
5.2.5 After releasing the device, further assessment for device stability is performed with 
fluoroscopy and ICE; Evaluation of nearby structures and assessment of any residual shunt 
is done again in short axis, septal and long axis views (FIGURE 9A-9B). 
It is very important to remember that before pulling out the ICE catheter from the sheath, it 
must be unlocked before withdrawal to the IVC. 
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Fig. 8A. Fluoroscopic pre-release assessment of device. A) Fluoroscopic image in the 
hepatoclavicular view with injection of contrast confirming appropriate position of the right 
atrial disk in the atrial septum. B) Fluoroscopic image in the hepatoclavicular view with contrast 
on levophase confirming appropriate position of the left atrial disk in the atrial septum. 
 
 
Fig. 8B. ICE pre-release assessment of device. A) ICE 2-D image in long axis view 
demonstrating the device well seated.a) ICE with color in long axis view demonstrating 
normal SVC flow and no residual shunt; delivery system still attached to the device. B) ICE 
2-D image in short axis view demonstrating the device well seated. b)ICE with color in short 
axis view demonstrating no residual shunt.  
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Fig. 9A. Fluoroscopic final assessment: Left) Fluoroscopic image in the hepatoclavicular view 
confirming device not attached to the delivery system and after contrast Injection, right atrial 
disk appeared to be in good position. Right) Fluoroscopic image with injection of contrast on 
levophase confirmed appropriate positioned of the left atrial disk after being released from the 
delivery system. 
 
Fig. 9B. ICE final assessment post release of device: A) ICE 2-D image in long axis view 
demonstrating the device well seated. a) ICE with color in long axis view demonstrating 
normal SVC flow and no residual shunt. B) ICE 2-D image in short axis view demonstrating 
the device well seated. b) ICE with color in short axis view demonstrating no residual shunt.  
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demonstrating the device well seated. a) ICE with color in long axis view demonstrating 
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the device well seated. b) ICE with color in short axis view demonstrating no residual shunt.  
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6. Advantages and limitations of ICE  
Transthoracic Echocardiogram (TTE) has been used for guidance of percutaneous closure of 
ASDs. However the pictures sometimes are not accurate to evaluate the size of the defect 
and it is difficult for evaluation of the rims, therefore risking stability of the device. Further, 
due to it being close to the working area of the intervention, there is risk to compromise 
sterility of the procedure. The advantages are that it can be done under conscious sedation 
and it is cheaper than ICE and TEE.  
The use of TEE is well known for guidance of percutaneous closure of ASDs. It provides 
excellent intracardiac resolution and has 3D capabilities. However, it requires sedation and 
possible endotracheal intubation, it is uncomfortable for patients, and may raise the cost of 
the procedure due to professional and procedural fees. 
ICE has been used in the last decade for guidance of percutaneous closure of ASDs and is 
lately gaining more acceptance in the interventional community. It provides excellent real 
time cardiac resolution as good as or even superior to TEE without exposing patients to the 
risks of deep sedation or endotracheal intubation. Several studies have shown decrease in 
fluoroscopy time, interventional procedure time, and catheterization laboratory time when 
compared with TEE and subsequent decrease in radiation exposure and procedure cost.  
ICE has the advantage of having an accurate evaluation of all ASDs as compared to TEE 
which sometimes can miss an inferior-posterior atrial septal defect (FIGURE 10A, 10B, 10C). 
It is also important in the evaluation of fenestrated ASDs by determining the larger defect 
and this allows accurate evaluation of the larger defect while it is being crossed by a wire 
and during balloon sizing (FIGURE 11).  
 
Fig. 10A. Inferior posterior ASD missed with TEE. TEE in four chamber, short axis and long 
axis view demonstrating intact atrial septum by 2-D and by color. Figure to the right 
demonstrating positive bubble study when injected in the right atrium. Right Atrium RA, 
Left Atrium LA, Right Ventricle RV, Left Ventricle LV, Superior vena Cava SVC. 
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Fig. 10B. Inferior posterior ASD detected with ICE. Modified septal view showed small 
inferior posterior atrial septal defect (arrow) and confirmed with bubbles from the RA to the 




Fig. 10C. TEE 3-D. Left) TEE detected small inferior posterior defect by 3D; Right) 
Demonstrating different cuts while performing standard TEE 2-D views and how an inferior 
posterior atrial defect can be missed if 3-D image is not performed. 
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Fig. 11. Fenestrated ASD assessment. ICE images to the left demonstrating fenestrated ASD 
crossed by a wire (arrow). Larger atrial septal defect (arrow) not crossed by the wire. 
Subsequent balloon partially inflated with waist (arrow), confirming smaller atrial septal 
defect crossed by the wire. ICE images to the bottom demonstrating correct position of the 
wire crossing larger defect with successful balloon stop flow diameter. Fluoroscopic image 
in the top demonstrating wire crossing atrial septal defect and positioned in the left upper 
pulmonary vein. 
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The limitations of ICE include its large shaft size (8 French), and cost. In addition, there is no 
real time three-dimensional (3D) available in the market yet.  
7. Complications related to ICE catheter
At the present time only vascular complications have been reported in the literature. There 
are some potential complications that may result from ICE and these are the same as the 
ones being reported during right heart catheterization. Transient arrhythmias can result 
from direct contact of the probe to the wall of the chamber. The arrhythmia should 
disappear after adjusting the position of the catheter. Thrombus formation around the 
catheter can also happen during any intracardiac procedure but can be prevented with 
adequate anticoagulation and decreasing the time of the ICE catheter inside the body. Other 
potential complications such as pericardial tamponade, pulmonary embolism, and 
bleeding/infection from the puncture site are infrequent but can occur as well. 
8. Conclusion  
ICE has shown to be helpful in guiding cardiac catheter interventions, especially EP studies 
and transcatheter closure of ASDs.  
The use of ICE is becoming more popular for guidance of interventional procedures, 
especially for ASD closure (evaluation of the defect and rims and live guidance during 
device deployment). It has also been found to be extremely helpful during guidance of 
closure of complex atrial septal defects.  
Currently ICE systems are easily available in the market; the skills in maneuvering the 
catheter and interpreting the images are not difficult to learn. The real time structural and 
hemodynamic information are comparable or even better than TEE with an accurate and 
safe procedural guidance for transcatheter closure of ASDs. The capabilities of identifying 
complications immediately during the procedure are exceptional.  
So far to our knowledge there are no major complication reported and the only minor 
complications that can be encountered are related to the site of access and during 
advancement of the catheter. Although the risk potential seems to be low, it is mandatory 
that the ICE catheter is handled with caution, since it is not wire-guided.  
Because the ICE catheter is inserted through the femoral vein, similar to other cardiac 
catheters; it allows the interventionist to perform procedures without general anesthesia, 
shortening procedure time, and reducing fluoro exposure with subsequent reduction of 
radiation exposure and costs in personnel and equipment. There is no need of an extra 
skilled person for the TEE, and, as such, fewer physicians are required to be present for the 
procedure. This results in a shorter turnaround time in the cardiac catheterization 
laboratory. 
In the future, the development of smaller and softer catheters will decrease the incidence of 
vascular complications. It may also be possible for the ICE catheter to be used in all pediatric 
age groups. Three-dimensional/four dimensional real time images are not so far away from 
being developed and an extraordinary understanding of the intracardiac anatomy during 
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Fig. 11. Fenestrated ASD assessment. ICE images to the left demonstrating fenestrated ASD 
crossed by a wire (arrow). Larger atrial septal defect (arrow) not crossed by the wire. 
Subsequent balloon partially inflated with waist (arrow), confirming smaller atrial septal 
defect crossed by the wire. ICE images to the bottom demonstrating correct position of the 
wire crossing larger defect with successful balloon stop flow diameter. Fluoroscopic image 
in the top demonstrating wire crossing atrial septal defect and positioned in the left upper 
pulmonary vein. 
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any intracardiac procedure will be achieved. Advancement of guidewires, catheters and 
devices through the ICE catheter can potentially be available as well.  
Along with fluoroscopy it is likely that ICE will improve the safety and outcome of 
percutaneous closure of ASDs. With all its inherent advantages, ICE may soon replace TEE 
as a guiding tool not only in adults but also in adolescents and children 
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1. Introduction 
The most common defects in the atrial septum are ostium secundum, ostium primum and 
sinus venosus atrial septal defects (ASDs) and patent foramen ovale. The management of 
ostium primum and sinus venosus defects is by surgery because of associated abnormalities, 
namely, cleft in the mitral valve causing mitral regurgitation in ostium primum defects and 
partial anomalous pulmonary venous connection in sinus venosus defects and is addressed 
in Chapter 1. Patent foramen ovale (PFO) in relation to presumed paradoxical embolism, 
platypnea-orthodeoxia syndrome, migraine, decompression illness and others may also 
require closure and the considerations for closure of such PFOs are different than those of 
closure of ostium secundum ASDs and some of these are discussed in other chapters in this 
book and will not be addressed in this chapter. In this chapter only ostium secundum ASDs 
in adult subjects will be discussed; I will address issues related to why, when and how 
should atrial septal defects be closed in these subjects. The methods of transcatheter closure 
in adults will also be reviewed as are the approaches to occlude complex forms of ASD. 
2. Why should atrial septal defects be closed in adults?  
In the past it was generally thought that closure ASDs in adult subjects is not necessary if 
they are not symptomatic. Some early studies (Ward 1994, Gatzoulis et al 1996, Webb 2001) 
suggested that there is no major benefit if surgical closure is performed in adulthood. Based 
on more recent analysis however, it would appear that the ASDs should be closed as and 
when they are identified. The purpose of this section of this chapter is to present evidence 
that the ASDs in adults should be closed.  
2.1 Evidence in favor of closing ASDs in adults 
In this section I will review some of the published evidence supporting closure of ASDs in 
all adults 
2.1.1 Complications in unrepaired ASD patients 
In a follow-up study (Rosas et al 2004) of 200 patients older than 40 years (49 ± 9 years) with 
unrepaired ASD for 2 to 22 years, it was found that 37 (18.5%) had major events, namely 
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heart failure in seven, sudden death in five, severe pulmonary infection in 13, embolism in 
five, stroke in four and miscellaneous complications in three. In addition, more than half of 
the patients had dyspnea at follow-up evaluation. Predictors of complications were 
analyzed and age at presentation, elevated pulmonary artery pressures and O2 saturation 
less than 80% were found to be associated with complications. These data suggest that major 
cardiovascular events are likely to occur in older adult patients with unrepaired ASD.  
2.1.2 Safety and efficacy of surgical closure      
Horvath et al (1991) examined safety and efficacy of surgical closure of ASDs. In this study, 
surgical closure was performed in 166 patients with a mean age of 44 years who had an 
average pulmonary to systemic flow ratio (Qp:Qs) of 3.0:1.0. The operative mortality was 
1.2% (two deaths). The remaining patients were followed for a mean of 7.5 years. The 
overall survival and event-free survival rates were 98% and 97% at five years, respectively. 
Similarly, ten-year overall (94%) and event-free (92%) survival rates were high. Their 
(Horvath et al 1991) conclusion was that surgical closure is safe and effective with high 
event-free survival rates. 
Konstantinides et al (1995) made a comparison of surgical closure with medical follow-up 
without surgery. One hundred-seventy-nine patients older than 40 years were examined; 84 
of these had surgical closure while 95 had no surgery. The follow-up duration for both 
groups was 10 years. The actuarial 10-Year survival rate was 95% for the surgery group and 
84% for no surgery group. In addition surgery also appears to have prevented deterioration 
of NYHA functional class. Based on these data the authors (Konstantinides et al 1995) 
conclude that surgical repair of ASD in adult subjects increases long-term survival and 
decreases functional deterioration when compared to medical therapy (no surgery). 
2.1.3 Effect of ASD closure on cardiac function  
Myocardial performance index (MPI), a Doppler-derived non-geometric measure of 
ventricular function, has been used to for quantitative assessment of ventricular function in 
patients with congenital heart disease both in adults and children; this measure appears to 
be relatively independent of changes in preload and afterload (Eidem 2000). Right 
ventricular (RV) MPI did not improve following surgical closure of ASD despite relief of RV 
volume overload (Eidem 2000). This was attributed to adverse effect of cardiopulmonary 
bypass on ventricular function. Salehian et al (2005) evaluated twenty-five patients at a 
mean age 46 years prior to and 3 months (mean) after device closure of ASD. Right 
ventricular MPI improved from 0.35 ± 0.14 to 0.28 ± 0.09 (p = 0.004) while left ventricular 
MPI enhanced from 0.37 ± 0.12 to 0.31 ± 0.11 (p = 0.04) (Figure 1). These authors (Salehian et 
al 2005) conclude that ASD closure improves cardiac function. 
2.1.4 Effect of ASD closure on functional capacity  
Improvement in functional capacity following ASD closure was studied by Brochu et al 
(2002). Thirty-seven patients with a mean age of 49 years whose mean Qp:Qs was 2:1 were 
evaluated. The VO2 max was measured and NYHA classification assessed prior to and 6 
months after ASD closure. They found that VO2 max improved from 23 ± 6 to 27 ± 7 (p < 
0.0001) following ASD closure. Fifteen out of 37 patients were in NYHA Class I prior to  
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Fig. 1. Bar diagram demonstrating improvement in right ventricular (RV) and left 
ventricular (LV) myocardial performance index (MPI) following closure of atrial septal 
defect (ASD). PRE, before atrial septal defect closure; POST, three months after closure 
(constructed from the data of Salehian et al 2005). 
surgery whereas 35 out of 37 patients were in NYHA Class I (p < 0.0001) six months after 
surgical closure. Thus, these authors' data demonstrated improvement in functional capacity 
following ASD closure (Brochu et al 2002). 
2.2 Summary of why should atrial septal defects should be closed in adults  
Based on review of the above and other reports, I conclude that untreated ASD patients tend 
to have decreased event-free survival rates when compared to normal population and 
surgical closure is safe and effective with high event-free survival rates. ASD closure also 
prevents functional deterioration, improves cardiac function and increases functional 
capacity. Consequently all adult patients with ASD should undergo closure of ASD. 
3. When should atrial septal defects be closed in adults?       
Murphy et al (1990) examined the effect of age at surgical closure of ASD. Patients who had 
surgical closure of ASD, performed between 1956 and 1960 at Mayo Clinic, were studied; 
they followed 123 patients and compared their actuarial survival rates with those of normal 
population. In the groups of patients who had surgery after 24 years of age, the actuarial 
survival rates are lower (Figure 2). When surgery is performed prior to 24 years of age, there 
was no significant difference in survival rates. The earlier the surgery was performed the 
better were the 27-year survival rates (Figure 2).  
Based on these data Murphy concludes that early intervention may be beneficial; earlier the 
closure, the better is the long-term outlook. Consequently, it is prudent to close 
hemodynamically significant ASDs in all adults. Since there is no advantage in waiting 
beyond 24 years of age, the closure should be performed at the time of identification of the 
case. 
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Fig. 2. Bar diagram (constructed from the data of Murphy et al 1990) depicting 27-year 
survival rates following closure of atrial septal defect by surgery; these data were compared 
with those of normal population. If surgery is performed prior to 24 years of age, there was 
no significant difference in survival rates. However, the survival rates are lower when 
surgical closure is performed later.  
4. How should atrial septal defects be closed in adults  
Following the introduction of cardiopulmonary bypass techniques for open heart surgery 
and the description of surgical closure of atrial septal defect (ASD) by Gibbon, Lillehei and 
Kirklin in 1950s, it rapidly became a standard form of treatment for atrial defects. The 
conventional treatment of choice of moderate and large defects until recently is surgical 
correction. Although surgical closure of ASDs is safe and effective with low mortality (Galal 
et al 1994, Pastorek et al 1994), the morbidity associated with sternotomy/thoracotomy is 
unavoidable. Consequently, substantial efforts have been made by the cardiology 
community to develop a non-surgical, catheter-based method of ASD occlusion. Since the 
initial description in mid 1970s by King & Mills and their associates (King and Mills 1974, 
Mills and King 1976, King et al 1976) of an atrial septal defect occluding device, a number of 
other devices, reviewed elsewhere (Chopra and Rao 2001, Rao 2003c) and in Chapter 1 of 
this book, were developed. However, Amplatzer Septal Occluder and HELEX are the only 
two devices approved for general clinical use by the US Food and Drug Administration 
(FDA) at the present time. Consequently, two methods of ASD closure, namely, surgical and 
transcatheter are now available. 
4.1 Surgical vs. transcatheter closure  
Studies, though limited in number, comparing surgical with device closure suggest similar 
effectiveness (Berger et al 1999, Du et al 2002, Durongpisitkul 2002, Bialkowski 2004). 
However, the device closure is less invasive, requires no cardio-pulmonary bypass. The 
device closure also appears to have less number of complications (10% vs. 31%), require less 
hospital stay (1 day vs. 4.3 days), and is less expensive (US $ 11,000 vs. $ 21,000) (Kim and 
Hijazi, 2002). The device closure techniques proved to be safe, cost-effective and favorably 
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compare with surgical closure (Berger et al 1999, Du et al 2002, Kim and Hijazi 2002, 
Durongpisitkul 2002, Bettencourt et al 2003, Bialkowski 2004). Transcatheter occlusion of 
ASDs using various devices (Rao 2003a) is now an established practice in most centers 
providing state of the art care to patients with heart disease. 
4.2 Surgical closure 
When surgical closure is contemplated, a median sternotomy or a right sub mammary 
incision is made under general anesthesia. The aorta and vena cavae are cannulated and the 
patient is placed on cardiopulmonary bypass and right atriatomy is performed. The defect is 
exposed and closed either by approximating the defect margins with suture material or by 
using a pericardial patch, depending upon the size of the defect. 
However, at the present time, surgical repair is largely reserved for ASDs with poor septal 
rims in which the interventional cardiologist opines that defect is difficult to close with 
trans-catheter methodology or was unsuccessful in closing the defect. If intra-cardiac repair 
of other defects is contemplated, surgical closure of ASD could also be performed at the 
same time. 
4.3 Transcatheter closure 
A number of devices are available to the interventional cardiologist for closure of ASD, but 
selection of an appropriate device is difficult because of lack of randomized clinical trials. 
Some studies (Formigari et al 1998, Walsh et al 1999, Sievert et al 1999, Keppeir 1999, Godart et 
al 2000, Butera et al 2004) compared the results of two or more devices, as and when the new 
deices became available. But, these studies are neither randomized nor blinded in their design 
and are unlikely to shed any more light than feasibility, safety and effectiveness studies of 
single devices. Given the current economical, ethical and medical considerations, a prospective 
randomized clinical trial utilizing all the eligible devices may not be possible. Therefore, 
selection of the device has largely been based on results of clinical trials conducted separately 
by the inventor or manufacturer of the device. I have carefully compared (Rao 1998a, Rao 
1998b, Rao 2000, Rao 2003c) the implantation feasibility (ratio of implantations vs. patients 
taken to the catheterization laboratory with the intent to occlude), percentage of device 
dislodgements/miss-placements/embolizations, percent of patients with effective occlusion 
and re-intervention-free rates during follow-up; these results were tabulated elsewhere (Rao 
2000, Rao 2003c). These comparisons revealed that these parameters are similar and 
comparable for most, if not all devices that I had the opportunity to evaluate. While the 
feasibility, safety and effectiveness are most important, availability, cost, size of the delivery 
sheath and other factors should also be considered in the process of device selection. 
Of the devices tabulated in the prior publications (Rao 2000, Rao 2003c) and others that 
entered clinical trials since those reviews (see chapter 1), some devices were discontinued, 
shelved or withdrawn because of different reasons and some others continue to be in clinical 
trials either within or outside the US. Amplatzer (AGA Medical Corp., Golden Valley, MN) 
and HELEX (W.L. Gore, Flagstaff, AZ) devices are the only devices approved by the FDA at 
the present time, for general clinical use for closure of the ASDs.  
The Amplatzer septal occluder is the most commonly used ASD closure device worldwide 
at the present time. The feasibility, safety and efficacy of device occlusion are based on self-
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Fig. 2. Bar diagram (constructed from the data of Murphy et al 1990) depicting 27-year 
survival rates following closure of atrial septal defect by surgery; these data were compared 
with those of normal population. If surgery is performed prior to 24 years of age, there was 
no significant difference in survival rates. However, the survival rates are lower when 
surgical closure is performed later.  
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expandable, retrievable and re-positionable design of the device (Hamdan et al 2003). Even 
very large defects can be closed successfully with Amplatzer device using a variety of 
techniques (Nagm and Rao 2004, Rao 2007). 
4.3.1 Protocol for ASD closure 
4.3.1.1 Diagnosis and indications 
After a clinical and echocardiographic diagnosis of moderate to large ostium secundum 
ASD is made, consideration for transcatheter closure should be given. Because of poor echo 
windows, most adult subjects require transesophageal echocardiography (TEE) to confirm 
the diagnosis, to quantify its size and define the septal rims. The indications for closure in 
adults are similar to those used in children (see Chapter 1) and are echocardiographic 
finding of right ventricular volume overloading and/or catheterization findings of Qp:Qs 
greater than 1.5:1.0. The reasons for closure of ASDs in children are prevention of 
pulmonary vascular obstructive disease in adulthood, to prevent arrhythmias and to 
prevent symptoms later in life. Additional reasons in adult subjects are to prevent heart 
failure, prevent functional deterioration, improve myocardial function and prevent 
paradoxical embolism. 
4.3.1.2 Consent, catheterization and transesophageal or intracardiac echocardiography 
Informed consent is obtained and cardiac catheterization is performed preparatory to 
transcatheter occlusion, at the same sitting. Right heart catheterization is undertaken 
percutaneously to confirm the clinical and echocardiographic diagnosis with particular 
attention to exclude partial anomalous pulmonary venous return. Some interventionalists 
perform left atrial cineangiogram in a left axial oblique view (300 LAO and 300 Cranial) with 
the catheter positioned in the right upper pulmonary vein at its junction with the left atrium 
while others do not routinely perform this angiogram. Transesophageal (TEE) or 
intracardiac (ICE) (Hijazi et al 2001) echocardiography to measure the size of the ASD, to 
visualize entry of all pulmonary veins into the left atrium and to examine the atrial septal 
rims is then undertaken. 
4.3.1.3 Device description and implantation  
Detailed descriptions of Amplatzer Septal Occluder and HELEX devices and their 
implantation were included in Chapter 1 of this book. Device placement protocol in adults is 
similar to that described for children and will not be detailed here except to state that the 
procedure is performed more often under ICE guidance in adults than in children and 
Clopidogrel 75 mg/day for the first 2 to 3 months after device implantation in addition to 
Aspirin 185 or 325 mg/Kg/day by mouth for six months is given in adults. However, 
discussion of some issues germane to adult subjects and device closure of complex ASDs 
will be included hereunder. 
4.3.1.4 Precautions in elderly subjects prior to ASD closure 
Reduced diastolic elasticity of the left ventricle is particularly seen in the elderly, causing 
restrictive filling of the left ventricle (Holzer et al 2005, Al-Hindi et al 2009). The ASD 
decompresses the left atrium and prevents high left ventricular end-diastolic pressure. The 
pop-off mechanism no longer exists after the ASD is closed. Consequently, the patients may 
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develop pulmonary edema and may require prolonged mechanical ventilation and inotropic 
support (Al-Hindi et al 2009). If the left atrial pressure is higher than 15 mmHg, temporary 
balloon occlusion of the defect for 10 to 15 minutes and re-measuring the left atrial pressure 
(or pulmonary artery wedge pressure) is recommended. If the pressure increases by more 
than 5 mmHg, the defect should not be closed at that sitting. But the patient should be 
treated with afterload reducing agents and diuretics for one to two weeks. The patient 
should be restudied following afore-mentioned treatment, measuring the left atrial 
pressures during balloon occlusion of the ASD. If the pressure does not increase by more 
than 5 mmHg, device occlusion of ASD may be undertaken. If the pressure continues to be 
high, a fenestrated device may have to be used (Peters et al 2006, Kretschmar et al 2010, 
MacDonald et al 2011, Kenny 2011). 
4.3.1.5 Precautions in subjects with pulmonary hypertension 
In some adult ASD patients pulmonary hypertension may be present. In these patients, a 
particular attention should be paid to calculate pulmonary vascular resistance. Pulmonary 
vascular resistance (PVR) may be calculated: 
PVR = (Mean PA presence - Mean LA pressure)/Pulmonary blood flow index 
Where, PA and LA are pulmonary artery and left atrium respectively. 
The calculated resistance is normally between 1 and 2 units and a resistance higher than 3.0 
units is considered elevated. Marked elevation of the resistance (>8.0 units) contraindicates 
closure of the ASD. When the resistance is elevated, oxygen and other vasodilating agents, 
particularly Nitric oxide (NO) should be administered to demonstrate the reversibility. In 
addition, pulmonary arterial wedge angiography and sometimes, even lung biopsy may be 
necessary to determine the suitability for closure. Patients with calculated pulmonary vascular 
resistance less than 8 wood units with a Qp:Qs >1.5 are generally considered suitable 
candidates for ASD occlusion. In patients with increased pulmonary vascular resistance, if the 
calculated resistance drops to levels below 8 units after administering oxygen or other 
vasodilator agents (NO), the patient becomes a candidate for closure of ASD. 
If the results of the testing of pulmonary vascular reactivity are marginal or the pulmonary 
vascular resistance remains elevated (>8.0 units) following vasodilator testing, a fenestrated 
Amplatzer device may be implanted across the ASD (Lammerset al 2007, Kretschmar et al 
2010). The device will reduce the left-to-right shunt, thus removing the effect of continued 
increase in pulmonary blood flow and may result in improvement. Should the pulmonary 
vascular resistance continue to increase despite the fenestrated device closure, the 
fenestrations in the device will serve as a pop-off escape mechanism and maintain near 
normal cardiac index, though at the expense of arterial oxygen desaturation. 
4.3.2 Approaches for closure of complex ASDs  
Secundum ASDs located centrally in the atrial septum are found in only 24% of cases 
(Podnar et al 2001). These authors reviewed the characteristic of ASDs in 190 patients who 
had transcatheter or surgical repair and found deficient superior anterior rim in 42%, 
deficient inferior posterior rim in 10%, perforated aneurysm of the atrial septum in 8%, 
multiple defects in 7%, deficient inferior anterior  and superior anterior rims in 3%, deficient 
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expandable, retrievable and re-positionable design of the device (Hamdan et al 2003). Even 
very large defects can be closed successfully with Amplatzer device using a variety of 
techniques (Nagm and Rao 2004, Rao 2007). 
4.3.1 Protocol for ASD closure 
4.3.1.1 Diagnosis and indications 
After a clinical and echocardiographic diagnosis of moderate to large ostium secundum 
ASD is made, consideration for transcatheter closure should be given. Because of poor echo 
windows, most adult subjects require transesophageal echocardiography (TEE) to confirm 
the diagnosis, to quantify its size and define the septal rims. The indications for closure in 
adults are similar to those used in children (see Chapter 1) and are echocardiographic 
finding of right ventricular volume overloading and/or catheterization findings of Qp:Qs 
greater than 1.5:1.0. The reasons for closure of ASDs in children are prevention of 
pulmonary vascular obstructive disease in adulthood, to prevent arrhythmias and to 
prevent symptoms later in life. Additional reasons in adult subjects are to prevent heart 
failure, prevent functional deterioration, improve myocardial function and prevent 
paradoxical embolism. 
4.3.1.2 Consent, catheterization and transesophageal or intracardiac echocardiography 
Informed consent is obtained and cardiac catheterization is performed preparatory to 
transcatheter occlusion, at the same sitting. Right heart catheterization is undertaken 
percutaneously to confirm the clinical and echocardiographic diagnosis with particular 
attention to exclude partial anomalous pulmonary venous return. Some interventionalists 
perform left atrial cineangiogram in a left axial oblique view (300 LAO and 300 Cranial) with 
the catheter positioned in the right upper pulmonary vein at its junction with the left atrium 
while others do not routinely perform this angiogram. Transesophageal (TEE) or 
intracardiac (ICE) (Hijazi et al 2001) echocardiography to measure the size of the ASD, to 
visualize entry of all pulmonary veins into the left atrium and to examine the atrial septal 
rims is then undertaken. 
4.3.1.3 Device description and implantation  
Detailed descriptions of Amplatzer Septal Occluder and HELEX devices and their 
implantation were included in Chapter 1 of this book. Device placement protocol in adults is 
similar to that described for children and will not be detailed here except to state that the 
procedure is performed more often under ICE guidance in adults than in children and 
Clopidogrel 75 mg/day for the first 2 to 3 months after device implantation in addition to 
Aspirin 185 or 325 mg/Kg/day by mouth for six months is given in adults. However, 
discussion of some issues germane to adult subjects and device closure of complex ASDs 
will be included hereunder. 
4.3.1.4 Precautions in elderly subjects prior to ASD closure 
Reduced diastolic elasticity of the left ventricle is particularly seen in the elderly, causing 
restrictive filling of the left ventricle (Holzer et al 2005, Al-Hindi et al 2009). The ASD 
decompresses the left atrium and prevents high left ventricular end-diastolic pressure. The 
pop-off mechanism no longer exists after the ASD is closed. Consequently, the patients may 
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The calculated resistance is normally between 1 and 2 units and a resistance higher than 3.0 
units is considered elevated. Marked elevation of the resistance (>8.0 units) contraindicates 
closure of the ASD. When the resistance is elevated, oxygen and other vasodilating agents, 
particularly Nitric oxide (NO) should be administered to demonstrate the reversibility. In 
addition, pulmonary arterial wedge angiography and sometimes, even lung biopsy may be 
necessary to determine the suitability for closure. Patients with calculated pulmonary vascular 
resistance less than 8 wood units with a Qp:Qs >1.5 are generally considered suitable 
candidates for ASD occlusion. In patients with increased pulmonary vascular resistance, if the 
calculated resistance drops to levels below 8 units after administering oxygen or other 
vasodilator agents (NO), the patient becomes a candidate for closure of ASD. 
If the results of the testing of pulmonary vascular reactivity are marginal or the pulmonary 
vascular resistance remains elevated (>8.0 units) following vasodilator testing, a fenestrated 
Amplatzer device may be implanted across the ASD (Lammerset al 2007, Kretschmar et al 
2010). The device will reduce the left-to-right shunt, thus removing the effect of continued 
increase in pulmonary blood flow and may result in improvement. Should the pulmonary 
vascular resistance continue to increase despite the fenestrated device closure, the 
fenestrations in the device will serve as a pop-off escape mechanism and maintain near 
normal cardiac index, though at the expense of arterial oxygen desaturation. 
4.3.2 Approaches for closure of complex ASDs  
Secundum ASDs located centrally in the atrial septum are found in only 24% of cases 
(Podnar et al 2001). These authors reviewed the characteristic of ASDs in 190 patients who 
had transcatheter or surgical repair and found deficient superior anterior rim in 42%, 
deficient inferior posterior rim in 10%, perforated aneurysm of the atrial septum in 8%, 
multiple defects in 7%, deficient inferior anterior  and superior anterior rims in 3%, deficient 
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inferior posterior and posterior rims in 2% and deficient inferior anterior, superior posterior  
and coronary sinus rims in 1 % each. In another study complex ASDs were present in 40 
(28%) of 143 patients (Pedra et al 2004). These authors arbitrarily defined complex anatomy 
as ASDs with stretched diameters larger than 26 mm with a deficient (<4 mm) rim in 23 
(16%), two separate defects with a distance greater than 7 mm in 8 (5.6%), fenestrated atrial 
septum in 5 (3.5%) or redundant and hyper mobile (>10 mm) atrial septum in 4 (2.8%). In 
the ensuing paragraphs I will address how the complex ASDs can be closed by transcatheter 
methodology.  
4.3.2.1 Large defects with deficient anterior-superior rim 
Pedra et al (2004) defined large ASD as a defect with a stretched diameter > 26 mm. Similar 
definitions were used by most other cardiologists. While it goes without saying that large 
defects need large devices to close, the interventionalist needs to consider whether the left 
atrium could accommodate a large device and whether such a large device would interfere 
with atrio-ventricular valve function or obstruct vena caval or pulmonary venous blood 
return. Deficient anterosuperior rim is frequently encountered with large ASDs and indeed, 
in my own personal experience most patients I attempted to occlude with various devices 
were found to have deficient anterior superior rim. Other cardiologists (Podnar et al 2001, 
Berger et al 2001, Chessa et al 2002, Mathewson et al 2004) had similar experiences. With 
deficient anterosuperiorr rim, the disks of the Amplatzer straddle the ascending aorta. With 
other double disk devices the left atrial disk sits on the back of aorta.  
4.3.2.1.1 Amplatzer device 
While deploying the Amplatzer device in ASDs with deficient anterior superior rim, the left 
atrial disk tends to become perpendicular to the atrial septum leading to prolapse of the left 
disk into the right atrium. Several techniques have been proposed to overcome such 
difficulties; these were reviewed elsewhere (Nagm and Rao 2004, Rao 2007). The left atrial 
disk of the device is deployed in the right upper or left upper pulmonary vein and the waist 
and the right atrial disk are released while simultaneously withdrawing the deployed left 
atrial disk against the atrial septum; this technique has been successfully used by several 
investigators (Berger et al 2001, Du et al 2002, Chessa et al 2002, Harper et al 2002, Varma et 
al 2004, Fu et al 2007). While the device placement may be successful with these techniques, 
there is some concern regarding the risk of injury to the pulmonary vein. Heat-bending the 
distal portion of the delivery sheath 360 degrees along with cutting off the tip of the sheath ≥ 
45 degrees toward its inner circumference is another technique used to help overcome the 
prolapse of the left disk into the right atrium (Cooke et al 2001, Mathewson et al 2004, 
Varma et al 2004). Hausdorf sheath (Cook, Bloomington, IN), a specially designed sheath 
with two curves at the end may help align the left atrial disk parallel to the septum and this 
delivery catheter has successfully been used by some workers (Staniloae et al 2003, Pedra et 
al 2004, Varma et al 2004). Holding the left atrial disk with the tip of a reinforced dilator 
(Abdul Wahab 2003), sizing balloon catheter (Dalvi et al 2005, Flores et al 2008) or a 
steerable guide catheter (Nounou et al 2008) to prevent its prolapse into the right atrium has 
also been employed successfully. Kutty et al (2007) cut the sheath to create a straight 
catheter with a side-hole, the so called SSH modification and were successful in positioning 
the device in 120 of 122 (98.4%) patients; this is in contradistinction to the successful 
deployment of the device in 14 of 18 (78%) patients with the use of standard Amplatzer 
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delivery sheath. The cardiologists should consider all options reviewed above and select the 
method that is most likely to result in successful implantation of the device in their patient. 
4.3.2.1.2 HELEX device  
Since the HELEX device is not suitable for large defects, it should not be used to occlude 
large ASDs. 
4.3.2.2 Large defects with deficient postero-inferior rim 
Some of the large ASDs are associated with deficient posterior-inferior (PI) rim (Pedra et al 
2004) making the device implantation difficult. Varma et al (2004) studied reasons for 
unsuccessful Amplatzer implantations and found deficient inferior rim as an explanation for 
unsuccessful deployments. Closure of a large ASD with deficient or absent PI rim is a real 
challenge. Insufficient number of cases with deficient PI rim reported in most series makes it 
even more difficult to have a consensus. Du et al (2002) reported 23 patients with deficient 
rims; of these 3 patients had deficient inferior or posterior rims. Two patients had 2 mm of 
posterior rim and the third had a 4 mm posterior rim. These 3 patients' ASDs were 
successfully closed. Mathewson et al (2004) defined absent PI rim as a rim < 3 mm. As the 
difference in radius length between right and left atrial disks of the Amplatzer device is 2-3 
mm, a rim < 3 mm will not allow both disks to hang on both sides of the rim. They found 
that defects with absent PI rim tend to be larger in diameter. They concluded that, although 
a stable Amplatzer device deployment is possible, these defects are more liable for 
complications such as pulmonary vein or inferior vena caval obstruction, encroachment 
onto the anterior mitral leaflet or frank embolization (Mathewson et al 2004). The number of 
cases reported is too small to make a generalized conclusion as to what is the best approach 
to address these ASDs. 
4.3.2.3 Multiple or fenestrated defects 
Multiple or fenestrated ASDs may be successfully occluded by different techniques or 
devices. One method used for addressing  fenestrated defects was to perform balloon atrial 
septostomy to create a single large defect which was then closed with a single large 
Amplatzer device (Carano et al 2001). While these authors were successful in occluding the 
defect, I am not in favor of using such a technique. A large single Amplatzer device may be 
deployed in the larger defect to occlude two or more smaller defects as used by Szkutnik et 
al (2004) and others (Roman et al 2002). While examining this technique, Szkutnik et al 
(2004) found that a smaller defect less than 7 mm distance from the larger defect had a 100% 
closure rate at 1 month follow-up. The device in the larger defect decreases the distance 
between the two defects or even compress the smaller defect (Szkutnik et al 2004). However, 
if the distance between the two defects is >7 mm, a residual left to right shunt persisted 
(Szkutnik et al 2004). Several investigators (Pedra et al 1998, Bandel et al 2002, Roman et al 
2002, Pinto and Dalvi 2005, Awad et al 2007, Tillman et al 2008, Butera et al 2010, Duygu et 
al 2010. Cho et al 2011) used two Amplatzer devices to close two ASDs concurrently. 
Extremely rarely three devices (Lander et al 2004, Arcidiacono et al 2008) may be required to 
completely close all the defects. Multiple defects may also be closed with a large single 
device such as CardioSeal device (Pedra et al 2000, Evert et al 2001) or Cribriform Amplatzer 
device (Hijazi et al 2003, Numan et al 2008).  
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delivery sheath. The cardiologists should consider all options reviewed above and select the 
method that is most likely to result in successful implantation of the device in their patient. 
4.3.2.1.2 HELEX device  
Since the HELEX device is not suitable for large defects, it should not be used to occlude 
large ASDs. 
4.3.2.2 Large defects with deficient postero-inferior rim 
Some of the large ASDs are associated with deficient posterior-inferior (PI) rim (Pedra et al 
2004) making the device implantation difficult. Varma et al (2004) studied reasons for 
unsuccessful Amplatzer implantations and found deficient inferior rim as an explanation for 
unsuccessful deployments. Closure of a large ASD with deficient or absent PI rim is a real 
challenge. Insufficient number of cases with deficient PI rim reported in most series makes it 
even more difficult to have a consensus. Du et al (2002) reported 23 patients with deficient 
rims; of these 3 patients had deficient inferior or posterior rims. Two patients had 2 mm of 
posterior rim and the third had a 4 mm posterior rim. These 3 patients' ASDs were 
successfully closed. Mathewson et al (2004) defined absent PI rim as a rim < 3 mm. As the 
difference in radius length between right and left atrial disks of the Amplatzer device is 2-3 
mm, a rim < 3 mm will not allow both disks to hang on both sides of the rim. They found 
that defects with absent PI rim tend to be larger in diameter. They concluded that, although 
a stable Amplatzer device deployment is possible, these defects are more liable for 
complications such as pulmonary vein or inferior vena caval obstruction, encroachment 
onto the anterior mitral leaflet or frank embolization (Mathewson et al 2004). The number of 
cases reported is too small to make a generalized conclusion as to what is the best approach 
to address these ASDs. 
4.3.2.3 Multiple or fenestrated defects 
Multiple or fenestrated ASDs may be successfully occluded by different techniques or 
devices. One method used for addressing  fenestrated defects was to perform balloon atrial 
septostomy to create a single large defect which was then closed with a single large 
Amplatzer device (Carano et al 2001). While these authors were successful in occluding the 
defect, I am not in favor of using such a technique. A large single Amplatzer device may be 
deployed in the larger defect to occlude two or more smaller defects as used by Szkutnik et 
al (2004) and others (Roman et al 2002). While examining this technique, Szkutnik et al 
(2004) found that a smaller defect less than 7 mm distance from the larger defect had a 100% 
closure rate at 1 month follow-up. The device in the larger defect decreases the distance 
between the two defects or even compress the smaller defect (Szkutnik et al 2004). However, 
if the distance between the two defects is >7 mm, a residual left to right shunt persisted 
(Szkutnik et al 2004). Several investigators (Pedra et al 1998, Bandel et al 2002, Roman et al 
2002, Pinto and Dalvi 2005, Awad et al 2007, Tillman et al 2008, Butera et al 2010, Duygu et 
al 2010. Cho et al 2011) used two Amplatzer devices to close two ASDs concurrently. 
Extremely rarely three devices (Lander et al 2004, Arcidiacono et al 2008) may be required to 
completely close all the defects. Multiple defects may also be closed with a large single 
device such as CardioSeal device (Pedra et al 2000, Evert et al 2001) or Cribriform Amplatzer 
device (Hijazi et al 2003, Numan et al 2008).  
Atrial Septal Defect 130 
While the conventional method of imaging the atrial septum and monitoring device 
deployment is two-dimensional TEE or ICE, more recently three-dimensional transthoracic 
(Arcidiacono et al 2008) or transesophageal (Kuo et al 2011) echocardiography has been 
used. However, it is not clear whether three dimensional imaging techniques are superior to 
two dimensional techniques.  
Based on these observations and other reports as well as our personal experience, the 
following recommendations may be made. If the smaller defect is hemodynamically 
significant, but is far (>7 mm) from the larger defect, two devices should be used. After 
verifying good position of both devices, release of smaller device should precede the release 
of larger device. Extremely rarely three devices (Lander et al 2004, Arcidiacono et al 2008) 
may be needed to completely close all the defects. If the defects are close to each other 
(<7mm) Cribriform Amplatzer device (Hijazi et al 2003, Zanchetta et al 2005, Numan et al 
2008), large enough to cover all the defects may be used. We used both these techniques 
with good success.  
4.3.2.4 Anuerysmal atrial septum 
Single or multiple defects with septal aneurysm represent a different type of complex ASD. 
Such defects may be better dealt with devices that don’t rely on stenting the defect (for 
example Amplatzer device) in order to achieve stabilization in the septum. Devices with two 
discs such as the hybrid buttoned device (Rao 2003d), the HELEX, the CardioSeal or the 
Cribriform Amplatzer (Musto et al 2009) are more appropriate choices to close such defects. 
Closing two small but distant defects within an aneurismal atrial septum may effectively 
close both defects but carry a higher risk of later development of thrombus formation 
(Krumsdorf et al 2004). We have successfully closed defects associated with atrial septal 
aneurysms with hybrid buttoned devices (Figure 3) by compressing the aneurysm between 
the occluder and the square shaped counter-occluder (Rao 2003d). 
COD BUTTONED DEVICE CLOSURE OF ASD 
WITH SEPTAL ANEURYSM
A B
C D  
Fig. 3. Selected left atrial (LA) cineangiographic (A) and transesophageal echocardiographic 
(B) frames showing atrial septal aneurysm (A, arrow). After closure of the atrial septal defect 
with a hybrid buttoned device (C), the aneurysm is sandwiched between the left atrial (LA) 
component of the device (LOcc) and right atrial (RA) component of the device (ROcc). No 
residual shunt is seen (D). The superior vena cava (SVC) is unobstructed. 
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4.3.3 Conclusions – Approaches for closure of complex ASDs  
It may be  concluded that most complex ASDs can be closed successfully either by using 
traditional or special devices or techniques. Defects with deficient or absent PI rim continue 
to be challenging for most interventionalists and may require surgical closure. 
4.3.4 Long-term complications of transcatheter closure  
Reports of erosion of the aortic wall by the Amplatzer device with development of aorta-to-
right atrium (Chun 2003) or aorta-to-left atrium (Aggoun et al 2002) fistulae led to the 
suggestion of over-sizing the device (4 mm larger than the measured stretched diameter) in 
large defects with deficient anterior superior rim. This is meant to ensure that the device 
disks straddle and remain flared around the ascending aorta to prevent discrete areas of 
pressure where erosion may occur. Of course, when over-sizing the device, care must be 
taken not to interfere with atrio-ventricular valve function and venous return. Device 
migration and erosion of aorta (Amin et al 2004, AGA 2006) was observed during follow-up 
in 37 out of 35,000 ( 0.11% or 1 in 1,000) Amplatzer device implants world-wide. This 
complication was also similar in the US study population: 18 out of 15,900 implants ( 0.12% 
or 1 in 1,000). Review of data by the Review Board and AGA Medical (AGA 2006) suggested 
that the device erosion is related to over-sizing of the device (Figure 4) and recommended 
that device size >1.5 times the TEE/ICE diameter of ASD should not be used. 
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Fig. 4. Bar diagram demonstrating relationship of atrial septal defect (ASD) and device size 
data between the group of patients without perforation (Trial) and those that had 
perforation (Erosion). The diameter (Dia) of the ASD was similar in both groups whereas the 
stretched diameter (Stretch), device size (Dev size) and ratio of device to ASD (Ratio) were 
larger in the patients who had perforation than those who did not. Based on these data a 
recommendation made not to use devices larger 1.5 X ASD size (Constructed from the data 
of AGA 2006). 
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to be challenging for most interventionalists and may require surgical closure. 
4.3.4 Long-term complications of transcatheter closure  
Reports of erosion of the aortic wall by the Amplatzer device with development of aorta-to-
right atrium (Chun 2003) or aorta-to-left atrium (Aggoun et al 2002) fistulae led to the 
suggestion of over-sizing the device (4 mm larger than the measured stretched diameter) in 
large defects with deficient anterior superior rim. This is meant to ensure that the device 
disks straddle and remain flared around the ascending aorta to prevent discrete areas of 
pressure where erosion may occur. Of course, when over-sizing the device, care must be 
taken not to interfere with atrio-ventricular valve function and venous return. Device 
migration and erosion of aorta (Amin et al 2004, AGA 2006) was observed during follow-up 
in 37 out of 35,000 ( 0.11% or 1 in 1,000) Amplatzer device implants world-wide. This 
complication was also similar in the US study population: 18 out of 15,900 implants ( 0.12% 
or 1 in 1,000). Review of data by the Review Board and AGA Medical (AGA 2006) suggested 
that the device erosion is related to over-sizing of the device (Figure 4) and recommended 
that device size >1.5 times the TEE/ICE diameter of ASD should not be used. 
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Fig. 4. Bar diagram demonstrating relationship of atrial septal defect (ASD) and device size 
data between the group of patients without perforation (Trial) and those that had 
perforation (Erosion). The diameter (Dia) of the ASD was similar in both groups whereas the 
stretched diameter (Stretch), device size (Dev size) and ratio of device to ASD (Ratio) were 
larger in the patients who had perforation than those who did not. Based on these data a 
recommendation made not to use devices larger 1.5 X ASD size (Constructed from the data 
of AGA 2006). 
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5. Summary and conclusions 
ASDs in adult subjects should be closed at presentation, electively, irrespective of their age. 
Evidence was presented to indicate that hemodynamically significant (right ventricular 
volume overload) ASDs in adults should be transcatheter occluded irrespective of 
symptomatology. While surgical closure is safe and effective, device closure carries less 
morbidity. Multiple devices have been investigated over the last few decades, but only 
Amplatzer and HELEX devices received FDA approval as of this time. The Amplatzer is 
useful in most ASDs while the HELEX device is useful in small and medium-sized defects. 
Some procedural details were mentioned with particular emphasis on the need for test 
occlusion of ASD in the elderly. Approaches taken to occlude ASDs with complex anatomy 
were also reviewed. Amplatzer device appears to be best available option at the present 
time. Careful attention to the details of the technique are mandatory to achieve a successful 
outcome  
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1. Introduction 
The prevalence of adults with congenital heart disease is rising in the general population (1). 
Similarly, the number of geriatric patients with congenital heart disease, such older than 70 
years old, is also rising. Furthermore, mortality rates in congenital heart disease have shifted 
away from the young and towards adults, with a steady increase in age at death. Actually, the 
mortality of congenital heart disease in patients whose age 60 years or more is increasing 
during past few decades reported in Japanese nationwide survey (2). Atrial septal defect 
(ASD) is the one of the most common congenital heart lesions in adults, and the most 
influenced heart disease for the death in geriatric population. Prevalence of ASD in children is 
noted to be 11.4% within the congenital heart defects (3). Majority of these children are 
asymptomatic and diagnosed by school physical examination, heart murmur detected primary 
care pediatrician, cardiac echo screening in the newborn period. If defect is smaller than 6 mm, 
spontaneous closure can be expected. Operation is scheduled based on children’s body size, 
usually before the elementally school with very low incidence of mortality rate (4). 
Although the pediatric or young adult ASD population has attracted research interest over 
the last 2 decades, the geriatric ASD population has yet to be characterized. Extrapolation of 
studies on younger patients is not appropriate in the geriatric patients. First, geriatric 
patients with ASD acquire comorbid conditions such as arrhythmia, hypertension, 
respiratory distress, kidney disease, etc., that always influence on significant role in their 
heart conditions. Second, geriatric ASD patients may have inherently superior resiliency, 
milder disease, or balanced physiology in contrast to those not surviving to an advanced age 
(5). Therefore, geriatric patients with ASD represent a distinct population for which focused 
studies are needed. 
Again, clinical features of atrial septal defect (ASD) in the elderly are significantly different 
from those in children and young adults. Elderly patients with ASD frequently present with 
hemodynamic abnormalities such as pulmonary hypertension, atrial arrhythmias, and 
valvular regurgitation, which cause congestive heart failure. Moreover, various 
comobidities, such as hypertension, chronic obstructive pulmonary disease, coronary artery 
disease and left ventricular diastolic dysfunction often complicate the clinical features in this 
population. Left ventricular diastolic dysfunction, which is also seen as part of normal aging 
and frequently occurs in elderly individuals with hypertension or increased arterial stiffness 
[6,7], may cause acute congestive heart failure after ASD closure [8].  
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After the introduction of Amplatzer Septal Occluder, transcatheter ASD closure has become 
a well-established treatment for secundum-type ASD, with hemodynamically significant 
left-to-right shunt in children and young adults. Several studies and our own experience 
have demonstrated clinical benefits and positive right-heart remodeling, with reduction of 
the right ventricular end-diastolic diameter.(8-17) However, few studies were published 
considering geriatric patients, who older than 70 years.(18–21) In this aged population, not 
only catheter closure of ASD but also surgical closure has been reported very limited 
experiences, little data are published on functional results. In this chapter, I would like to 
report our current experience of catheter closure of ASD in geriatric patients (70 years or 
more), and its long-term outcome.  
2. Patient’s background 
From 2005 to 2010, transcatheter closure of ASD was attempted in 420 patients in our 
hospital. Of those patients, 30 patients who were older than 70 years were retrospectively 
assessed. Patient characteristics, clinical, hemodynamic and echocardiographic data, and 
ASD morphology are shown in Table 1. There were 10 males and 20 females with a mean  
 
Total patients 30 
Gender, F/M  20/10 
Age, (range), yrs 75.8 ± 3.8 (70-85) 
BSA, m2 1.5 ± 0.2 
Hypertension 12 (40%) 
Stroke 4 (13%) 
CAD 2 (7%) 
COPD 5 (17%) 
Atrial fibrillation 16 (53%) 
   Paroxysmal 3 (10%) 
   Permanent 13 (43%) 
RBBB 22 (74%) 
Systolic PAP *, mmHg 35.6 ± 11.8 
PAH 16 (53%) 
E', cm/s 7.1 ± 1.9 
E/E` 11.0 ± 3.9 
Diuretic use 17 (57%) 
Hospitarization for HF 9 (30%) 
NYHA functional class, I / II / III 5 /17 / 8 
Qp/Qs* 2.4 ± 0.7 
ASD size, mm 20.3 ± 6.4 
Rim type    Sufficient rim, n (%) 8 (27%) 
  Aortic rim deficient, n (%) 19 (63%) 
  Aortic and anterosuperior rim deficient, n (%) 1 (3%) 
  IVC rim deficient, n (%) 2 (7%) 
BSA, body surface area; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease 
RBBB, right bundle branch block;  PAP, pulmonary artery pressure; PAH, pulmonary artery 
hypertension 
E, early diastolic mitral valve flow velocity; E', early diastolic mitral annular velocity; HF, heart failure 
NYHA, New York Heart Association; Qp, pulmonary flow; Qs, systemic flow; IVC, inferior vena cava 
Table 1. Patients Characteristics 
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age of 75.8 ± 3.8 years and age range of 70 to 85 years. Eighteen of the 30 patients had been 
diagnosed with ASD within 2 years before transcatheter closure was attempted but the 
others well before that. Most of the patients had at least one major comorbidity, including 
systemic hypertension, stroke, coronary artery disease, and atrial fibrillation. Mean systolic 
pulmonary artery pressure at the time of diagnostic catheterization was 35.6 ± 11.8 mmHg. 
Mean early diastolic mitral annular velocity (e') and the ratio of early diastolic mitral valve 
flow velocity (E) to e' (E/e') suggested that our cohort generally had impaired myocardial 
relaxation.(22,23) Twelve patients had been diagnosed with ASD well before transcatheter 
closure was attempted but they had refused or hesitated to receive ASD closure. We think 
that this was partially because they had no recognizable symptom, but mainly because 
surgical closure was the only treatment at the time when they had been first diagnosed with 
ASD. More than half of the patients were being treated with a diuretic for congestive heart 
failure, and 30% of the patients had a history of hospitalization due to heart failure. 
Seventeen patients were classified as NYHA functional class II and 8 patients were classified 
as class III. Only 5 patients had no symptoms despite significant shunt flow and were 
classified as NYHA functional class I. One patient had two defects. Mean defect diameter 
was 20.3 ± 6.4 mm, and a circumferentially sufficient rim (> 5 mm rim around the defect) 
was observed in only 8 patients. Mean pulmonary-systemic flow ratio (Qp/Qs) calculated 
by using the Fick principle was 2.4 ± 0.7.  
3. Hemodynamic features during ASD closure in geriatric patients 
Previous studies have suggested that development of acute congestive heart failure is due to 
abrupt elevation in left ventricular preload following transcatheter ASD closure, especially in 
elderly patients with impaired left ventricular systolic or diastolic function (6,24,25) In our 
experience, despite the fact that our patients had impaired left ventricular diastolic function 
estimated by decreased e' and increased E/e' (23,26) as well as various comorbidities such as 
systemic hypertension, pulmonary artery hypertension and atrial fibrillation, acute congestive 
heart failure after the ASD closure did not develop in any of the patients except in one patient 
in whom the procedure was abandoned due to PCWP elevation during test balloon occlusion. 
Schubert et al. reported that peri-procedural anticongestive medication was effective in 
preventing congestive heart failure after ASD closure in elderly patients (27). In our 
experience, 57% of the 30 patients previously used oral diuretics, and this high rate of diuretic 
usage might have contributed to prevention of acute congestive heart failure after closure. 
4. Transcatheter ASD closure 
Transcatheter ASD closure was conducted under general anesthesia with the guidance of 
fluoroscopy and TEE. Amplatzer® Septal Occluder (St. Jude Medical, St. Paul, MN) was 
used for all closures, and the procedure was performed as previously described (28). For 
patients who had a history of heart failure and were considered to be hemodynamically 
high-risk, we placed a Swan-Ganz catheter into pulmonary artery from the internal jugular 
vein or femoral vein and monitored pulmonary artery wedge pressure (PCWP) during 
subsequent procedure. If mean PCWP increased > 5 mmHg from the baseline value during 
balloon occlusion of the defect (test balloon occlusion), we judged the procedure should not 
be indicated. (Fig. 1) Medications such as diuretics, warfarin, and antihypertension and 
antiarrhythmia drugs were continued at the same doses after the procedure. 
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After the introduction of Amplatzer Septal Occluder, transcatheter ASD closure has become 
a well-established treatment for secundum-type ASD, with hemodynamically significant 
left-to-right shunt in children and young adults. Several studies and our own experience 
have demonstrated clinical benefits and positive right-heart remodeling, with reduction of 
the right ventricular end-diastolic diameter.(8-17) However, few studies were published 
considering geriatric patients, who older than 70 years.(18–21) In this aged population, not 
only catheter closure of ASD but also surgical closure has been reported very limited 
experiences, little data are published on functional results. In this chapter, I would like to 
report our current experience of catheter closure of ASD in geriatric patients (70 years or 
more), and its long-term outcome.  
2. Patient’s background 
From 2005 to 2010, transcatheter closure of ASD was attempted in 420 patients in our 
hospital. Of those patients, 30 patients who were older than 70 years were retrospectively 
assessed. Patient characteristics, clinical, hemodynamic and echocardiographic data, and 
ASD morphology are shown in Table 1. There were 10 males and 20 females with a mean  
 
Total patients 30 
Gender, F/M  20/10 
Age, (range), yrs 75.8 ± 3.8 (70-85) 
BSA, m2 1.5 ± 0.2 
Hypertension 12 (40%) 
Stroke 4 (13%) 
CAD 2 (7%) 
COPD 5 (17%) 
Atrial fibrillation 16 (53%) 
   Paroxysmal 3 (10%) 
   Permanent 13 (43%) 
RBBB 22 (74%) 
Systolic PAP *, mmHg 35.6 ± 11.8 
PAH 16 (53%) 
E', cm/s 7.1 ± 1.9 
E/E` 11.0 ± 3.9 
Diuretic use 17 (57%) 
Hospitarization for HF 9 (30%) 
NYHA functional class, I / II / III 5 /17 / 8 
Qp/Qs* 2.4 ± 0.7 
ASD size, mm 20.3 ± 6.4 
Rim type    Sufficient rim, n (%) 8 (27%) 
  Aortic rim deficient, n (%) 19 (63%) 
  Aortic and anterosuperior rim deficient, n (%) 1 (3%) 
  IVC rim deficient, n (%) 2 (7%) 
BSA, body surface area; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease 
RBBB, right bundle branch block;  PAP, pulmonary artery pressure; PAH, pulmonary artery 
hypertension 
E, early diastolic mitral valve flow velocity; E', early diastolic mitral annular velocity; HF, heart failure 
NYHA, New York Heart Association; Qp, pulmonary flow; Qs, systemic flow; IVC, inferior vena cava 
Table 1. Patients Characteristics 
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4. Transcatheter ASD closure 
Transcatheter ASD closure was conducted under general anesthesia with the guidance of 
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subsequent procedure. If mean PCWP increased > 5 mmHg from the baseline value during 
balloon occlusion of the defect (test balloon occlusion), we judged the procedure should not 
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antiarrhythmia drugs were continued at the same doses after the procedure. 
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(a) Chest x ray before the procedure 
 
(b) ECG finings before the procedure 
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(c) apical 4 chamber view of transthoracic echocardiography: RA and RV are significantly enlarged 
 
(d) transesophageal echocardiography demonstrated 30mm defect with aortic rim deficiency 
 
(e) 3d transesophageal echocardiography demonstrated the elliptical shape of ASD 
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(f) Catheter closure of ASD using 34mm device, PCW pressure monitored continuously 
 
(g) Chest x-ray 6 months after the ASD closure, clinical symptoms also resolved completely 
Fig. 1. 82 years old female, ASD with permanent atrial fibrillation. 
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Prior to ASD closure, test balloon occlusion were performed in 7 of 30 cases. As a result, 
the procedure was abandoned in one case due to a significant elevation of PCWP during 
test occlusion of the ASD. This patient was an 84-year-old thin woman who had 
permanent atrial fibrillation, hypertension, chronic kidney disease, chronic anemia and 
severe TR. She had been repeatedly hospitalized with congestive heart failure in  
past years. Her ASD diameter was 24 mm and Qp/Qs was 2.6. During test balloon 
occlusion, her PCWP immediately increased from 8 mmHg to 22 mmHg and remained at 
16 mmHg after 20 minutes, thus procedure was abandoned. In the other 2 cases, the 
device was difficult to deploy because of large size defect. One of those cases proceeded to 
surgical closure, and the other case was successfully closed in the second attempt of 
catheter intervention on a later day. Finally, 28 (93%) of the 30 patients were treated 
successfully by catheter closure. A single device was placed in 27 patients. In the 
remaining patient with multiple defects, 2 devices were deployed at the time of the same 
procedure. Mean device diameter was 23.3 ± 6.0 mm. Mean follow-up period was 19.1 ± 
11.3 months.  
5. Procedural outcomes 
Table 2 shows the procedural and mid-term results. Device closure was successfully 
performed in 28 (93%) of the 30 patients without acute complications. In the other 2 patients, 
the procedures were abandoned because of technical issues. While only 8 (27%) of the 30 
patients had sufficient rim type ASD, 19 (63%) had aortic rim deficient type. However, there 
was not much difference in our device selection between sufficient rim and aortic rim 
deficient type. Therefore, we think that the small percentage of patients with sufficient rim 
did not have a great impact on device size selection in the present study. Although the 
majority of our patients were complicated with various comorbidities, such as pulmonary 
artery hypertension, systemic hypertension and atrial fibrillation, high procedural success 
rate can be expected even in this aged group. Also, significant improvement of NYHA 
functional class was observed after closure even though about 30% of the patients in this  
 
Procedural results (n=30)   Success deployment, n (%) 28 (93%) 
 Device size, mm 23.3 ± 6.0 
 Acute complication, n (%) 0 (0%) 
Mid-term results (n=28)   Meam follow-up period, m 19.1 ± 11.3  
 Residual shunt, n (%) 2 (8%) 
 Major events     Death, n (%) 2 (8%) 
      sudden death, n 1 (4%)* 
      prostate cancer, n 1 (4%) 
   Pacemaker implantation, n (%) 1 (4%) 
   TIA, n (%) 1 (4%)* 
   Persistent AF, n (%) 1 (4%) 

* the same case 
TIA, transient ischemic attack; AF, atrial fibrillation 
Table 2. Procedural and Mid-term Results  
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study had a history of hospitalization for congestive heart failure. No patient required 
additional hospitalization for congestive heart failure during the follow-up period. The first 
procedure was successful in 27 of 30 cases in which transcatheter ASD closure was 
attempted. On the other hand, the procedure was abandoned in 3 cases.  
Two patients died during the follow-up period. One died of prostatic cancer 20 months after 
ASD closure. The other patient died 2 months after the procedure. This patient was a 70-
year-old woman who had permanent atrial fibrillation, severe chronic obstructive 
pulmonary disease, mild left ventricular dysfunction, history of pacemaker implantation for 
sick sinus syndrome, and mitral valve replacement and was in NYHA functional class III. 
Her ASD was 22 mm with a sufficient atrial rim, and a 26 mm device was used for closure. 
She died from unknown cause at home; however, a history of transient cerebral ischemic 
attack was reported one week before her death. Autopsy was not performed. During the 
follow-up period, 3 complications occurred. One patient who was complicated with several 
cardiac comorbidities died 2 months after the procedure. An autopsy was not performed 
and it was therefore not known whether the cause of sudden death was ASD device-
associated. 
6. Atrial arrhythmias 
Two patients were complicated with new arrhythmia. One patient who had permanent 
atrial fibrillation underwent pacemaker implantation for slow ventricular response 6 
months after ASD closure. The other patient with paroxysmal atrial fibrillation before ASD 
closure developed persistent atrial fibrillation during the follow-up period. The remaining 
24 patients had no late complication during the follow-up period. No patient had 
hemodynamically significant residual shunt.  
Table 3 shows time course changes in clinical and echocardiographic parameters. Follow-up 
data (at more than 6 months after the procedure) were available in all of the 28 patients with 
exception of one patient who died 2 months after the procedure. NYHA functional class was 
significantly improved in 20 (74%) of the 27 patients at the latest follow-up (Fig. 2). One 
patient who remained in NYHA class III was complicated with severe chronic obstructive 
pulmonary disease. There was also a significant improvement in plasma BNP level (175.9 ± 
64.7 vs. 99.2 ± 83.2 pg/ml, P=0.013). Resting heart rate also decreased significantly (74.4 ± 
14.5 vs. 66.7 ± 8.7 beats/min, P=0.005), although no cardiac chronotropic drug was 
administered to any of the patients. Pacemaker implantation was required in one patient 6 
months after the procedure, even though bradycardia was not observed before or just after 
ASD closure. In one patient, paroxysmal atrial fibrillation progressed into persistent atrial 
fibrillation 2 years after ASD closure. In previous studies, the incidence of atrial fibrillation 
in patients after transcatheter ASD closure was estimated to be 5% to 18% (29-31), however, 
especially in elderly patients, atrial fibrillation is one of the expected findings for their 
natural course after ASD closure.   
7. Cardiac remodeling 
RVEDD and estimated systolic pulmonary artery pressure decreased significantly (40.8 ± 6.0 
vs. 31.6 ± 4.5 mm, P<0.001, 38.5 ± 12.7 vs. 27.2 ± 7.3 mmHg, P<0.001, respectively). At the  
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BNP, brain natriuretic peptide; PAP, pulmonary artery pressure; RVEDD, right ventricular end-
diastolic dimension; LAD, left ventricular dimension; LVEF, left ventricular ejection fraction; TR, 
tricuspid regurgitation; MR, mitral regurgitation 
Table 3. Changes of Clinical Echocardiographic Parameters 
 
Fig. 2. NYHA functional class before the procedure and at follow-up.  
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same time, LVEDD increased significantly (39.7 ± 4.8 vs. 45.3 ± 4.6 mm, P<0.001). Therefore, 
the RVEDD/LVEDD ratio significantly decreased (1.05 ± 0.24 vs. 0.70 ± 0.12 mm, reduction 
of 67%, P<0.001), indicating ventricular reverse remodeling. Left atrial dimension, above the 
normal level at baseline, did not change significantly during the follow-up period. Left 
ventricular ejection fraction also did not change. During the follow-up period, NYHA 
functional class significantly improved in 20 (74%) of the 27 patients. Our data also 
demonstrated significant decreases of heart rate, pulmonary artery pressure and plasma 
BNP level, and these changes contributed to the improvement of NYHA functional class. 
Decrement of heart rate is presumably evidence of increment of left ventricular stroke 
volume following increased left ventricular preload after abolishment of left-to-right shunt. 
Significant decrease in RVEDD/LVEDD ratio was observed even in our geriatric patients, 
although RVEDD did not reach the normal level. Interestingly, percentage change in 
RVEDD/LVEDD ratio in our cohort was equivalent to results of other studies in younger 
populations (25,32). Furthermore, it was revealed that RVEDD/LVEDD ratio was 
independently correlated with NYHA functional class in the follow-up period. 
8. AV valve regurgitation 
Improvement of TR was observed in 11 of 17 patients (65%) with moderate or severe degree 
of regurgitation during the follow-up period (Fig. 3). On the other hand, MR was increased 
in 10 (37%) of the 27 patients and was unchanged in the others (63%) during the follow-up 
period (Fig. 4). In our cohort, there was no patient with mitral valve prolapse as a cause for 





Fig. 3. Degrees of TR before the procedure and at follow-up. 
 




Fig. 4. Degrees of MR before the procedure and at follow-up.  
TR was not observed during the follow-up period. Interestingly, in the case of moderate or 
severe TR before ASD closure, the degree of TR was improved in 11 (65%) of the 17 patients. 
TR can be improved functionally following decrement of right ventricular preload after ASD 
closure. Improvement of TR also can be expected following improvement of right 
ventricular geometric abnormality (33,34). Our results suggest that TR can be improved 
even in geriatric patients and that the severity of TR does not become a factor to exclude 
them as candidates for transcatheter ASD closure. On the other hand, the degree of MR was 
slightly increased in 10 patients (37%) and unchanged in the others (63%) during the follow-
up period. Wilson et al. reported that the degree of MR was unchanged in 83% and 
increased in 10% of their 194 patients, including 78 patients aged younger than 15 years, 
after transcatheter ASD closure (35). In elderly ASD patients, the severity of MR might be 
masked by the presence of ASD effectively reducing left ventricular preload. Additionally, 
degenerated change of the mitral valve leaflet also influenced the increase in MR. Although 
the degree of MR and the increase in MR were not associated with NYHA functional class in 
the follow-up period in our study, further long-term follow-up is mandatory. 
Associations between NYHA functional class and echocardiographic parameters in the 
follow-up period  
Table 4 shows associations of clinical and echocardiographic parameters with NYHA 
functional class. In the follow-up period, RVEDD/LVEDD ratio was identified as a factor 
associated with NYHA functional class. On the other hand, E/e', e', degree of TR or MR and 
increase in MR were not associated with NYHA functional class.  
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Table 4. Association betwwen Clinical and Echocardiographic Parameters and NYHA class 
at Follow-up Period 
9. Conclusions 
Although our experience is still small, even in elderly patients older than 70 years, 
transcatheter closure of ASD can be performed safely and contributes to significant 
improvement of NYHA functional class and positive cardiac remodeling. Further 
investigation is required especially for the outcome of MR 
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1. Introduction 
Migraine headaches affect approximately 13% of US population, affecting women in a 3:1 
ratio and with a 60–80% familial inheritance. Migraine is a relevant social health problem; in 
fact it significantly restricts the social life of those who are affected. Recently, migraine 
headache has been suspected to be a potential risk factor for stroke, particularly in women, 
smokers and for those making use of oral contraception. 
Onset of migraine is usually between the ages of 20–64, with over 80% having their first 
episode before age 30 and tends to decrease in middle age. Migraine with aura (MA) is a 
variant characterized by transient neurological visual, verbal, sensory or motor symptoms 
that last from five to sixty minutes. MA is also known as “classic migraine” though only 
25% of migraneurs experience an aura. 
Increased frequency of patent foramen Ovale (PFO) in migraneurs was first reported in 1998 
in a case–control study. 
An increased prevalence between patent foramen Ovale (PFOs) and migraine exists but 
there is conflicting data of a causal relationship between these two conditions. It remains 
controversial whether cardiac screening and intervention provides a treatment benefit in 
migraneurs and is an area currently investigated for demonstrating clinical benefit of PFO 
closure. This topic is an intersection between the practice of primary care physicians, 
neurologists, and cardiologists on the best practice and management of patients with 
difficult to control migraines given the billions spent on physician visits and 
pharmacotherapy. 
Several mechanisms linking PFO to migraine have been hypothesized, including humoral 
causes (serotonin-platelet activation, aggregation, and embolism causing cortical spreading 
depression) and genetic causes (autosomal dominant inheritance with incomplete 
penetrance). The presence of a right to left shunt (RLS) may be the most potent trigger of 
migraine attacks with or without aura, and researchers have speculated that a large RLS 
may contribute to the high risk of ischemic stroke in migraneurs with PFO. 
Diagnostic Modalities to evaluate the presence or absence of PFO in the migraine patients 
are another controversial subject. Mostly agree that the Trans –thoracic echocardiography is 
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less sensitive test particularly in adolescents and adults. Trans- Esophageal and Intra-
Cardiac Echocardiography carry more reliability in detecting left to right shunt. Recently 
Trans-Cranial Doppler has been postulated as more accurate test to detect the right to left 
shunting in those patients. 
PFO closure (particularly device closure) carries the most controversial issue in this subject. 
With only –so far- one randomized large clinical trial and several prospective cohorts and 
case control studies, there is conflicting data about the benefit of PFO closure in relieving or 
treating the Migraine headache. 
This chapter will talk first about the anatomy and physiology of Patent Foramen Ovale in 
normal population, anatomical variants of the PFO, the current diagnostic methods used by 
different institutions then seeks to summarize the current literature on the association of 
PFO and migraine headache and studies that have investigated PFO closure in this 
population. 
1.1 Definitions 
The topic of Migraine headache in association with Patent Foramen Ovale (PFO) has been 
one of the controversial topics in the literature. Since 1998 when the first scientific 
observation that patients with migraine headaches have higher prevelance of PFO(1), the 
dogma between causation, association and prevention has continued.  
In order to make reading through this chapter easier, some definitions will be instated: 
2. Patent foramen ovale in normal population 
Several studies reported high prevalence of PFO in normal subjects. The highest prevalence 
reported was in autopsy studies. With a probe inserted in the region of the foremen ovale, if 
the probe can be passed through it then he/she will be labeled to have PFO. Such studies 
reported incidence of 25% (2). While looking for the incidence of PFO in Normal population by 
Trans Esophageal Echocardiogram reported to be less than autopsy studies about 15% (3-4). 
The foramen ovale is composed of the septum primum and the septum secundum joined in 
parallel, forming a tunnel-like structure allowing the oxygenated blood from the placenta to 
pass towards the systemic circulation. Postnatally, it closes with a valve-like mechanism. 
Patent foramen ovale results from lack of post neonatal closure. Under certain 
hemodynamic conditions, when there is a transient pressure gradient from the right to left 
atria, a PFO can open and enable blood or any blood borne substances to pass from the 
venous to the arterial circulation. This process is the mechanism of paradoxical embolism, 
which has been frequently reported in the literature (5-8). There are multiple anatomical 
variants of PFO morphology (figure 1). Occasionally the PFO has an association with atrial 
septal aneurysm (figure 2). These variants and atrial aneurysm has been believed to play a 
major role of the amount and the direction of shunt across the PFO.  
3. Migraine headache 
Migraine is a common, disabling, largely inherited neurological disorder with a prevalence of 8% 
to 13% in the population of the Western hemisphere (9, 10), with a 3:1 female preponderance.  
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Fig. 1. Several Morphologies of Patent Foramen Ovale. a: the common type of PFO with a 
tunnel (white arrows) that can stretch with Valsava. b: Multi fenestration defects in the PFO 
region. c: a deficient part of the secundum septum covering the PFO from the left side of the 
atrial septum. 
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tunnel (white arrows) that can stretch with Valsava. b: Multi fenestration defects in the PFO 
region. c: a deficient part of the secundum septum covering the PFO from the left side of the 
atrial septum. 
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Fig. 2. Echocardiographic appearance of different PFO morphologies, a: Intra Cardiac Echo 
(ICE) of a tunnel shape PFO. b: Large atrial aneurysm (orange arrow heads) by trans 
thoracic echo(TTE). c: small multi fenestration by TTE color Doppler. d: larger fenestrations 
by TEE color Doppler. 
Migraine is a common, chronic, disabling neurovascular disorder characterized by attacks of 
severe headache, autonomic nervous system dysfunction, and, in some patients, an aura and 
neurological symptoms (11). The suffering associated with migraine headaches accounts for a 
significant loss in productivity and a substantial increase in healthcare-related costs. About 
60% of the patients with Migraine reported that they can’t go to work while having the 
headache. In approximately one third of sufferers, an aura—consisting of reversible 
neurological symptoms such as visual illusions, unilateral paresthesias, and 
expressive/receptive language dysfunction—will precede or occur during some attacks. A 
typical migraneurs has one to two attacks per month, with a median duration of 24 hours. In 
addition, approximately 2% of the population experiences a more disabling form of migraine, 
known as chronic migraine, which is characterized by headache on more than 15 days/month. 
The diagnosis of migraine is purely clinical, and its physiopathology is complex and not 
fully understood, with both genetic and environmental factors appearing to play an 
important role. Genetic effects, including autosomal dominant inheritance with incomplete 
penetrance (12, 15) and coinheritance, (13) have also been reported.  
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The prevailing hypothesis regarding the pathogenesis of migraine is an inherited excitability of 
certain brain networks that, when triggered by particular endogenous or exogenous factors, 
leads to a cascade of events that result in head pain, in addition to a multitude of other 
symptoms, including a heightened sensitivity to movement and ambient light, noise, and 
odor; nausea; emesis; cognitive impairment; vertigo; depression; and lethargy (14). Commonly 
used preventive medications such as Propranolol, Amitryptiline or anticonvulsants reduce 
headache frequency in the range of 30-50%, as compared to placebo (16-17).  
Migraine occurs in about 15% of the pediatric population, with approximately 
One-third of cases associated with an aura (18). 
3.1 The association of migraine headache and patent foramen ovale 
The initial observation of this association came from the studies of vascular embolic strokes 
and PFO. The initial observation of increased prevalence of PFO in migraneurs came out in 
1998 (1). Then subsequently several studies looked specifically for the prevalence of PFO in 
Migraneurs. Anzola and colleagues performed a case control study including 113 
consecutive patients with migraine with aura, 53 patients with migraine without aura and 
25 ages matched no migraine subjects. The presence of PFO was assessed indirectly by using 
transcranial Doppler sonography with IV. Injection of agitated saline. The prevalence of 
PFO was 48% in patients with migraine with aura, 23% in patients with migraine without 
aura and 20% in controls. The difference between migraine with aura and migraine without 
aura was significant (odds ratio=3.13) as well as between migraine with aura and control 
group (odds ratio=3.66) (19).  
Schwedt et al. (2008) performed a systematic review of 18 out of 134 identified articles to 
examine the prevalence of migraine in patients with PFO. The results demonstrated that 
people with migraine with aura are more likely to have a PFO than people with migraine 
without aura or healthy controls (20). Migraine with aura not related with diving occurred 
significantly more frequently in patients with large right to left shunt which was present at 
rest (38 of 80, 47.5%), compared with patients who had a smaller shunt (four of 40, 10%) or 
with patients with no shunt at all (11 of 80, 13.8%). The prevalence of migraine without aura 
was similar in all groups. Authors concluded that migraine with aura was associated with 
presence or absence of PFO but also with the shunt size (21). 
McCandless et al (2011) conducted pediatric study involved a population consisted of 109 
children with migraine; 38 (35%) with aura and 71 (65%) without aura. The overall PFO 
prevalence was 35%, similar to the general population (35% vs. 25%; P = .13). However, 
compared with the general population (25%), the PFO prevalence was significantly greater 
in subjects with aura (50%, P = .0004) but similar in those without aura (27%, P = .73). Atrial 
shunt size was not associated with the presence or absence of aura. Their conclusion was 
that Children with migraine with aura have a significantly higher prevalence of PFO 
compared with those without aura or the general population. These data suggest that PFO 
may contribute to the pathogenesis of migraine with aura in children and have implications 
for clinical decision making (22). 
A meta analysis of 7 studies in adult population with migraine headache and aura showed 
association of PFO in this particular population ranging from 41- 62% (composite of 56% by 
meta-analysis) (23-29). 
Atrial Septal Defect 158 
   
(a) (b) 
   
(c) (d) 
Fig. 2. Echocardiographic appearance of different PFO morphologies, a: Intra Cardiac Echo 
(ICE) of a tunnel shape PFO. b: Large atrial aneurysm (orange arrow heads) by trans 
thoracic echo(TTE). c: small multi fenestration by TTE color Doppler. d: larger fenestrations 
by TEE color Doppler. 
Migraine is a common, chronic, disabling neurovascular disorder characterized by attacks of 
severe headache, autonomic nervous system dysfunction, and, in some patients, an aura and 
neurological symptoms (11). The suffering associated with migraine headaches accounts for a 
significant loss in productivity and a substantial increase in healthcare-related costs. About 
60% of the patients with Migraine reported that they can’t go to work while having the 
headache. In approximately one third of sufferers, an aura—consisting of reversible 
neurological symptoms such as visual illusions, unilateral paresthesias, and 
expressive/receptive language dysfunction—will precede or occur during some attacks. A 
typical migraneurs has one to two attacks per month, with a median duration of 24 hours. In 
addition, approximately 2% of the population experiences a more disabling form of migraine, 
known as chronic migraine, which is characterized by headache on more than 15 days/month. 
The diagnosis of migraine is purely clinical, and its physiopathology is complex and not 
fully understood, with both genetic and environmental factors appearing to play an 
important role. Genetic effects, including autosomal dominant inheritance with incomplete 
penetrance (12, 15) and coinheritance, (13) have also been reported.  
Atrial Septal Defect/Patent Foramen Ovale and Migraine Headache 159 
The prevailing hypothesis regarding the pathogenesis of migraine is an inherited excitability of 
certain brain networks that, when triggered by particular endogenous or exogenous factors, 
leads to a cascade of events that result in head pain, in addition to a multitude of other 
symptoms, including a heightened sensitivity to movement and ambient light, noise, and 
odor; nausea; emesis; cognitive impairment; vertigo; depression; and lethargy (14). Commonly 
used preventive medications such as Propranolol, Amitryptiline or anticonvulsants reduce 
headache frequency in the range of 30-50%, as compared to placebo (16-17).  
Migraine occurs in about 15% of the pediatric population, with approximately 
One-third of cases associated with an aura (18). 
3.1 The association of migraine headache and patent foramen ovale 
The initial observation of this association came from the studies of vascular embolic strokes 
and PFO. The initial observation of increased prevalence of PFO in migraneurs came out in 
1998 (1). Then subsequently several studies looked specifically for the prevalence of PFO in 
Migraneurs. Anzola and colleagues performed a case control study including 113 
consecutive patients with migraine with aura, 53 patients with migraine without aura and 
25 ages matched no migraine subjects. The presence of PFO was assessed indirectly by using 
transcranial Doppler sonography with IV. Injection of agitated saline. The prevalence of 
PFO was 48% in patients with migraine with aura, 23% in patients with migraine without 
aura and 20% in controls. The difference between migraine with aura and migraine without 
aura was significant (odds ratio=3.13) as well as between migraine with aura and control 
group (odds ratio=3.66) (19).  
Schwedt et al. (2008) performed a systematic review of 18 out of 134 identified articles to 
examine the prevalence of migraine in patients with PFO. The results demonstrated that 
people with migraine with aura are more likely to have a PFO than people with migraine 
without aura or healthy controls (20). Migraine with aura not related with diving occurred 
significantly more frequently in patients with large right to left shunt which was present at 
rest (38 of 80, 47.5%), compared with patients who had a smaller shunt (four of 40, 10%) or 
with patients with no shunt at all (11 of 80, 13.8%). The prevalence of migraine without aura 
was similar in all groups. Authors concluded that migraine with aura was associated with 
presence or absence of PFO but also with the shunt size (21). 
McCandless et al (2011) conducted pediatric study involved a population consisted of 109 
children with migraine; 38 (35%) with aura and 71 (65%) without aura. The overall PFO 
prevalence was 35%, similar to the general population (35% vs. 25%; P = .13). However, 
compared with the general population (25%), the PFO prevalence was significantly greater 
in subjects with aura (50%, P = .0004) but similar in those without aura (27%, P = .73). Atrial 
shunt size was not associated with the presence or absence of aura. Their conclusion was 
that Children with migraine with aura have a significantly higher prevalence of PFO 
compared with those without aura or the general population. These data suggest that PFO 
may contribute to the pathogenesis of migraine with aura in children and have implications 
for clinical decision making (22). 
A meta analysis of 7 studies in adult population with migraine headache and aura showed 
association of PFO in this particular population ranging from 41- 62% (composite of 56% by 
meta-analysis) (23-29). 
Atrial Septal Defect 160 
On the other hand; NOMAS study (30) involved screening of population from Northern 
Manhattan area showed no significant association of PFO with Migraine headache 
population. This study has several limitations though. It included only non-stroke patients 
who are older than 39 years, they used Trans thoracic Echocardiography for the screen of 
PFO with no Trans Cranial Doppler evaluation of the bubble study and they depended on 
self-reporting headache with obvious recall bias. 
Table one summarized the major studies of PFO association with Migraine headache. It is 
clear from all previously mentioned studies that Migraine with Aura has higher association 
of PFO compared to migraine without aura. Both (with and without aura) has higher 
prevalence of PFO compared to general population please see Table 1. 
 
  Migraine With Aura, Migraine Without Aura, 
Study PFO Method n/N (%) n/N (%) 
Del Sette et al TCD 18/44 (41) NA 
Anzola et al TCD 54/113 (48) 12/53 (23) 
Schwerzmann et al TEE 44/93 (47) NA 
Dalla Volta et al TCD 161/260 (62) 12/74 (16) 
Carod-Artal et al TCD 25/48 (52) 32/93 (34) 
Domitrz et al TCD 33/61 (54) 15/60 (25) 
NOMAS TTE 26/140 (19) 4/38 (11) 
TCD indicates transcranial Doppler; TEE, transesophageal echocardiography.  
Table 1. Prevalence of PFO Among Subjects With Migraine Selected From the Literature 
The prevailing hypothesis regarding the pathogenesis of migraine is an inherited 
excitability of certain brain networks that, when triggered by particular endogenous or 
exogenous factors, leads to a cascade of events that result in head pain. The presence of 
PFO might trigger this process by allowing substances or metabolites to pass from the 
hepatic or portal circulation to the carotids circulation. Migraneurs have increased platelet 
activation and aggregation in response to serotonin. Normally serotonin is metabolized by 
lung mono amino oxidase (MAO), but if blood is shunted through a PFO and avoids the 
pulmonary circulation it has been postulated that this can trigger migraine onset and 
precipitate aura (31). Another mechanism could possibly be transient hypoxemia caused 
by the PFO, causing subclinical infarcts in the brain, leading to irritation and propensity 
for migraines. Naqvi et al. report different manifestations of PFO including resting and 
stress hypoxemia related to left to right shunting across a PFO in the absence of 
pulmonary hypertension (32). 
4. Results of studies of PFO closure to relief migraine headaches 
Initial observation from studies involves Stroke prevention by PFO device-closure, showed 
patients with Migraine headaches improve after the procedures (34-38).  
Recently Wahl et al (2010) reported a large cohort of Migraneurs (150 patients 96 of them 
had aura) who underwent closure of PFO for stroke prevention. Of those 34% showed 
complete resolution of the headache and 48% showed significant improvement of their 
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headaches, making total of 82% of the migraneurs benefited from the closure. The presence 
of aura was associated with higher improvement in their study population. Still they 
showed improvement in non-aura migraneurs. 
Daniela Trabattoni reviewed 305 patients who underwent closure of their PFO for stroke 
prevention, 77 of them have migraine headache (~55% are female). Follow up of these 
migraine patients at 3 months showed complete cessation of headache in 46% of the 
patients and 40% had improvement of their headache intensity score ( total improvement 
of 86% of the patients). They found maintenance of these results up to 5 years of follow  
up (44).  
After these initial observations of improved migraine headache in the patients who 
underwent prevention of stroke by device-closure of their PFO (table 2), then several studies 
were conducted primarily for Migraine headaches relief. 
 
Table 2. Meta Analysis of 11 studies reported by Gianfranco Butera et al (40) 
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of aura was associated with higher improvement in their study population. Still they 
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prevention, 77 of them have migraine headache (~55% are female). Follow up of these 
migraine patients at 3 months showed complete cessation of headache in 46% of the 
patients and 40% had improvement of their headache intensity score ( total improvement 
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Luciane Piazza et al. evaluated 42 patients with migraine headache (28 with aura and 14 
without aura) after PFO closure for the migraine headache as a primary reason. After 6 
months follow up they found complete resolution of the migraine in 26%, and significant 
improvement in 52% of the study group. Interestingly they found patients improvement 
(total 78%) regardless of the presence of aura history. Multiple logistic regression analysis 
showed that the improvement in migraine with aura and migraine without aura was 
independent of migraine type, sex, age, cerebrovascular risk factors and cerebrovascular 
events, type of cardiac defect, and thrombophilic conditions (41). 
Another study by Andreas Wahl and his group was conducted on 17 patients with Migraine 
headache underwent closure of the PFO primarily for the headache reason (no stroke). They 
found total improvement in 71% of their patients with complete resolution of the headache 
in 26%. Their follow up was up to 30 months. They found slightly higher improvement in 
patients with aura (42). 
Gianluca Rigatelli et al. conducted prospective study on 34 patients with Migraine headache 
(22 females and 12 male) and underwent closure of the atrial defect by one of two devices 
(Amplatz cribriform, AGA PFO device or Premere Occlusion System). They found about 
55% of their study group have moderate to large atrial septal aneurysm. After a median of 9 
months follow up period they have significant improvement in all the patients with 20 
patients stopped completely their anti headache medications and the rest have improvement 
with less number of their medications (43). 
The only randomized prospective study with patients blinded for PFO closure conducted for 
migraine headache is MIST trial. They included about 147 patients randomized for device 
closure or Sham procedure (patients will have general anesthesia with incision in the groin 
without device implantation). The study had an ambitious primary end point which was 
complete cessation of Migraine headache in 40% of the patients who receive PFO device 
closure. They chose STARFlex® and they have much higher rate of complications in their 
study (~12%) compared to other PFO device studies. They showed in 6 months no statistical 
difference between the two groups in complete cessation of Migraine headache. Post-hoc 
analysis revealed that, when two extreme outliers were removed, a significant reduction in the 
median total headache days was observed in patients assigned to PFO closure (P = 0.027). A 
number of methodological reasons could explain why the primary end point of the MisT trial 
was not achieved. First, this ambitious primary end point, presumably selected to justify the 
risks of an interventional procedure, was so strict as to be unrealistic, and was arguably less 
clinically relevant than a quantifiable reduction in headache days. Although the path 
physiology of migraine is not fully elucidated, the probable multifactorial nature of migraine 
triggers means that correction of one potential trigger is unlikely to result in headache cure. 
Second, the patients for whom migraine improvement was previously reported had PFO 
closure for either cryptogenic stroke or decompression illness. However, such patients were 
specifically excluded from the MIST trial. The amount of residual shunt in MIST trial was 
extremely high (~35%) in 6 months follow up probably due to inherent device limitations used 
in the study. Other potential confounding factors include the ‘hangover effect’ of antiplatelet 
therapy and the difficulty of distinguishing between cardiac-level and pulmonary-level shunt 
when using transthoracic echocardiography (TTE). nonetheless, as the first randomized, 
controlled trial of its kind, the MIST trial has pioneered a robust study design for PFO closure 
trials and raised questions to be addressed in future studies. 
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In Summery: The association of migraine headache with Patent Foramen Ovale is higher 
than normal population (more than double) by most of the studies. Trans Cranial Doppler 
has higher sensitivity than Echo (TTE, TEE or ICE) in detecting the right to left shunt across 
the atrial septum. Because of the anatomical orientation of the Inferior Vena Cava towards 
the Foramen Ovale, injection of bubble contrast in lower limbs veins might be higher 
sensitive than injection in upper limbs veins. Whether the PFO/Migraine association means 
also a causation relationship: a question still needs more definite answer. Most of the studies 
(from stroke studies and primary studies for Migraine relief) are pointing towards the 
causation relationship. Although the only randomized prospective study in the literature 
failed to show a definite answer, several confounding factors (as mentioned above in the 
text) can explain the negativity of this study. Most of the studies showed higher response 
and benefit to patients suffer from Migraine with aura compared to others. 
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1. Introduction 
Stroke is the third most common cause of death in the United States. Stroke also results in 
substantial health-care expenditures with an estimated lifetime cost from an ischemic stroke 
of $140,000 per patient (Rosamond K, 2007). Each year, approximately 795,000 people 
experience a new or recurrent stroke, of which an estimated 610,000 are first attacks. 
Mortality data from 2006 indicates stroke accounted for approximately 1 of every 18 deaths 
in the United States. On average, every 40 seconds, someone in the United States has a 
stroke (Heart Disease and Stroke Statistics, AHA 2009). 
Cryptogenic infarction has had a predominant status among the causes of ischemic strokes, 
originally demonstrated in the Stroke Data Bank. Sacco and Mohr reported a 40% incidence 
of cryptogenic stroke in their population (Sacco, Ellenberg, Mohr et al., 1989). A cryptogenic 
infarction does not have a defined cause despite a complete work-up. It differs from 
infarction of undetermined causes, which may involve overlapping causes or an incomplete 
investigation.  
Numerous studies have established a higher prevalence of patent foramen ovale (PFO)  
or atrial septal defect (ASD) in patients with cryptogenic stroke when compared to 
patients with stroke of determined cause despite correction for recognized stroke risk 
factors. This relationship has perpetuated the paradoxical embolism theory as a likely 
stroke mechanism in this patient population (Lechat 1988, Webster 1988, DeBelder 1992, 
DiTullio 1992). 
Emboli leading to stroke can originate either in the systemic arterial circulation or in the 
systemic venous circulation (paradoxical embolism). A paradoxical embolus originates in 
the systemic venous circulation and enters the systemic arterial circulation through a PFO, 
ASD, ventricular septal defect (VSD), or extracardiac communication such as a pulmonary 
arteriovenous malformation (AVM). 
Therapeutic measures for secondary prevention in this patient population can encompass 
medical treatment or surgical/percutaneous closure of the patent foramen ovale or atrial 
septal defect as well as coil embolization of pulmonary arteriovenous malformations. 
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Ongoing randomized clinical studies aim at comparing medical treatment versus closure of 
atrial septal defects to determine the most effective treatment strategy in this patient 
population (RESPECT PFO trial, CLOSURE I trial, Gore REDUCE Clinical Study  
“HLX 06-03).  
Embryology of atrial septal defects 
Patent Foramen Ovale 
The foramen ovale is a pivotal feature during intrauterine life. The interatrial 
communication is necessary for the shunting of oxygenated blood from right atrium to left 
atrium. Beginning at four weeks of pregnancy the primordial atrial septum divides into 
right and left sides by formation and fusion of two septa: the septum primum and septum 
secundum. The interatrial septum primum on the left side and interatrial septum secundum 
on the right side maintain a central opening after having grown from the periphery to the 
center. This perforation is positioned caudally in the septum secundum and cranially in the 
septum primum, forming a slit valve that opens when right atrial pressure exceeds the left 
atrial pressure. The oxygenated blood from the umbilical vein entering through the inferior 
vena cava from the bottom of the right atrium keeps this window open until after birth.  
Postnatal physiologic changes 
At birth, right heart pressure and pulmonary vascular resistance drop as pulmonary 
arterioles open in reaction to oxygen filling the alveoli. Left atrial pressure may also rise as 
the amount of the blood returning from the lung increases. Either or both of these 
mechanisms may cause flap closure against the septum secundum. 
This fusion is complete by age two in about 75% of individuals, but persistent patency 
occurs in the other 25% (Hagen, Scholz & Edwards, 1984). The reasons PFOs fail to close are 
unknown, but it is currently assumed they are likely related to multifactorial inheritance. 
Atrial Septal Defect 
One of the most common adult congenital heart defects, an atrial septal defect (ASD) is a 
persistent communication between the atria. Much like a patent foramen ovale, an ASD 
arises from incomplete fusion of the septum primum and septum secundum. 
There are several different types of ASDs (see Figure 1):  
 Secundum ASD in the region of the fossa ovalis;  
 Primum ASD, positioned inferiorly near the crux of the heart;  
 Sinus venosus ASD, located superiorly near the superior vena caval entry or inferiorly 
near the inferior vena caval entry; and  
 The uncommon coronary sinus septal defect, which causes shunting into the left atrium 
via a communication in the superior aspect of the coronary sinus, posterior to the left 
atrium. 
PFO Anatomy and Associated Anomalies 
The autopsy-derived prevalence of PFO is 27% with decreasing prevalence at each decade of 
life. The PFO is a residual, oblique, slit-shaped defect resembling a tunnel. In adults,  
the persistent patent foramen ovale slit width ranges from 1 to 19 mm (mean 4.9 mm)  
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Fig. 1. Types of atrial septal defects. The European Association of Echocardiography 
Textbook. 
(Hagen, Scholz & Edwards, 1984). The PFO size increases with age, reflecting size-based 
selection over time where larger PFOs remain patent and smaller defects close. Greater PFO 
size increases the risk of paradoxical embolism (Steiner, DiTullio, Rundek et al., 1998). 
Heterogeneity of size and morphology are pertinent to interventional device closure 
selection. 
The histopathology of the PFO has not been thoroughly addressed in literature, although it 
is a point of increasing importance as percutaneous closure technologies must interact with 
these tissues at cellular level. The muscular atrial wall consists of endocardium having 
endothelium and thick subendothelial layers of connective tissue rich in collagen and 
elastin. A thicker myocardium lies beneath these structures, with loosely arranged 
musculature.  
PFOs are associated with several anatomic anomalies, most commonly with atrial septal 
aneurysms (ASA) and Chiari networks. 
An ASA represents an aneurysmal dilatation of a part or all of the septum primum, 
protruding into either atrium. The ASA is defined as phasic septal excursion of at least 10 
mm during the cardiorespiratory cycle. M-mode transesophageal echocardiography (TEE) 
or intracardiac echocardiography is essential for precisely measuring septal excursion of the 
ASA. A persistent ASA can be isolated finding but generally is associated with other ASDs 
or a PFO. Fenestrated ASA may present with the clinical findings of an ASD with a 
significant left to right shunt, especially if there are multiple defects. 
The Chiari network is a remnant of the right valve of the sinus venosus, and its role is 
poorly understood. It originates from a region of the Eustachian and Thebesian valves with 
attachment to the upper wall of the right atrium or atrial septum. The Eustachian valve is 
common but it should be distinguished from Chiari networks because it does not attach to 
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PFO Anatomy and Associated Anomalies 
The autopsy-derived prevalence of PFO is 27% with decreasing prevalence at each decade of 
life. The PFO is a residual, oblique, slit-shaped defect resembling a tunnel. In adults,  
the persistent patent foramen ovale slit width ranges from 1 to 19 mm (mean 4.9 mm)  
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Fig. 1. Types of atrial septal defects. The European Association of Echocardiography 
Textbook. 
(Hagen, Scholz & Edwards, 1984). The PFO size increases with age, reflecting size-based 
selection over time where larger PFOs remain patent and smaller defects close. Greater PFO 
size increases the risk of paradoxical embolism (Steiner, DiTullio, Rundek et al., 1998). 
Heterogeneity of size and morphology are pertinent to interventional device closure 
selection. 
The histopathology of the PFO has not been thoroughly addressed in literature, although it 
is a point of increasing importance as percutaneous closure technologies must interact with 
these tissues at cellular level. The muscular atrial wall consists of endocardium having 
endothelium and thick subendothelial layers of connective tissue rich in collagen and 
elastin. A thicker myocardium lies beneath these structures, with loosely arranged 
musculature.  
PFOs are associated with several anatomic anomalies, most commonly with atrial septal 
aneurysms (ASA) and Chiari networks. 
An ASA represents an aneurysmal dilatation of a part or all of the septum primum, 
protruding into either atrium. The ASA is defined as phasic septal excursion of at least 10 
mm during the cardiorespiratory cycle. M-mode transesophageal echocardiography (TEE) 
or intracardiac echocardiography is essential for precisely measuring septal excursion of the 
ASA. A persistent ASA can be isolated finding but generally is associated with other ASDs 
or a PFO. Fenestrated ASA may present with the clinical findings of an ASD with a 
significant left to right shunt, especially if there are multiple defects. 
The Chiari network is a remnant of the right valve of the sinus venosus, and its role is 
poorly understood. It originates from a region of the Eustachian and Thebesian valves with 
attachment to the upper wall of the right atrium or atrial septum. The Eustachian valve is 
common but it should be distinguished from Chiari networks because it does not attach to 
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the upper wall of the right atrium or atrial septum, although it may be mobile and 
fenestrated.  
In a study of 1436 adult patients, 83% of patients were found to have both Chiari networks 
and a PFO, suggesting a strong association. Large right-to-left shunting was found 
significantly more often in patients with Chiari networks than in controls (55% vs. 12%). 
This study also found Chiari networks associated with ASAs in 24% of patients. The Chiari 
network is more common in cryptogenic stroke patients than in patients evaluated for other 
indications (4.6% vs. 0.5%), and it may facilitate paradoxical embolism (Schneider, 
Hofmann, Justen et al., 1995). 
Diagnosis of Patent Foramen Ovale 
A patent foramen ovale may be detected by transthoracic echocardiography (TTE), TEE, 
transcranial Doppler (TCD), and sometimes by transmitral Doppler. These techniques were 
compared in studies of proven embolic stroke.  
Although the PFO can occasionally be documented in adults with a TTE, the result is rarely 
unequivocal. TEE, rather than TTE, remains the diagnosis method of choice, due to 
increased sensitivity.  
PFO detection can be augmented by cough or releasing of a sustained Valsalva maneuver, 
while injecting an aerated colloidal solution into the systemic venous circulation (the bubble 
test, agitated saline, or contrast study). These maneuvers open the foramen when the right 
atrium fills with blood from the abdomen, while the left atrium volume is depleted before 
blood coming through the pulmonary veins, and thus the right atrial pressure exceeds the 
left atrial pressure.  
The Valsalva maneuver is now considered necessary to find right-to-left shunts when 
performing echocardiography of any type, with or without contrast injection. The physical 
hole in the atrial wall may not be imaged, but detecting its shunt clearly improves 
sensitivity and specificity. 
TCD is comparable to contrast TEE for detecting PFO-related right-to-left shunts 
echocardiography and is easy to perform at bedside (Sloan, Alexandrov, Tegeler et al., 2004). 
TCD has recently been augmented by power M-Mode, a technology that allows power 
display with Doppler velocity and velocity signals over selectable depth ranges along the 
transducer beam. TCD M-mode enhances sensitivity to contrast bubble emboli over single-
gated examination (Spencer, Moehring, Jesurum et al., 2004; Moehring & Spencer, 2002). 
Rationale for PFO and ASD treatment in patients with paradoxical embolism 
As mentioned before, approximately 40% of ischemic strokes have no clear etiology (i.e., 
cryptogenic strokes). Treatment of this particular type of stroke could have a significant 
impact on decreasing the stroke burden in the general population. 
One study of 60 adults under 55 years of age with ischemic stroke compared contrast 
echocardiographic examinations with 100 normal subjects. PFO prevalence was significantly 
higher in the stroke group than in controls (40% vs. 10%). PFO was found in 26 stroke 
patients with no other identifiable cause, and the study concluded that the PFO-induced 
paradoxical embolism is a cause of stroke (Lechat, Mas, Lascault et al., 1988).  
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The PFO-ASA Study supports these findings, where 46% of young cryptogenic stroke 
patients had PFO (Lamy, Giannesini, Zuber et al., 2002). 
Cramer et al. evaluated young stroke patients (18 to 60 years old) early after stroke using 
magnetic resonance imaging venography (Cramer, Rordorf, Maki, et al., 2004). Pelvic 
deep venous thrombosis was increased in the cryptogenic stroke population compared to 
controls (20% vs. 4%). The cryptogenic stroke group was significantly younger (42 vs. 49 
years) with fewer risk factors for atherosclerosis, such as hypertension and smoking. PFO 
prevalence was significantly higher in the cryptogenic stroke group than in controls (59% 
vs. 19%). 
A prospective study of 598 patients (ages 18 to 55 years) presenting with cryptogenic 
stroke showed that 36% had PFO, 1.7% had ASA and 8.5% had both abnormalities. 
Patients with both PFO and ASA who have had a stroke, are thus at higher risk for 
recurrent stroke, and preventive strategies other than aspirin should be considered (Mas, 
Arquizan, Lamy et al., 2001). 
Decompression illness in divers is another PFO-associated clinical syndrome. 
Decompression syndrome (DCS) is categorized in type I and type II. Type I DCS is 
composed of localized joint pain, musculoskeletal pain, and/or skin rash, and type II DCS 
consists of neurologic symptoms (limb tingling, paresthesias, severe headache with mental 
confusion, paraplegia, loss of consciousness, audio vestibular symptoms, and dyspnea with 
chest pain). The PFO at rest is significantly associated with type II DCS.  
In a seminal study, TCD ultrasonography detected a right-to-left shunt in all divers with 
multiple brain lesions suggesting the presence of a PFO (Knauth, Ries, Pohimann et al., 
1997). A comparative investigation regarding brain lesions and the presence of a PFO in 
sport divers and non-diving controls showed that brain lesions were more common in 
individuals with a PFO, although divers had more brain lesions than non-divers, 
irrespective of the presence of a PFO (Schwerzmann, Seiler, Lipp et al., 2001). This has led 
some diving schools to recommend screening for the presence of a PFO for professional 
divers or avid amateurs. 
The presumed mechanism of cerebral vascular events in patients with a patent foramen 
ovale or an atrial septal defect is a transient increase in right-sided pressure, which causes a 
right-to-left shunt. In this scenario, embolization into the left circulation may be produced 
from a small right-sided thrombus. It is possible, therefore, for paradoxical embolization to 
occur into other vascular beds such as the coronary artery system and cause an acute 
myocardial infarction. Few such cases of paradoxical coronary embolisms have been 
reported in the literature and the diagnosis was made by excluding other sources of 
coronary artery disease or embolization (Deborah, Gersony, Sang et al., 2001; Agostoni, 
Gasparini & Destro, 2004). 
Medical versus surgical treatment of symptomatic atrial septal defects 
Surgical closure has been demonstrated to be effective in the prevention of recurrent stroke 
(Mohr, Thompson, Lazar et al., 2001). However, due to the risks and expense of open-heart 
surgery, subjects are largely treated with oral anticoagulation and antiplatelet agents on an 
empirical basis. 
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The present empirical therapy of subjects with PFO and paradoxical embolism is far from 
ideal and it is uncertain whether anticoagulants such as warfarin and antiplatelet agents are 
effective as primary or secondary therapy in preventing stroke in patients with PFO.  
The PFO in the Cryptogenic Stroke Study Investigators found no difference in primary end-
points (recurrent stroke and death) between aspirin and warfarin treatment of PFO patients 
at two years (Bridges, Hellenbrand, Latson et al., 1992). 
The Warfarin-Aspirin Recurrent Stroke Study was a prospective trial of 2206 patients with 
prior stroke (Homma, Sacco, Di Tullio et al., 2002). Patients were randomized to aspirin (325 
mg/day) or warfarin (INR 1.4 to 2.8). After two years, the investigators concluded that there 
were no significant differences between aspirin and warfarin treatment for recurrent stroke 
or death. The incidence of recurrent stroke, transient ischemic attacks or death was 17.8 % 
per year in the warfarin group vs. 16% per year in the aspirin group. Patients with 
cryptogenic stroke showed no significant benefit in either treatment group. 
The incidence of major hemorrhage (per 100 patients per year) was 2.2 in the warfarin group 
vs. 1.5 in the aspirin group. The authors note that higher target INRs (3.0-4.5) have been 
associated with excessive rates of major hemorrhage. 
Bridges et al. found that despite 32 of 36 subjects being on warfarin therapy before device 
closure, the recurrence rate of stroke was 50% (Bridges, Hellenbrand, Latson et al., 1992). 
The appropriate duration of warfarin therapy is unknown and empirical and the incidence 
of major bleeding events ranges from 1.5 to 11% per year. 
Catheter-Based PFO and ASD Closure 
Some cerebrovascular events and other systemic arterial emboli, especially in young 
patients, are presumed to be due to paradoxical embolism through an atrial defect, most 
frequently a patent foramen ovale (PFO). Closure of such defects is an alternative to life-
long anticoagulation.  
Initial techniques of percutaneous ASD closure were documented with King’s device in 1976 
(Mills and King, 1976), Rashkind in the 1980’s, and Sideris et al. in the 1990’s (Mills and King 
1976, Rashkind 1983, Sideris 1990). 
Bridges et al. first proposed that PFO closure would reduce the incidence of recurrent 
strokes and demonstrated a statistically significant effect of PFO closure on a small group  
of high-risk patients (Bridges, Hellenbrand, Latson et al., 1992). Since then, numerous  
studies have shown that transcatheter PFO closure with current techniques is safe and  
seems to protect against recurrent strokes in this patient population (Kramer 2010,  
Krizanic 2010).  
In the 1980s, the Rashkind occluder was introduced and revived the interest in the topic, 
focusing for the first time on the patent foramen ovale. The Rashkind Clamshell occluder 
was withdrawn from the market because of high incidence of stress fractures and breakage 
of arms. The clamshell device was modified by introducing an additional bend of the arms 
and reintroduced as the CardioSEAL device (1996). Subsequently the CardioSeal device was 
modified by introducing a self-centering mechanism and was renamed STARFlex (Nitinol 
Medical Technologies, Boston, Massachusetts, USA) (Kramer 2010). 
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In 1997, a new self-expanding Nitinol prosthesis was developed by Dr. Kurt Amplatz, which 
consists of two self-expandable round disks connected to each other with a short waist. 
Nitinol is a nickel-titanium alloy that has the property of resuming its initial shape when 
deployed (shape memory) (Krizanic 2010; Masura, Gavora et al., 1997). The Amplatzer 
device was approved by FDA in 2001 for ASD closure and has been widely used since. 
Several modifications of the Amplatzer device were introduced since its original design, 
such as the Amplatzer PFO occluder in 1999 and a cribriform device to occlude multiple or 
fenestrated ASDs.  
In 2000, the CardioSEAL device (NMT Medical, Inc. - Boston, MA) and in 2002, the 
Amplatzer PFO Occluder (AGA Medical Corporation - Golden Valley, MN) became 
available for PFO closure in high-risk patients in the United States. Both devices were 
subsequently restricted to use in clinical trials evaluating device closure vs. medical therapy 
in patients with cryptogenic stroke and patent foramen ovale. 
One of the devices used in current clinical trials for PFO closure is the Gore HELEX septal 
occluder. The HELEX device is made up of a single length nitinol wire covered by a thin 
membrane of expanded polytetrafluoroethylene (ePTFE). ePTFE (Gore-Tex) is a carbon and 
fluorine based synthetic polymer that is biologically inert and non-biodegradable in the body.  
The configuration of the HELEX device consists of two flexible disks elongated around a 
central mandrel and delivered through a 9F sheath. The device was FDA approved in 2006 
for ASD closure and is currently used in the REDUCE trial for PFO closure (The Gore 
REDUCE Clinical Study “HLX 06-03; Latson, Zahn & Wilson 2000). 
A comprehensive review of the ASD closure devices has been addressed in several other 
chapters of this book and will not be further discussed. 
The Amplatzer PFO occluder (AGA Medical Corporation - Golden Valley, MN) is currently 
the most used PFO closure device. 
The Amplatzer occluder device consists of a nitinol double disk containing polyester fabric 
inside the two disks. A thin neck formed by the woven wires connects the two atrial disks. 
The neck is twisted around its long axis and hence is extendable. The device has to be 
screwed on to a pusher/puller cable and pulled into the introducer sheath. When pushed 
out of the sheath, it resumes its double-disk shape instantly. The whole process is fully 
reversible, as many times as required, up to the moment the device is unscrewed from the 
pusher/puller cable.  
Three sizes of Amplatzer PFO closure devices are available and named after the diameter of 
the right sided disk- 18 mm, 25 mm, and 35 mm. The 18 mm PFO occluder comprises of two 
18 mm disks and is meant for small PFOs with a stable septum primum. The 35 mm 
occluder is destined for large PFOs with atrial septal aneurysm and features a 35 mm disk 
on the right side and a 28 mm disk on the left side. It requires a 9 French sheath in contrast 
with the two smaller devices fitting through an 8 French sheath (Meier 2005). 
The implantation can be performed with a single femoral venous puncture under 
fluoroscopy without echocardiographic guidance; however, in most institutions ICE is 
routinely performed to guide device placement both fluoroscopically and with ICE imaging 
(Image 1-5). 
Atrial Septal Defect 172 
The present empirical therapy of subjects with PFO and paradoxical embolism is far from 
ideal and it is uncertain whether anticoagulants such as warfarin and antiplatelet agents are 
effective as primary or secondary therapy in preventing stroke in patients with PFO.  
The PFO in the Cryptogenic Stroke Study Investigators found no difference in primary end-
points (recurrent stroke and death) between aspirin and warfarin treatment of PFO patients 
at two years (Bridges, Hellenbrand, Latson et al., 1992). 
The Warfarin-Aspirin Recurrent Stroke Study was a prospective trial of 2206 patients with 
prior stroke (Homma, Sacco, Di Tullio et al., 2002). Patients were randomized to aspirin (325 
mg/day) or warfarin (INR 1.4 to 2.8). After two years, the investigators concluded that there 
were no significant differences between aspirin and warfarin treatment for recurrent stroke 
or death. The incidence of recurrent stroke, transient ischemic attacks or death was 17.8 % 
per year in the warfarin group vs. 16% per year in the aspirin group. Patients with 
cryptogenic stroke showed no significant benefit in either treatment group. 
The incidence of major hemorrhage (per 100 patients per year) was 2.2 in the warfarin group 
vs. 1.5 in the aspirin group. The authors note that higher target INRs (3.0-4.5) have been 
associated with excessive rates of major hemorrhage. 
Bridges et al. found that despite 32 of 36 subjects being on warfarin therapy before device 
closure, the recurrence rate of stroke was 50% (Bridges, Hellenbrand, Latson et al., 1992). 
The appropriate duration of warfarin therapy is unknown and empirical and the incidence 
of major bleeding events ranges from 1.5 to 11% per year. 
Catheter-Based PFO and ASD Closure 
Some cerebrovascular events and other systemic arterial emboli, especially in young 
patients, are presumed to be due to paradoxical embolism through an atrial defect, most 
frequently a patent foramen ovale (PFO). Closure of such defects is an alternative to life-
long anticoagulation.  
Initial techniques of percutaneous ASD closure were documented with King’s device in 1976 
(Mills and King, 1976), Rashkind in the 1980’s, and Sideris et al. in the 1990’s (Mills and King 
1976, Rashkind 1983, Sideris 1990). 
Bridges et al. first proposed that PFO closure would reduce the incidence of recurrent 
strokes and demonstrated a statistically significant effect of PFO closure on a small group  
of high-risk patients (Bridges, Hellenbrand, Latson et al., 1992). Since then, numerous  
studies have shown that transcatheter PFO closure with current techniques is safe and  
seems to protect against recurrent strokes in this patient population (Kramer 2010,  
Krizanic 2010).  
In the 1980s, the Rashkind occluder was introduced and revived the interest in the topic, 
focusing for the first time on the patent foramen ovale. The Rashkind Clamshell occluder 
was withdrawn from the market because of high incidence of stress fractures and breakage 
of arms. The clamshell device was modified by introducing an additional bend of the arms 
and reintroduced as the CardioSEAL device (1996). Subsequently the CardioSeal device was 
modified by introducing a self-centering mechanism and was renamed STARFlex (Nitinol 
Medical Technologies, Boston, Massachusetts, USA) (Kramer 2010). 
Transcatheter Occlusion of Atrial  
Septal Defects for Prevention of Recurrence of Paradoxical Embolism 173 
In 1997, a new self-expanding Nitinol prosthesis was developed by Dr. Kurt Amplatz, which 
consists of two self-expandable round disks connected to each other with a short waist. 
Nitinol is a nickel-titanium alloy that has the property of resuming its initial shape when 
deployed (shape memory) (Krizanic 2010; Masura, Gavora et al., 1997). The Amplatzer 
device was approved by FDA in 2001 for ASD closure and has been widely used since. 
Several modifications of the Amplatzer device were introduced since its original design, 
such as the Amplatzer PFO occluder in 1999 and a cribriform device to occlude multiple or 
fenestrated ASDs.  
In 2000, the CardioSEAL device (NMT Medical, Inc. - Boston, MA) and in 2002, the 
Amplatzer PFO Occluder (AGA Medical Corporation - Golden Valley, MN) became 
available for PFO closure in high-risk patients in the United States. Both devices were 
subsequently restricted to use in clinical trials evaluating device closure vs. medical therapy 
in patients with cryptogenic stroke and patent foramen ovale. 
One of the devices used in current clinical trials for PFO closure is the Gore HELEX septal 
occluder. The HELEX device is made up of a single length nitinol wire covered by a thin 
membrane of expanded polytetrafluoroethylene (ePTFE). ePTFE (Gore-Tex) is a carbon and 
fluorine based synthetic polymer that is biologically inert and non-biodegradable in the body.  
The configuration of the HELEX device consists of two flexible disks elongated around a 
central mandrel and delivered through a 9F sheath. The device was FDA approved in 2006 
for ASD closure and is currently used in the REDUCE trial for PFO closure (The Gore 
REDUCE Clinical Study “HLX 06-03; Latson, Zahn & Wilson 2000). 
A comprehensive review of the ASD closure devices has been addressed in several other 
chapters of this book and will not be further discussed. 
The Amplatzer PFO occluder (AGA Medical Corporation - Golden Valley, MN) is currently 
the most used PFO closure device. 
The Amplatzer occluder device consists of a nitinol double disk containing polyester fabric 
inside the two disks. A thin neck formed by the woven wires connects the two atrial disks. 
The neck is twisted around its long axis and hence is extendable. The device has to be 
screwed on to a pusher/puller cable and pulled into the introducer sheath. When pushed 
out of the sheath, it resumes its double-disk shape instantly. The whole process is fully 
reversible, as many times as required, up to the moment the device is unscrewed from the 
pusher/puller cable.  
Three sizes of Amplatzer PFO closure devices are available and named after the diameter of 
the right sided disk- 18 mm, 25 mm, and 35 mm. The 18 mm PFO occluder comprises of two 
18 mm disks and is meant for small PFOs with a stable septum primum. The 35 mm 
occluder is destined for large PFOs with atrial septal aneurysm and features a 35 mm disk 
on the right side and a 28 mm disk on the left side. It requires a 9 French sheath in contrast 
with the two smaller devices fitting through an 8 French sheath (Meier 2005). 
The implantation can be performed with a single femoral venous puncture under 
fluoroscopy without echocardiographic guidance; however, in most institutions ICE is 
routinely performed to guide device placement both fluoroscopically and with ICE imaging 
(Image 1-5). 
Atrial Septal Defect 174 
 
Image 1. ICE imaging of patent foramen ovale with Doppler ultrasound, showing blood 
flow in the tunnel between the septum primum and septum secundum. 
 
Image 2. ICE imaging of the diagnostic catheter engaging and crossing the tunnel between 
the septum primum and septum secundum. 
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Image 3. Positioning of the left atrial disk under ICE guidance, against the left atrial side of 
the interatrial septum. 
 
Image 4. Positioning of the right atrial disk under ICE guidance, on the right atrial side of 
the interatrial septum. 
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Image 1. ICE imaging of patent foramen ovale with Doppler ultrasound, showing blood 
flow in the tunnel between the septum primum and septum secundum. 
 
Image 2. ICE imaging of the diagnostic catheter engaging and crossing the tunnel between 
the septum primum and septum secundum. 
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Image 3. Positioning of the left atrial disk under ICE guidance, against the left atrial side of 
the interatrial septum. 
 
Image 4. Positioning of the right atrial disk under ICE guidance, on the right atrial side of 
the interatrial septum. 
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Image 5. Pulmonary vein angiogram through the Counard catheter, after crossing the PFO. 
The PFO can be crossed by sliding along the septum primum, coming from the inferior vena 
cava with a wire or a curved catheter. A transvenous sheath (diameter 3 to 5 mm according to 
the device selected) is placed in to the left atrium (Image 3) and the position of the catheter is 
documented by pulmonary vein injection (Image 5). The left-sided disk is unfolded and pulled 
back against the septum, thereby pulling the septum primum against the septum secundum 
and closing the slit valve (Image 3). The right-sided disk is then deployed and the device 
released (Image 4). The perfect seat can be assessed before release by echocardiography or by 
hand-injected dye into the right atrium through the introducer (Image 6-9). 
Follow-up treatment includes acetylsalicylic acid (80 to 300 mg) for a few months, with the 
addition of clopidogrel (75 mg) or warfarin (International Normalized Ratio 2.5 to 3.5) at 
some centers. Antibiotics during the interventions are commonplace, and prevention against 
endocarditis is recommended for a few months until the device is completely covered by 
tissue. 
A follow-up transthoracic echocardiogram after a few months with no residual shunting 
signals the cessation of all treatment and controls. 
Technical failures have become extremely rare (for example, inability to cannulate the PFO 
is less than 1%). Complications may include cardiac tamponade, symptomatic air embolism, 
loss of device, or puncture site problems.  
Complete closure at follow-up can be expected in 90% to 95% of cases with the two US 
currently available devices. Some trivial residual shunt may be acceptable, albeit undesirable, 
as the device will act as a filter for particulate matter. Events have recurred in cases where 
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Image 8. Deployed PFO occluder under ICE imaging. 
 
Image 9. Doppler image of a successfully deployed PFO occluder, with significant reduction 
in the interatrial shunt and no obstruction of the superior vena cava flow. 
the PFO was not responsible for the index event, in cases where small emboli formed on the 
left side of the device, or in cases where closure is incomplete (Wahl, Meier, Haxel et al., 
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2001). Thrombosis on the device has been found in about 6% of devices used for PFO closure 
at one month TEE control in 1000 patients, except for the Amplatzer PFO occluder where it 
was found in less than 1% (Khairy, O’Donnell & Landzberg 2003).  
Pooling the results of the published studies on percutaneous PFO closure, it appears that 
the intervention yields favorable clinical results over the conservative treatment. Until 
recently, what came closest to a randomized trial was a matched control follow up study 
in about 300 patients, of which half were arbitrarily sent for PFO closure by neurologists 
and half were treated conservatively by the same physicians. Already at a follow up of 
four years, there was a trend in favor of device closure with an average of 5% events per 
year (counting all neurological or peripheral symptoms) compared with 7% in the 
conservative group. This advantage was significant in terms of major strokes, which only 
occurred in the conservative group. It was also significant in the subgroup of patients who 
had had more than two events before treatment allocation as well as in those who had 
complete closure at the six month follow up TEE in the device group (Windecker, Wahl & 
Nedeltchev, 2004).The few randomized trials in this field have, for years, struggled to 
enroll sufficient numbers of patients, owing to a variety of factors, including off-label 
device use. 
CLOSURE I 
CLOSURE I was the first completed, randomized, and controlled trial comparing the 
safety and efficacy of percutaneous PFO closure plus medical therapy versus medical 
therapy alone for secondary TIA and stroke prevention in patients with PFO (CLOSURE I 
Trial, 2010). CLOSURE I enrolled 909 patients randomized equally to PFO closure  
using the STARFlex closure device (NMT Medical, Inc. - Boston, MA) as well as six 
months of aspirin and clopidogrel (and an additional 18 months of aspirin) or to best 
medical therapy—aspirin or warfarin or a combination. The original endpoint was the 2-
year rate of TIA, stroke, or death. Based on a conservative estimate of the expected  
event rate (6%) from the literature available before 2003, CLOSURE I was originally 
designed to enroll 1600 patients. However, after 4 years (2003–2006), CLOSURE I had 
recruited only 611 patients. In April 2007, the FDA approved a proposed revision to the 
statistical plan that decreased the sample size from 1600 to 800 patients based on an 
expected event rate of 6% in the medical arm and 2% in the device arm. Patients with 
cryptogenic TIA or stroke within 6 months and a PFO were screened for study eligibility 
under the direction of a treating neurologist. To be included, a PFO must have been 
documented by TEE and amenable to percutaneous closure with STARFlex. For patients 
randomized to the device arm, the STARFlex device was implanted via percutaneous 
intervention. The implant procedure was scheduled as soon as possible from the point of 
randomization, preferably within 1 week. Either TEE or ICE was used during placement 
of the device.  
In the device arm, patients followed a standardized antiplatelet regimen of clopidogrel 75 
mg daily for 6 months plus aspirin for the duration of the trial. Patients randomized to 
medical therapy were treated with one of the following medications throughout the 
duration of the study: (1) warfarin with a target International Normalized Ratio of 2.0 to 
3.0 with an ideal target of 2.5; (2) aspirin 325 mg daily; (3) aspirin 81 mg daily only, 
Atrial Septal Defect 178 
 
Image 8. Deployed PFO occluder under ICE imaging. 
 
Image 9. Doppler image of a successfully deployed PFO occluder, with significant reduction 
in the interatrial shunt and no obstruction of the superior vena cava flow. 
the PFO was not responsible for the index event, in cases where small emboli formed on the 
left side of the device, or in cases where closure is incomplete (Wahl, Meier, Haxel et al., 
Transcatheter Occlusion of Atrial  
Septal Defects for Prevention of Recurrence of Paradoxical Embolism 179 
2001). Thrombosis on the device has been found in about 6% of devices used for PFO closure 
at one month TEE control in 1000 patients, except for the Amplatzer PFO occluder where it 
was found in less than 1% (Khairy, O’Donnell & Landzberg 2003).  
Pooling the results of the published studies on percutaneous PFO closure, it appears that 
the intervention yields favorable clinical results over the conservative treatment. Until 
recently, what came closest to a randomized trial was a matched control follow up study 
in about 300 patients, of which half were arbitrarily sent for PFO closure by neurologists 
and half were treated conservatively by the same physicians. Already at a follow up of 
four years, there was a trend in favor of device closure with an average of 5% events per 
year (counting all neurological or peripheral symptoms) compared with 7% in the 
conservative group. This advantage was significant in terms of major strokes, which only 
occurred in the conservative group. It was also significant in the subgroup of patients who 
had had more than two events before treatment allocation as well as in those who had 
complete closure at the six month follow up TEE in the device group (Windecker, Wahl & 
Nedeltchev, 2004).The few randomized trials in this field have, for years, struggled to 
enroll sufficient numbers of patients, owing to a variety of factors, including off-label 
device use. 
CLOSURE I 
CLOSURE I was the first completed, randomized, and controlled trial comparing the 
safety and efficacy of percutaneous PFO closure plus medical therapy versus medical 
therapy alone for secondary TIA and stroke prevention in patients with PFO (CLOSURE I 
Trial, 2010). CLOSURE I enrolled 909 patients randomized equally to PFO closure  
using the STARFlex closure device (NMT Medical, Inc. - Boston, MA) as well as six 
months of aspirin and clopidogrel (and an additional 18 months of aspirin) or to best 
medical therapy—aspirin or warfarin or a combination. The original endpoint was the 2-
year rate of TIA, stroke, or death. Based on a conservative estimate of the expected  
event rate (6%) from the literature available before 2003, CLOSURE I was originally 
designed to enroll 1600 patients. However, after 4 years (2003–2006), CLOSURE I had 
recruited only 611 patients. In April 2007, the FDA approved a proposed revision to the 
statistical plan that decreased the sample size from 1600 to 800 patients based on an 
expected event rate of 6% in the medical arm and 2% in the device arm. Patients with 
cryptogenic TIA or stroke within 6 months and a PFO were screened for study eligibility 
under the direction of a treating neurologist. To be included, a PFO must have been 
documented by TEE and amenable to percutaneous closure with STARFlex. For patients 
randomized to the device arm, the STARFlex device was implanted via percutaneous 
intervention. The implant procedure was scheduled as soon as possible from the point of 
randomization, preferably within 1 week. Either TEE or ICE was used during placement 
of the device.  
In the device arm, patients followed a standardized antiplatelet regimen of clopidogrel 75 
mg daily for 6 months plus aspirin for the duration of the trial. Patients randomized to 
medical therapy were treated with one of the following medications throughout the 
duration of the study: (1) warfarin with a target International Normalized Ratio of 2.0 to 
3.0 with an ideal target of 2.5; (2) aspirin 325 mg daily; (3) aspirin 81 mg daily only, 
Atrial Septal Defect 180 
allowed for documented gastrointestinal intolerance; or (4) aspirin 81 mg daily with 
warfarin. Clopidogrel, ticlopidine, and aspirin plus extended-release dipyridamole were 
not allowed in the medical arm. Heparin was permitted during the initial warfarin 
treatment period to provide sufficient anticoagulation.At two years, the composite 
primary endpoints, as well as rates of stroke or TIA alone, were no different between 
groups. An analysis of outcomes according to baseline characteristics, including shunt 
size or presence/absence of atrial shunts, also found no differences between groups. Both 
major vascular complications and atrial fibrillation, mostly periprocedural, were 
significantly more common in the intervention group, but other safety endpoints were no 
different between study arms. Procedural and technical success rates (no or trace residual 
leaking) were suboptimal, with only 86.7% percent of PFOs closed at one year. The 
majority of the adverse events occurred in the device arm during implantation, raising 
concerns regarding device delivery techniques by the investigators, as this issue has not 
arisen in larger trials.  
REDUCE 
REDUCE is an FDA approved prospective, randomized, multicenter, international trial 
designed to demonstrate the safety and effectiveness of the Gore Helex Septal Occluder for 
PFO closure in patients with a history of cryptogenic stroke or imaging-confirmed transient 
ischemic attack. The FDA approved the Gore Helex Septal Occluder for treatment of atrial 
septal defect in 2006. The ongoing study includes up to 50 investigational sites in the US and 
Europe. The Gore REDUCE Study investigators aim to address the CLOSURE I limitations 
by design- all TIAs must be confirmed by neuroimaging studies such as MRI, which will 
prevent the inclusion of spurious neurological events that are not vascular in origin. Patients 
with non-cryptogenic strokes or with a substantial burden of vascular risk factors will be 
excluded from the trial and a uniform medical therapy regimen will be applied for both test 
and control subjects (The Gore REDUCE Clinical Study “HLX 06-03”). 
RESPECT 
The RESPECT trial is a randomized, multi-center study investigating whether closure of 
PFOs using the AMPLATZER PFO Occluder device is safe and effective compared to 
current standard-of-care treatment in the prevention of a cryptogenic stroke. The RESPECT 
trial started recruiting patients in 2003 and completed enrollment in January 2012. 
According to St Jude, RESPECT has enrolled 980 patients over its eight years running, 
yielding more than 2300 patient-years of data. 
The trial is designed to continue until sufficient events have accumulated to be able to assess 
treatment effectiveness. By protocol, patients enrolled in the trial will continue to be 
followed until regulatory approval is granted by the FDA, thus providing substantial long-
term follow-up on this patient population (RESPECT PFO Clinical Trial). 
2. Conclusion 
The indication for PFO closure in the face of paradoxical embolism has been widely 
accepted in the presence of an atrial septal aneurysm or after several embolic events, outside 
the United States.  
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Some clinicians choose to close patent foramen ovale in patients with high-risk features, 
such as stroke despite adequate aspirin or warfarin therapy, large right-to- left interatrial 
shunts or presence of atrial septal aneurysm. 
If the current randomized clinical trials will favor device closure in the setting of 
paradoxical embolism, it is likely that percutaneous PFO closure will increase significantly 
in the United States. 
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Atrial Septal Defects (ASDs) are relatively common both in children and adults. Recent 
reports of increase in the prevalence of ASD may be related use of color Doppler 
echocardiography. The etiology of the ASD is largely unknown. While the majority of 
the book addresses closure of ASDs, one chapter in particular focuses on creating atrial 
defects in the fetus with hypoplastic left heart syndrome. This book, I hope, will give 
the needed knowledge to the physician caring for infants, children, adults and elderly 
with ASD which may help them provide best possible care for their patients.
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